0000875320-16-000078.txt : 20160503 0000875320-16-000078.hdr.sgml : 20160503 20160503170332 ACCESSION NUMBER: 0000875320-16-000078 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160503 DATE AS OF CHANGE: 20160503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 161616299 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 a2016q110-q.htm 10-Q 10-Q

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2016
or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM              TO             
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
04-3039129
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
50 Northern Avenue, Boston, Massachusetts
02210
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (617) 341-6100
____________________________________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o 
Smaller reporting company o
 
                                       (Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
247,349,864
Class
Outstanding at April 20, 2016

 


VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2016

TABLE OF CONTENTS
 
 
Page
 
 
 
Condensed Consolidated Statements of Operations - Three Months Ended March 31, 2016 and 2015
 
Condensed Consolidated Statements of Comprehensive Loss - Three Months Ended March 31, 2016 and 2015
 
Condensed Consolidated Balance Sheets - March 31, 2016 and December 31, 2015
 
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest - Three Months Ended March 31, 2016 and 2015
 
Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2016 and 2015
 
 
 
“We,” “us,” “Vertex” and the “Company” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex,” “KALYDECO®” and “ORKAMBI®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.



Part I. Financial Information
Item 1.    Financial Statements
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)
 
Three Months Ended March 31,
 
2016
 
2015
Revenues:
 
 
 
Product revenues, net
$
394,410

 
$
130,875

Royalty revenues
3,596

 
6,792

Collaborative revenues
74

 
842

Total revenues
398,080

 
138,509

Costs and expenses:
 
 
 
Cost of product revenues
49,789

 
9,381

Royalty expenses
860

 
2,926

Research and development expenses
255,860

 
215,599

Sales, general and administrative expenses
105,214

 
85,860

Restructuring expenses (income), net
687

 
(3,272
)
Total costs and expenses
412,410

 
310,494

Loss from operations
(14,330
)
 
(171,985
)
Interest expense, net
(20,698
)
 
(21,307
)
Other income (expenses), net
4,411

 
(5,113
)
Loss from continuing operations before provision for income taxes
(30,617
)
 
(198,405
)
Provision for income taxes
5,485

 
299

Net loss
(36,102
)
 
(198,704
)
(Income) loss attributable to noncontrolling interest
(5,529
)
 
98

Net loss attributable to Vertex
$
(41,631
)
 
$
(198,606
)
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
Net loss:
 
 
 
Basic
$
(0.17
)
 
$
(0.83
)
Diluted
$
(0.17
)
 
$
(0.83
)
Shares used in per share calculations:
 
 
 
Basic
243,831

 
239,493

Diluted
243,831

 
239,493

The accompanying notes are an integral part of these condensed consolidated financial statements.


2

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Loss
(unaudited)
(in thousands)
 
Three Months Ended March 31,
 
2016
 
2015
Net loss
$
(36,102
)
 
$
(198,704
)
Changes in other comprehensive loss:
 
 
 
Unrealized holding gains on marketable securities
229

 
176

Unrealized (losses) gains on foreign currency forward contracts, net of tax
(5,212
)
 
306

Foreign currency translation adjustment
(1,740
)
 
(608
)
Total changes in other comprehensive loss
(6,723
)
 
(126
)
Comprehensive loss
(42,825
)
 
(198,830
)
Comprehensive (income) loss attributable to noncontrolling interest
(5,529
)
 
98

Comprehensive loss attributable to Vertex
$
(48,354
)
 
$
(198,732
)
The accompanying notes are an integral part of these condensed consolidated financial statements.


3

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
 
March 31,
 
December 31,
 
2016
 
2015
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
604,245

 
$
714,768

Marketable securities, available for sale
421,373

 
327,694

Restricted cash and cash equivalents (VIE)
76,273

 
78,910

Accounts receivable, net
181,878

 
177,639

Inventories
63,200

 
57,207

Prepaid expenses and other current assets
55,866

 
50,935

Total current assets
1,402,835

 
1,407,153

Property and equipment, net
690,521

 
697,715

Intangible assets
284,340

 
284,340

Goodwill
50,384

 
50,384

Cost method investment in CRISPR
30,138

 
—

Notes Receivable
—

 
30,000

Restricted cash
22,088

 
22,083

Other assets
7,600

 
6,912

Total assets
$
2,487,906

 
$
2,498,587

Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
75,221

 
$
74,942

Accrued expenses
272,665

 
305,820

Deferred revenues, current portion
14,705

 
16,296

Accrued restructuring expenses, current portion
7,790

 
7,894

Capital lease obligations, current portion
17,292

 
15,545

Senior secured term loan, current portion
146,251

 
71,296

Other liabilities, current portion
18,117

 
14,374

Total current liabilities
552,041

 
506,167

Deferred revenues, excluding current portion
8,490

 
9,714

Accrued restructuring expenses, excluding current portion
6,145

 
7,464

Capital lease obligations, excluding current portion
38,886

 
42,923

Deferred tax liability
112,259

 
110,439

Construction financing lease obligation, excluding current portion
472,494

 
472,611

Senior secured term loan, net of current portion and discount
149,571

 
223,863

Other liabilities, excluding current portion
31,822

 
31,778

Total liabilities
1,371,708

 
1,404,959

Commitments and contingencies


 


Shareholders’ equity:
 
 
 
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at March 31, 2016 and December 31, 2015
—

 
—

Common stock, $0.01 par value; 500,000,000 and 500,000,000 shares authorized at March 31, 2016 and December 31, 2015, respectively; 247,286,705 and 246,306,818 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively
2,429

 
2,427

Additional paid-in capital
6,262,964

 
6,197,500

Accumulated other comprehensive (loss) income
(4,899
)
 
1,824

Accumulated deficit
(5,303,415
)
 
(5,261,784
)
Total Vertex shareholders' equity
957,079

 
939,967

Noncontrolling interest
159,119

 
153,661

Total shareholders’ equity
1,116,198

 
1,093,628

Total liabilities and shareholders’ equity
$
2,487,906

 
$
2,498,587

The accompanying notes are an integral part of these condensed consolidated financial statements.


4

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity and Noncontrolling Interest
(unaudited)
(in thousands)
 
Common Stock
 
Additional
Paid-in Capital
 
Accumulated
Other
Comprehensive (Loss) Income
 
Accumulated Deficit
 
Total Vertex
Shareholders’ Equity
 
Noncontrolling
Interest
 
Total
Shareholders’ Equity
 
Shares
 
Amount
 
 
 
 
 
 
Balance at December 31, 2014
241,764

 
$
2,385

 
$
5,777,154

 
$
917

 
$
(4,705,450
)
 
$
1,075,006

 
$
21,177

 
$
1,096,183

Other comprehensive loss, net of tax
—

 
—

 
—

 
(126
)
 
—

 
(126
)
 
—

 
(126
)
Net loss
—

 
—

 
—

 
—

 
(198,606
)
 
(198,606
)
 
(98
)
 
(198,704
)
Issuance of common stock under benefit plans
1,816

 
14

 
41,902

 
—

 
—

 
41,916

 
—

 
41,916

Stock-based compensation expense
—

 
—

 
58,268

 
—

 
—

 
58,268

 
—

 
58,268

Balance at March 31, 2015
243,580

 
$
2,399

 
$
5,877,324

 
$
791

 
$
(4,904,056
)
 
$
976,458

 
$
21,079

 
$
997,537

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2015
246,307

 
$
2,427

 
$
6,197,500

 
$
1,824

 
$
(5,261,784
)
 
$
939,967

 
$
153,661

 
$
1,093,628

Other comprehensive loss, net of tax
—

 
—

 
—

 
(6,723
)
 
—

 
(6,723
)
 
—

 
(6,723
)
Net loss
—

 
—

 
—

 
—

 
(41,631
)
 
(41,631
)
 
5,529

 
(36,102
)
Issuance of common stock under benefit plans
980

 
2

 
9,147

 
—

 
—

 
9,149

 
—

 
9,149

Stock-based compensation expense
—

 
—

 
56,317

 
—

 
—

 
56,317

 
(71
)
 
56,246

Balance at March 31, 2016
247,287

 
$
2,429

 
$
6,262,964

 
$
(4,899
)
 
$
(5,303,415
)
 
$
957,079

 
$
159,119

 
$
1,116,198

The accompanying notes are an integral part of these condensed consolidated financial statements.


5

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
 
Three Months Ended March 31,
 
2016
 
2015
Cash flows from operating activities:
 
 
 
Net loss
$
(36,102
)
 
$
(198,704
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Stock-based compensation expense
55,472

 
57,384

Depreciation and amortization expense
16,415

 
16,363

Deferred income taxes
2,060

 
—

Other non-cash items, net
(3,835
)
 
629

Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
(2,512
)
 
(5,863
)
Inventories
(4,771
)
 
(2,635
)
Prepaid expenses and other assets
(7,325
)
 
(15,233
)
Accounts payable
(343
)
 
(23,556
)
Accrued expenses and other liabilities
(29,922
)
 
(20,921
)
Accrued restructuring expense
(1,459
)
 
(24,367
)
Deferred revenues
(2,815
)
 
(5,333
)
Net cash used in operating activities
(15,137
)
 
(222,236
)
Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(224,624
)
 
(125,655
)
Maturities of marketable securities
131,173

 
371,423

Expenditures for property and equipment
(11,974
)
 
(10,558
)
Increase in restricted cash and cash equivalents
(3
)
 
(21,971
)
Decrease in restricted cash and cash equivalents (VIE)
2,637

 
—

Decrease in other assets
83

 
799

Net cash (used in) provided by investing activities
(102,708
)
 
214,038

Cash flows from financing activities:
 
 
 
Issuances of common stock under benefit plans
8,846

 
41,616

Payments on capital lease obligations
(4,041
)
 
(4,497
)
Proceeds from capital lease financing
—

 
13,386

Payments on construction financing lease obligation
(103
)
 
(91
)
Net cash provided by financing activities
4,702

 
50,414

Effect of changes in exchange rates on cash
2,620

 
(2,596
)
Net increase in cash and cash equivalents
(110,523
)
 
39,620

Cash and cash equivalents—beginning of period
714,768

 
625,259

Cash and cash equivalents—end of period
$
604,245

 
$
664,879

 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 
Cash paid for interest
$
20,603

 
$
21,538

Cash paid for income taxes
$
581

 
$
60

Issuances of common stock exercises from employee benefit plans receivable
$
593

 
$
964

The Company has reclassified certain amounts in the period ending March 31, 2015 between operating, investing, and financing to correct improper classifications. 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)


A. Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2016 and 2015.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2016 (the "2015 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2015 Annual Report on Form 10-K.
Recent Accounting Pronouncements
In 2016, the Financial Accounting Standards Board (“FASB”) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2015 Annual Report on Form 10-K. The Company did not adopt any


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

new accounting pronouncements during the three months ended March 31, 2016 that had a material effect on its condensed consolidated financial statements.
B.
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its “Customers”). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customers' locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and Customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.
The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2016:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2015
$
2,089

 
$
44,669

 
$
1,228

 
$
1,310

 
$
49,296

Provision related to current period sales
4,707

 
31,138

 
924

 
3,280

 
40,049

Adjustments related to prior period sales
(38
)
 
(2,181
)
 
(75
)
 
—

 
(2,294
)
Credits/payments made
(4,698
)
 
(19,132
)
 
(260
)
 
(3,281
)
 
(27,371
)
Balance at March 31, 2016
$
2,060

 
$
54,494

 
$
1,817

 
$
1,309

 
$
59,680

C.
Collaborative Arrangements
Cystic Fibrosis Foundation Therapeutics Incorporated
In April 2011, the Company entered into an amendment (the “April 2011 Amendment”) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) pursuant to which CFFT agreed to provide financial support for (i) development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii) additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein.
Under the April 2011 Amendment, CFFT agreed to provide the Company with up to $75.0 million in funding over approximately five years for corrector compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor and VX-661. The Company recognized no collaborative revenues from this collaboration during the three months ended March 31, 2016 and 2015.


8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs first synthesized or tested during the research term that ended in 2008, including ivacaftor, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds first synthesized or tested during the research term that ended in February 2014. In each of 2012 and 2013, CFFT earned a commercial milestone payment of $9.3 million from the Company upon achievement of certain sales levels for KALYDECO. In each of the fourth quarter of 2015 and first quarter of 2016, CFFT earned a commercial milestone payment of $13.9 million from the Company upon achievement of certain sales levels of lumacaftor. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO or ORKAMBI.
The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in 2015. The Company received approval for ORKAMBI in the European Union in 2015 and in Canada and Australia in 2016. The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and VX-661 until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of VX-661 that expire in 2027 and 2028, respectively, subject to potential extension.
CRISPR Therapeutics AG
On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to six CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of $75.0 million and a $30.0 million investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed $75.0 million to research and development, and the $30.0 million investment was recorded at cost and is classified as a long-term asset on the Company’s condensed consolidated balance sheet.
The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to six targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net product sales.
The Company may terminate the CRISPR Agreement upon 90 days’ notice to CRISPR prior to any product receiving marketing approval or upon 270 days’ notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.
Janssen Pharmaceutica NV
The Company has a collaboration agreement (the “Janssen HCV Agreement”) with Janssen Pharmaceutica NV (“Janssen NV”) for the development, manufacture and commercialization of telaprevir, which Janssen NV began marketing under the brand name INCIVO in certain of its territories in September 2011. Pursuant to the Janssen HCV Agreement, as amended, Janssen NV has a fully-paid license to manufacture and commercialize INCIVO in its territories including Europe, South America, the Middle East, Africa and Australia, subject to the payment of third-party royalties on net sales of INCIVO. In addition to the collaborative revenues, the Company recorded royalty revenues and corresponding royalty expenses related to third-party royalties that Janssen NV remains responsible for based on INCIVO net sales.


9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

During the three months ended March 31, 2016 and 2015, the Company recognized the following revenues attributable to the Janssen NV collaboration:
 
Three Months Ended March 31,
 
2016
 
2015
 
(in thousands)
Royalty revenues (INCIVO)
$
78

 
$
1,525

Collaborative revenues (telaprevir)
—

 
642

  Total revenues attributable to the Janssen NV collaboration
$
78

 
$
2,167


Variable Interest Entities
The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the Company's condensed consolidated financial statements as VIEs. In order to account for the fair value of the contingent milestone and royalty payments related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop the drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are reflected in the Company's financial statements as consolidated VIEs:
Parion Sciences, Inc.
License and Collaboration Agreement

On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (“Parion”).  Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.  The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.

Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion’s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion’s research program.  Parion received an $80.0 million up-front payment and has the potential to receive up to an additional (i) $490.0 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360.0 million related to global filing and approval milestones, (ii) $370.0 million in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii) $230.0 million in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion’s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.

The Company may terminate the Parion Agreement upon 90 days’ notice to Parion prior to any licensed product receiving marketing approval or upon 180 days’ notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon 30 days’ notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a


10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i) the date the last-to-expire patent covering a licensed product expires or (ii) ten years after the first commercial sale in the country.

The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly affect the economic performance of Parion.  Accordingly, the Company consolidated Parion's financial statements beginning on June 4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement. In particular, the Company did not acquire any equity interest in Parion, any interest in Parion's cash and cash equivalents or any control over Parion's activities that do not relate to the Parion Agreement.
Consideration for the Parion Agreement

The Company determined that the fair value of the consideration from the Company to Parion was $255.3 million as of June 4, 2015, which consisted of (i) an $80.0 million up-front payment, (ii) the estimated fair value of the contingent research and development milestones potentially payable by the Company to Parion and (iii) the estimated fair value of potential royalty payments payable by the Company to Parion. The Company valued the contingent milestone and royalty payments using (a) discount rates ranging from 4.1% to 5.9% for the development milestones and (b) a discount rate of 6.6% for royalties. The consideration paid and the fair value of the contingent milestone and royalty payments payable by the Company pursuant to the Parion Agreement are set forth in the table below:
 
June 4, 2015
 
(in thousands)
Up-front payment
$
80,000

Fair value of contingent milestone and royalty payments
175,340

Total
$
255,340

Allocation of Assets and Liabilities

For the purposes of the condensed consolidated balance sheets at June 4, 2015 and March 31, 2016, the Company allocated the total consideration, which is comprised of the up-front payment and the fair value of the contingent milestone and royalty payments, intangible assets, goodwill, deferred tax liability, net and net other assets and liabilities.

The Company recorded $255.3 million of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The difference between the fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill.

The following table summarizes the fair values of the assets and liabilities recorded on the effective date of the Parion Agreement:
 
June 4, 2015
 
(in thousands)
Intangible assets
$
255,340

Goodwill
10,468

Deferred tax liability
(91,023
)
Net other assets (liabilities)
(10,468
)
Net assets attributable to noncontrolling interests
$
164,317



11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

BioAxone Biosciences, Inc.
In October 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone Biosciences, Inc. (“BioAxone”), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of $10.0 million in the fourth quarter of 2014.
BioAxone has the potential to receive up to $90.0 million in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of $29.0 million for VX-210 and a corresponding deferred tax liability of $11.3 million attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company’s option to extend this date by one year.
Aggregate VIE Financial Information

An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three months ended March 31, 2016 and 2015 is as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
839

 
$
287

Provision for (benefit from) income taxes
3,062

 
(64
)
Increase in fair value of contingent milestone and royalty payments
(9,430
)
 
(125
)
Net (income) loss attributable to noncontrolling interest
$
(5,529
)
 
$
98


During the three months ended March 31, 2016 and 2015, the fair value of the contingent milestone and royalty payments related to the BioAxone Agreement increased by $0.4 million and $0.1 million, respectively. During the three months ended March 31, 2016 the fair value of the contingent milestone and royalty payments related to the Parion Agreement increased by $9.0 million. The changes in the fair value of the contingent milestone and royalty payments were primarily due to the changes in market interest rates and the time value of money. As of March 31, 2016, the fair value of the contingent milestone and royalty payments related to the BioAxone Agreement and the Parion Agreement was $28.4 million and $188.0 million, respectively. As of December 31, 2015, the fair value of the contingent milestone and royalty payments related to the BioAxone collaboration and the Parion collaboration was $28.0 million and $179.0 million, respectively.

The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:


12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
March 31, 2016
 
December 31, 2015
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
76,273

 
$
78,910

Prepaid expenses and other current assets
2,818

 
3,138

Intangible assets
284,340

 
284,340

Goodwill
19,391

 
19,391

Other assets
434

 
455

Accounts payable
1,569

 
676

Taxes payable
24,512

 
24,554

Other current liabilities
6,595

 
7,100

Deferred tax liability, net
112,259

 
110,438

Other liabilities
310

 
300

Noncontrolling interest
159,119

 
153,661


The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i) the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii) the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company's VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets.
Outlicense Arrangements
In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration.

Janssen Pharmaceuticals, Inc.
In June 2014, the Company entered into an agreement (the “Janssen Influenza Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen Inc.”), which was amended in October 2014 to clarify certain roles and responsibilities of the parties.

Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of $35.0 million from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any.
Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During the three months ended March 31, 2016 and 2015, the Company recorded reimbursement for these development activities of $3.5 million and $7.6 million, respectively. The reimbursements are recorded as a reduction to development expense in the Company's condensed consolidated statements of operations primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon six months' notice.


13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

D.
Earnings Per Share
Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Stock options
12,619

 
12,682

Unvested restricted stock and restricted stock units
3,565

 
3,474

E.
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of March 31, 2016, the Company’s investments were in money market funds, short-term government-sponsored enterprise securities, U.S. Treasury securities, corporate debt securities and commercial paper.
As of March 31, 2016, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, short-term government-sponsored enterprise securities and U.S. Treasury securities. The Company’s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations.


14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:
 
Fair Value Measurements as
of March 31, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
190,601

 
$
190,601

 
$
—

 
$
—

Corporate debt securities
13,557

 
—

 
13,557

 
—

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities
33,104

 
33,104

 
—

 
—

Government-sponsored enterprise securities
126,478

 
126,478

 
—

 
—

Corporate debt securities
120,229

 
—

 
120,229

 
—

Commercial paper
141,562

 
—

 
141,562

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
3,654

 
—

 
3,654

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
182

 
—

 
182

 
—

Total financial assets
$
629,367


$
350,183

 
$
279,184

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(3,765
)
 
$
—

 
$
(3,765
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(657
)
 
—

 
(657
)
 
—

Total financial liabilities
$
(4,422
)
 
$
—

 
$
(4,422
)
 
$
—



15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
Fair Value Measurements as
of December 31, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
199,507

 
$
199,507

 
$
—

 
$
—

Government-sponsored enterprise securities
85,994

 
85,994

 
—

 
—

Commercial paper
34,889

 
—

 
34,889

 
—

Corporate debt securities
11,533

 
—

 
11,533

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
87,162

 
87,162

 
—

 
—

Commercial paper
141,409

 
—

 
141,409

 
—

Corporate debt securities
99,123

 
—

 
99,123

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
5,161

 
—

 
5,161

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
605

 
$
—

 
605

 
$
—

Total financial assets
$
665,383

 
$
372,663

 
$
292,720

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(769
)
 
$
—

 
$
(769
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(132
)
 
—

 
(132
)
 
—

Total financial liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
—

The Company's VIEs invested in cash equivalents consisting of money market funds of $76.0 million as of March 31, 2016, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company’s noncontrolling interest related to VIEs includes the fair value of the contingent milestone and royalty payments, which are valued based on Level 3 inputs. Please refer to Note C, “Collaborative Arrangements,” for further information.
As of March 31, 2016, the fair value and carrying value of the Company's Term Loan was $295.8 million. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current market rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.


16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

F.
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of March 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
590,688

 
$
—

 
$
—

 
$
590,688

Corporate debt securities
13,557

 
—

 
—

 
13,557

Total cash and cash equivalents
$
604,245

 
$
—

 
$
—

 
$
604,245

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
33,108

 
$
—

 
$
(4
)
 
$
33,104

Government-sponsored enterprise securities (due within 1 year)
126,461

 
17

 
—

 
126,478

Commercial paper (due within 1 year)
141,243

 
319

 
—

 
141,562

Corporate debt securities (due within 1 year)
120,206

 
23

 
—

 
120,229

Total marketable securities
$
421,018

 
$
359

 
$
(4
)
 
$
421,373

Total cash, cash equivalents and marketable securities
$
1,025,263

 
$
359

 
$
(4
)
 
$
1,025,618

 
 
 
 
 
 
 
 
As of December 31, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
582,352

 
$
—

 
$
—

 
$
582,352

Government-sponsored enterprise securities
85,994

 
—

 
—

 
85,994

Commercial paper
34,889

 
—

 
—

 
34,889

Corporate debt securities
11,533

 
—

 
—

 
11,533

Total cash and cash equivalents
$
714,768

 
$
—

 
$
—

 
$
714,768

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
87,176

 
$
—

 
$
(14
)
 
$
87,162

Commercial paper (due within 1 year)
98,877

 
246

 
—

 
99,123

Corporate debt securities (due within 1 year)
141,515

 
—

 
(106
)
 
141,409

Total marketable securities
$
327,568

 
$
246

 
$
(120
)
 
$
327,694

Total cash, cash equivalents and marketable securities
$
1,042,336

 
$
246

 
$
(120
)
 
$
1,042,462

The Company has a limited number of marketable securities in insignificant loss positions as of March 31, 2016, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three months ended March 31, 2016 and 2015.


17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

G.
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, net of tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(1,740
)
 
229

 
(3,827
)
 
(5,338
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(1,385
)
 
(1,385
)
Net current period other comprehensive (loss) income
$
(1,740
)
 
$
229

 
$
(5,212
)
 
$
(6,723
)
Balance at March 31, 2016
$
(3,820
)
 
$
355

 
$
(1,434
)
 
$
(4,899
)
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized (Losses) Gains on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
(608
)
 
176

 
2,004

 
1,572

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(1,698
)
 
(1,698
)
Net current period other comprehensive (loss) income
$
(608
)
 
$
176

 
$
306

 
$
(126
)
Balance at March 31, 2015
$
(1,579
)
 
$
53

 
$
2,317

 
$
791

H.
Hedging
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2016, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:


18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
As of March 31, 2016
 
As of December 31, 2015
Foreign Currency
(in thousands)
Euro
$
215,343

 
$
103,362

British pound sterling
76,395

 
78,756

Australian dollar
28,837

 
27,167

Total foreign currency forward contracts
$
320,575

 
$
209,285

The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of March 31, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
3,654

 
Other liabilities, current portion
 
$
(3,765
)
Other assets
 
182

 
Other liabilities, excluding current portion
 
(657
)
Total assets
 
$
3,836

 
Total liabilities
 
$
(4,422
)
As of December 31, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
5,161

 
Other liabilities, current portion
 
$
(769
)
Other assets
 
605

 
Other liabilities, excluding current portion
 
(132
)
Total assets
 
$
5,766

 
Total liabilities
 
$
(901
)
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:
 
As of March 31, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
3,836

 
$
—

 
$
3,836

 
$
(3,836
)
 
$
—

Total liabilities
$
(4,422
)
 
$
—

 
$
(4,422
)
 
$
3,836

 
$
(586
)
 
As of December 31, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
5,766

 
$
—

 
$
5,766

 
$
(901
)
 
$
4,865

Total liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
901

 
$
—



19
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

I. Inventories
Inventories consisted of the following:
 
As of March 31, 2016
 
As of December 31, 2015
 
(in thousands)
Raw materials
$
9,936

 
$
8,696

Work-in-process
37,899

 
40,695

Finished goods
15,365

 
7,816

Total
$
63,200

 
$
57,207

J. Intangible Assets and Goodwill
Intangible Assets
As of March 31, 2016 and December 31, 2015, in-process research and development intangible assets of $284.3 million were recorded on the Company's condensed consolidated balance sheet.
In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of $255.3 million based on the Company’s estimate of the fair value of Parion’s lead investigational ENaC inhibitors, including VX-371 and VX-551, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of $29.0 million based on the Company’s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of 7.1% and 7.5% in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively.
The Company also conducted an evaluation of Parion and BioAxone's other programs at the effective date of the Parion Agreement and BioAxone Agreement, respectively, and determined that market participants would not have ascribed value to those programs because of the stage of development of the assets in each program and uncertainties related to the potential development and commercialization of the programs.
Goodwill
As of March 31, 2016 and December 31, 2015, goodwill of $50.4 million was recorded on the Company's condensed consolidated balance sheet.
K. Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings (the “Buildings”) at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the


20
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.
Property and equipment, net, included $499.0 million and $502.3 million as of March 31, 2016 and December 31, 2015, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was $472.9 million and $473.0 million as of March 31, 2016 and December 31, 2015, respectively.
San Diego Lease
On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC. Pursuant to this agreement, the Company agreed to lease approximately 170,000 square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the second half of 2017, and will extend for 16 years from the commencement date. Pursuant to the lease agreement, during the initial 16-year term, the Company will pay an average of approximately $10.2 million per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to two additional five-year terms.

Term Loan
In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a $300.0 million senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed $200.0 million.
The Term Loan initially bore interest at a rate of 7.2% per annum, which was reduced to 6.2% per annum based on the FDA's approval of ORKAMBI. The Term Loan will bear interest at a rate of LIBOR plus 5.0% per annum during the third year of the term.
The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of $75 million from October 1, 2016 through the maturity date.
The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of two years of interest payments over the life of the loan. The Company accounted for the amendment as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.
The Company's obligations under the Term Loan are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the Term Loan, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries.
The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended March 31, 2016.


21
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.
The Company incurred $5.3 million in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company’s condensed consolidated statements of operations. As of March 31, 2016 and December 31, 2015, the unamortized discount associated with the Term Loan that was included in the senior secured term loan caption on the Company’s condensed consolidated balance sheet was $4.0 million and $4.6 million, respectively.


22
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

L. Stock-based Compensation Expense
During the three months ended March 31, 2016 and 2015, the Company recognized the following stock-based compensation expense included in loss from continuing operations:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Stock-based compensation expense by type of award:
 
 
 
Stock options
$
26,260

 
$
28,959

Restricted stock and restricted stock units
27,533

 
27,169

ESPP share issuances
2,524

 
2,140

Less stock-based compensation expense capitalized to inventories
(845
)
 
(884
)
Total stock-based compensation included in costs and expenses
$
55,472

 
$
57,384

 
 
 


Stock-based compensation expense by line item:
 
 
 
Research and development expenses
$
34,448

 
$
38,217

Sales, general and administrative expenses
21,024

 
19,167

Total stock-based compensation included in costs and expenses
$
55,472

 
$
57,384

The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of March 31, 2016
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
206,783

 
2.83
Restricted stock and restricted stock units
$
223,184

 
2.78
ESPP share issuances
$
3,143

 
0.49
The following table summarizes information about stock options outstanding and exercisable at March 31, 2016:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
138

 
1.85
 
$
18.93

 
138

 
$
18.93

$20.01–$40.00
 
2,124

 
3.56
 
$
34.30

 
2,119

 
$
34.29

$40.01–$60.00
 
2,210

 
6.33
 
$
48.09

 
1,590

 
$
48.77

$60.01–$80.00
 
1,396

 
7.83
 
$
75.92

 
654

 
$
75.31

$80.01–$100.00
 
3,550

 
8.81
 
$
90.65

 
815

 
$
88.04

$100.01–$120.00
 
1,677

 
8.80
 
$
109.32

 
402

 
$
109.26

$120.01–$134.69
 
1,524

 
9.28
 
$
130.63

 
339

 
$
129.57

Total
 
12,619

 
7.36
 
$
78.61

 
6,057

 
$
59.71



23
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

M. Other Arrangements
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of March 31, 2016, the Company had $23.2 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
N. Income Taxes
The Company is subject to United States federal, state, and foreign income taxes. For the three months ended March 31, 2016, the Company recorded a provision for income taxes of $5.5 million. The provision for income taxes recorded in the three months ended March 31, 2016 included $3.1 million, related to the Company's VIE's income tax provision. The Company has no liability for taxes payable by the Company's VIEs and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For the three months ended March 31, 2015, the Company recorded a provision for income taxes of $0.3 million, related to state income taxes and income earned in various foreign jurisdictions.
As of each of March 31, 2016 and December 31, 2015, the Company had unrecognized tax benefits of $0.4 million. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. As of March 31, 2016, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of March 31, 2016 and December 31, 2015. In 2016, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately $0.4 million due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company’s effective tax rate.
The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses.
The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Delaware, Canada and Quebec for varying periods including the years ended December 31, 2011 through 2013. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Pennsylvania and Texas during 2016 and Massachusetts and New York during 2015 with no material adjustments.
The Company currently intends to reinvest the total amount of its unremitted earnings. At March 31, 2016, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.
O. Restructuring Liabilities
2003 Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018. The Company has not used more than 50% of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties.
The activities related to the restructuring liability for the three months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
7,944

 
$
11,596

Cash payments
(3,931
)
 
(3,985
)
Cash received from subleases
3,008

 
2,476

Restructuring expense (income)
203

 
(581
)
Liability, end of the period
$
7,224

 
$
9,506


Fan Pier Move Restructuring
In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning three facilities in Cambridge. During the first quarter of 2015, the Company terminated two of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company’s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company’s landlord on the effective date of the termination. The third major facility included in this restructuring activity is 120,000 square feet of the Kendall Square Facility that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the Kendall Square Facility was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company’s estimated future cash flows related to this portion of the Kendall Square Facility, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of 9%.
The activities related to the restructuring liability for the three months ended March 31, 2016 and 2015 were as follows:

24
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
5,964

 
$
33,390

Cash payments
(3,156
)
 
(19,256
)
Cash received from subleases
2,408

 
—

Restructuring expense (income)
233

 
(2,997
)
Liability, end of the period
$
5,449

 
$
11,137

Other Restructuring Activities
The Company has engaged in several other restructuring activities that are unrelated to its 2003 Kendall Restructuring and the Fan Pier Move Restructuring. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in CF and other research and development programs.
The activities related to the Company's other restructuring liabilities for the three months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
1,450

 
$
869

Cash payments
(439
)
 
(330
)
Restructuring expense
251

 
306

Liability, end of the period
$
1,262

 
$
845

P. Commitments and Contingencies
Financing Arrangements
As of March 31, 2016, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling $21.9 million that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of March 31, 2016, on the Company's condensed consolidated balance sheet.
Litigation
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company’s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of the Company’s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs’ opposition to its motion to dismiss.  The court heard oral argument on the motion to dismiss on March 6, 2015 and


25
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The First Circuit Court of Appeals issued a scheduling order on December 24, 2015. On February 2, 2016, the Plaintiff filed their opening brief and the Company filed its opposition brief on March 7, 2016. On March 24, 2016, the plaintiff filed their reply brief. The Company believes the claims to be without merit and intend to vigorously defend the litigation. As of March 31, 2016, the Company has not recorded any reserves for this purported class action.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of March 31, 2016 or December 31, 2015.


26

Item 2.     Management's Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. We use precision medicine approaches with the goal of creating transformative medicines for patients in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other indications, while maintaining our financial strength. Our two marketed products are ORKAMBI and KALYDECO.
Cystic Fibrosis
ORKAMBI
ORKAMBI (lumacaftor in combination with ivacaftor) was approved by the United States Food and Drug Administration, or FDA, in July 2015 and by the European Commission in November 2015, for the treatment of patients with CF twelve years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene. ORKAMBI was approved for this patient population in Canada and Australia in the first quarter of 2016. Our future ORKAMBI net product revenues in the United States will reflect the number of patients for whom treatment with ORKAMBI is initiated, the proportion of initiated patients who remain on treatment, patient compliance with the recommended treatment regimen and the level of rebates, chargebacks, discounts and other adjustments to our ORKAMBI gross product revenues. We believe that there currently are approximately 8,500 patients in the United States who are eligible for treatment with ORKAMBI. We have begun the country-by-country reimbursement approval process in ex-U.S. markets. We believe that there are approximately 12,000 patients with CF twelve years of age and older who are homozygous for the F508del mutation in Europe and approximately an aggregate of 2,500 patients with CF twelve years of age and older who are homozygous for the F508del mutation in Canada and Australia.
In late March 2016, we submitted a supplemental New Drug Application, or sNDA, to the FDA for ORKAMBI for the treatment of patients with CF six to eleven years of age who are homozygous for the F508del mutation in their CFTR gene. The sNDA included a request for priority review, which if granted, would reduce the FDA's anticipated review time from approximately ten months to approximately six months. The sNDA was based upon the results of a Phase 3 clinical trial evaluating lumacaftor in combination with ivacaftor in 58 patients with CF six to eleven years of age who are homozygous for the F508del mutation in their CFTR gene. We have completed enrollment in a second Phase 3 clinical trial evaluating lumacaftor in combination with ivacaftor in approximately 200 patients in this same patient population. If this clinical trial is successful, we expect to submit a Marketing Authorization Application to the European Medicines Agency seeking approval of ORKAMBI in this patient population in the European Union in the first half of 2017.
KALYDECO
KALYDECO (ivacaftor) was approved in 2012 in the United States and European Union as a treatment for patients with CF six years of age and older who have the G551D mutation in their CFTR gene. Since 2012, we have increased the number of patients who are being treated with KALYDECO in the United States and non-U.S. markets by expanding the label for KALYDECO to include patients with CF who have additional mutations in their CFTR gene and to include patients in additional age demographics. We believe that there are approximately 4,000 patients in North America, Europe and Australia who are currently eligible for treatment with KALYDECO.
We recently initiated a Phase 3 clinical trial for ivacaftor in patients with CF less than two years of age to evaluate the effect of ivacaftor on markers of CF disease in young children. The clinical trial will utilize a weight-based dose of ivacaftor granules that can be mixed in soft foods or liquids. The clinical trial will enroll patients with one of the ten CFTR gene mutations for which KALYDECO is currently approved.
VX-661
VX-661 is an orally-administered CFTR corrector drug candidate that we are evaluating in a Phase 3 development program in combination with ivacaftor in multiple CF patient populations who have at least one copy of the F508del mutation in their CFTR gene. Details of the patient population and status of each of these clinical trials is as follows:

•
Two copies of the F508del in their CFTR gene: We expect to complete enrollment in mid-2016 and data from this clinical trial to be available in early 2017.
•
One copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in a gating defect in the CFTR protein: We plan to complete enrollment in this clinical trial in late 2016 or early 2017.


27

•
One copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in residual CFTR function: We have revised the enrollment target for this clinical trial. We originally expected to enroll up to 300 patients in this clinical trial and currently expect to enroll approximately 200 patients. We expect to complete enrollment in this clinical trial in the second half of 2016.
•
One copy of the F508del mutation in their CFTR gene and a second mutation that results in minimal CFTR function: Enrollment is complete in the first part of this clinical trial and we expect an interim futility analysis of efficacy data to be completed in the third quarter of 2016.
In addition to evaluating the efficacy of the combination regimen, these Phase 3 clinical trials will provide safety data on the combination of VX-661 and ivacaftor to support the planned development of a triple combination regimen that includes a next-generation corrector in combination with VX-661 and ivacaftor.

ENaC Inhibition
VX-371 is an investigational epithelial sodium channel, or ENaC, inhibitor, we are evaluating in a Phase 2 development program in collaboration with Parion Sciences, Inc., or Parion. Parion recently completed a Phase 2 clinical trial in approximately 142 patients with CF with no restriction on the mutations in their CFTR gene. The primary endpoint of the clinical trial was safety as compared to patients on placebo. Secondary endpoints evaluated the effect on mean absolute forced expiratory volume in one second, or FEV1 and patient-reported respiratory symptoms as reported in the CF questionnaire-revised, or CFQ-R. The clinical trial met its primary safety endpoint and data from the clinical trial showed that VX-371 was generally well tolerated. There were no statistically significant changes in FEV1 or CFQ-R for patients who received VX-371.

In the first quarter of 2016, we initiated a Phase 2a clinical trial evaluating VX-371 in approximately 150 patients on ORKAMBI, both with and without the addition of hypertonic saline, who have two copies of the F508del mutation in their CFTR gene. The primary endpoints of this clinical trial are safety and mean absolute change from baseline in FEV1 at day 28 as compared to patients on placebo.
In vitro, VX-371 showed a meaningful change in cilia beat frequency when VX-371 was used in combination with ORKAMBI in human bronchial epithelial cells with two copies of the F508del mutation, but did not show a meaningful change in cilia beat frequency when VX-371 was used alone.

Next-generation CFTR Corrector Compounds
We are developing two next-generation CFTR corrector compounds, VX-152 and VX-440, that we plan to evaluate as part of triple combination treatment regimens. We initiated Phase 1 clinical trials in healthy volunteers of each of VX-152 and VX-440, alone and as part of a triple combination with VX-661 and ivacaftor, in the fourth quarter of 2015. If these clinical trials are successful, we plan to initiate Phase 2 proof-of-concept clinical trials of VX-152 and/or VX-440 in the second half of 2016.

Research and Development
We are engaged in a number of other research and mid- and early-stage development programs, including in the areas of oncology, pain and neurology.
Oncology
We are conducting two Phase 1/2 clinical trials of VX-970, a protein kinase inhibitor of ataxia telangiectasia and Rad3-related, or ATR, in combination with commonly used DNA-damaging chemotherapies across a range of solid tumor types, including triple-negative breast cancer and non-small cell lung cancer. We also are in Phase 1 development of VX-803, a second ATR inhibitor, alone and in combination with chemotherapy. We recently initiated Phase 1 clinical development of VX-984, a third oncology drug candidate, alone and in combination with pegylated liposomal doxorubicin.
Pain
We are developing VX-150 and VX-241, two drug candidates for the treatment of pain. We recently initiated a six-week cross-over Phase 2 proof-of-concept clinical trial to evaluate VX-150 in approximately 100 patients with symptomatic osteoarthritis of the knee. We expect to complete enrollment of this clinical trial in the second half of 2016. We expect to begin clinical development of VX-241 in the first half of 2016.


28

Acute Spinal Cord Injury
We are developing VX-210, a drug candidate for the treatment of acute spinal cord injury, that we exclusively licensed from BioAxone BioSciences, Inc. VX-210 is designed to inhibit a protein known as Rho that blocks neural regeneration after injury. We recently initiated a Phase 2b/3 clinical trial to evaluate the efficacy and safety of VX-210 in patients with certain acute cervical spinal cord injuries.
Research
We plan to continue investing in our research programs and fostering scientific innovation in order to identify and develop transformative medicines. We believe that pursuing research in diverse areas allows us to balance the risks inherent in drug development and may provide drug candidates that will form our pipeline in future years.
Drug Discovery and Development
Discovery and development of a new pharmaceutical product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise and can take 10 to 15 years or more. Potential drug candidates are subjected to rigorous evaluations, driven in part by stringent regulatory considerations, designed to generate information concerning efficacy, side-effects, proper dosage levels and a variety of other physical and chemical characteristics that are important in determining whether a drug candidate should be approved for marketing as a pharmaceutical product. Most chemical compounds that are investigated as potential drug candidates never progress into development, and most drug candidates that do advance into development never receive marketing approval. Because our investments in drug candidates are subject to considerable risks, we closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our drug development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in abrupt changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
If we believe that data from a completed registration program support approval of a drug candidate, we submit an NDA to the FDA requesting approval to market the drug candidate in the United States and seek analogous approvals from comparable regulatory authorities in foreign jurisdictions. To obtain approval, we must, among other things, demonstrate with evidence gathered in nonclinical studies and well-controlled clinical trials that the drug candidate is safe and effective for the disease it is intended to treat and that the manufacturing facilities, processes and controls for the manufacture of the drug candidate are adequate. The FDA and foreign regulatory authorities have substantial discretion in deciding whether or not a drug candidate should be granted approval based on the benefits and risks of the drug candidate in the treatment of a particular disease, and could delay, limit or deny regulatory approval. If regulatory delays are significant or regulatory approval is limited or denied altogether, our financial results and the commercial prospects for the drug candidate involved will be harmed.
Regulatory Compliance
Our marketing of pharmaceutical products is subject to extensive and complex laws and regulations. We have a corporate compliance program designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems, and through the promotion of a culture of compliance. Among other laws, regulations and standards, we are subject to various United States federal and state laws, and comparable foreign laws pertaining to health care fraud and abuse, including anti-kickback and false claims statutes, and laws prohibiting the promotion of drugs for unapproved or off-label uses. Anti-kickback laws make it illegal for a prescription drug manufacturer to solicit, offer, receive or pay any remuneration to induce the referral of business, including the purchase or prescription of a particular drug. False claims laws prohibit anyone from presenting for payment to third-party payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. We expect to continue to devote substantial resources to maintain, administer and expand these compliance programs globally.
Reimbursement
Sales of our products depend, to a large degree, on the extent to which our products are covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the United States and ex-U.S. markets. In the United States, we continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states. Following the European Commission’s November 2015 approval of ORKAMBI in Europe, we are working to obtain government reimbursement for


29

ORKAMBI on a country-by-country basis, because in many foreign countries patients are unable to access prescription pharmaceutical products that are not reimbursed by their governments. Consistent with our experience with KALYDECO when it was first approved, we expect reimbursement discussions in ex-U.S. markets may take a significant period of time.


30

RESULTS OF OPERATIONS
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
Revenues
$
398,080

 
$
138,509

 
$
259,571

 
187
 %
Operating costs and expenses
412,410

 
310,494

 
101,916

 
33
 %
Other items, net
(27,301
)
 
(26,621
)
 
(680
)
 
(3
)%
Net loss attributable to Vertex
$
(41,631
)
 
$
(198,606
)
 
$
(156,975
)
 
(79
)%
Net Loss Attributable to Vertex
Net loss attributable to Vertex was $41.6 million in the first quarter of 2016 compared to a net loss attributable to Vertex of $198.6 million in the first quarter of 2015. Our revenues increased significantly in the first quarter of 2016 as compared to the first quarter of 2015 due to net product revenues from ORKAMBI, which was approved by the FDA in July 2015, and increased KALYDECO net product revenues. Our operating costs and expenses increased in the first quarter of 2016 as compared to the first quarter of 2015 primarily due to increases in research and development expenses, sales, general and administrative expenses and cost of product revenues. In the near term, we expect net loss (income) attributable to Vertex will be dependent on expected increases in ORKAMBI net product revenues.
Diluted Net Loss Per Share Attributable to Vertex Common Shareholders
Diluted net loss per share attributable to Vertex common shareholders was $0.17 in the first quarter of 2016 as compared to a diluted net loss per share attributable to Vertex common shareholders of $0.83 in the first quarter of 2015.
Revenues
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
Product revenues, net
$
394,410

 
$
130,875

 
$
263,535

 
201
 %
Royalty revenues
3,596

 
6,792

 
(3,196
)
 
(47
)%
Collaborative revenues
74

 
842

 
(768
)
 
(91
)%
Total revenues
$
398,080

 
$
138,509

 
$
259,571

 
187
 %
Product Revenues, Net
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
ORKAMBI
$
223,128

 
$
—

 
N/A

 
N/A

KALYDECO
170,509

 
130,174

 
40,335

 
31
%
INCIVEK
773

 
701

 
72

 
10
%
Total product revenues, net
$
394,410

 
$
130,875

 
$
263,535

 
201
%
Our total net product revenues increased in the first quarter of 2016 as compared to the first quarter of 2015 due to net product revenues from ORKAMBI, which was approved by the FDA in July 2015, and increased KALYDECO net product revenues.
We believe that the level of our ORKAMBI revenues for the remainder of 2016 will be dependent on:
•the number of additional patients who begin treatment with ORKAMBI;
•the rate at which additional patients initiate treatment;
•the proportion of initiated patients who remain on treatment; and
•the compliance rate for patients who remain on treatment.


31

In the first quarter of 2016, revenues from additional patients who began treatment with ORKAMBI in the United States were largely offset by discontinuations by patients who had previously initiated treatment with ORKAMBI. We expect ORKAMBI net product revenues to increase during the remainder of 2016 as compared to the first quarter of 2016. Initially, we expect that our ex-U.S. ORKAMBI net product revenues will be primarily from Germany due to the time it will take to complete the reimbursement discussions in other European countries. In the first quarter of 2016, we recognized approximately $8.8 million in ex-U.S. revenues, which were mainly from Germany.
KALYDECO net product revenues were $170.5 million in the first quarter of 2016, including $75.6 million of net product revenues from ex-U.S. markets. The increase in KALYDECO net product revenues in the first quarter of 2016, as compared to the first quarter of 2015, was primarily due to additional patients being treated with KALYDECO as we completed reimbursement discussions in various jurisdictions and increased the number of patients eligible to receive KALYDECO through multiple label expansions.
We have withdrawn INCIVEK from the market in the United States. We may continue to recognize small incremental INCIVEK revenues over the next several quarters as we adjust our INCIVEK reserves for rebates, chargebacks and discounts.
Royalty Revenues
Our royalty revenues were $3.6 million in the first quarter of 2016 as compared to $6.8 million in the first quarter of 2015. Our royalty revenues consist of (i) revenues related to a cash payment we received in 2008 when we sold our rights to certain HIV royalties and (ii) revenues related to certain third-party royalties payable by our collaborators on sales of HIV and HCV drugs that also result in corresponding royalty expenses.
Collaborative Revenues
Our collaborative revenues were $0.1 million in the first quarter of 2016 as compared to $0.8 million in the first quarter of 2015. Our collaborative revenues have historically fluctuated significantly from one period to another and may continue to fluctuate in the future.
Operating Costs and Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
Cost of product revenues
$
49,789

 
$
9,381

 
$
40,408

 
431
 %
Royalty expenses
860

 
2,926

 
(2,066
)
 
(71
)%
Research and development expenses
255,860

 
215,599

 
40,261

 
19
 %
Sales, general and administrative expenses
105,214

 
85,860

 
19,354

 
23
 %
Restructuring expenses (income), net
687

 
(3,272
)
 
N/A

 
N/A

Total costs and expenses
$
412,410

 
$
310,494

 
$
101,916

 
33
 %
Cost of Product Revenues
Our cost of product revenues includes the cost of producing inventories that correspond to product revenues for the reporting period, plus the third-party royalties payable on our net sales of our products. Pursuant to our agreement with Cystic Fibrosis Foundation Therapeutics Incorporated, or CFFT, our tiered third-party royalties on sales of KALYDECO and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens. Our cost of product revenues increased in the first quarter of 2016 as compared to the first quarter of 2015 due to increased net product revenues as well as the second and final $13.9 million commercial milestone that was earned by CFFT in the first quarter of 2016 related to sales of ORKAMBI. In future periods, our cost of product revenues will not be affected by commercial milestones on ORKAMBI, with our cost of product revenues generally tracking our net product revenues.
Royalty Expenses
Royalty expenses include third-party royalties payable upon net sales of telaprevir by our collaborators in their territories and expenses related to a subroyalty payable to a third party on net sales of an HIV protease inhibitor sold by GlaxoSmithKline. Royalty expenses do not include royalties we pay to CFFT on sales of KALYDECO and ORKAMBI, which instead are included in cost of product revenues. Royalty expenses in the first quarter of 2016 decreased by $2.1 million, or 71%, as compared to the first quarter of 2015, primarily as a result of decreased INCIVO (telaprevir) sales by our collaborator Janssen NV.


32

Research and Development Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
Research expenses
$
63,010

 
$
65,562

 
$
(2,552
)
 
(4
)%
Development expenses
192,850

 
150,037

 
42,813

 
29
 %
Total research and development expenses
$
255,860

 
$
215,599

 
$
40,261

 
19
 %
Our research and development expenses include internal and external costs incurred for research and development of our drugs and drug candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual drugs or drug candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. These internal costs are significantly greater than our external costs, such as the costs of services provided to us by clinical research organizations and other outsourced research, which we allocate by individual program. All research and development costs for our drugs and drug candidates are expensed as incurred.
Since January 1, 2013, we have incurred $3.0 billion in research and development expenses associated with drug discovery and development. The successful development of our drug candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the drug candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available.
In 2015 and the three months ended March 31, 2016, costs related to our CF programs represented the largest portion of our development costs. Any estimates regarding development and regulatory timelines for our drug candidates are highly subjective and subject to change. We cannot make a meaningful estimate when, if ever, our clinical development programs will generate revenues and cash flows.
Research Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
Research Expenses:
 
 
 
 
 
 
 
Salary and benefits
$
20,710

 
$
20,456

 
$
254

 
1
 %
Stock-based compensation expense
10,656

 
13,776

 
(3,120
)
 
(23
)%
Laboratory supplies and other direct expenses
9,874

 
9,168

 
706

 
8
 %
Outsourced services
4,161

 
4,558

 
(397
)
 
(9
)%
Infrastructure costs
17,609

 
17,604

 
5

 
—
 %
Total research expenses
$
63,010

 
$
65,562

 
$
(2,552
)
 
(4
)%
We maintain a substantial investment in research activities. Our research expenses decreased by 4% in the first quarter of 2016 as compared to the first quarter of 2015. We expect to continue to invest in our research programs with a focus on identifying drug candidates with the goal of creating transformative medicines.


33

Development Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
Development Expenses:
 
 
 
 
 
 
 
Salary and benefits
$
44,351

 
$
42,195

 
$
2,156

 
5
 %
Stock-based compensation expense
23,792

 
24,441

 
(649
)
 
(3
)%
Laboratory supplies and other direct expenses
8,250

 
6,944

 
1,306

 
19
 %
Outsourced services
84,488

 
50,094

 
34,394

 
69
 %
Drug supply costs
2,653

 
1,583

 
1,070

 
68
 %
Infrastructure costs
29,316

 
24,780

 
4,536

 
18
 %
Total development expenses
$
192,850

 
$
150,037

 
$
42,813

 
29
 %
Our development expenses increased by $42.8 million or 29% in the first quarter of 2016 as compared to the first quarter of 2015, primarily due to an increase in outsourced services related to ongoing clinical trials, including our Phase 3 development program for VX-661 in combination with ivacaftor, and an increase in infrastructure costs.
Sales, General and Administrative Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2016
 
2015
 
$
 
%
 
(in thousands)
 
 
Sales, general and administrative expenses
$
105,214

 
$
85,860

 
$
19,354

 
23
%
Sales, general and administrative expenses increased by 23% in the first quarter of 2016 as compared to the first quarter of 2015, primarily due to increased investment in commercial support for ORKAMBI in ex-U.S. markets. We expect sales, general and administrative expenses during the remainder of 2016 will be similar to our sales, general and administrative expenses in the first quarter of 2016.
Restructuring Expense, Net
We recorded restructuring expenses of $0.7 million in the first quarter of 2016 as compared to restructuring credits of $3.3 million in the first quarter of 2015. Our restructuring credits in the the first quarter of 2015 were primarily related to the early termination of two leases in Cambridge, Massachusetts in connection with the relocation of our corporate headquarters to Boston, Massachusetts for which we had accrued a restructuring liability in excess of the termination fee we ultimately paid. Our restructuring expenses in the the first quarter of 2016 primarily relates to adjustments to our restructuring liability in connection with this relocation.
Other Items
Interest Expense, Net
Interest expense, net was $20.7 million in the first quarter of 2016 as compared to $21.3 million in the first quarter of 2015. During the remainder of 2016, we expect to incur approximately $45 million of interest expense associated with the leases for our corporate headquarters and approximately $13 million of interest expense related to our credit agreement.
Other Income (Expense), Net
Other income (expense), net was $4.4 million in the first quarter of 2016 as compared to an expense of $5.1 million in the first quarter of 2015. Other income (expense), net in each of the first quarter of 2016 and the first quarter of 2015 was primarily due to foreign exchange gains and losses, respectively.
Income Taxes
We recorded a provision for income taxes of $5.5 million in the first quarter of 2016 as compared to $0.3 million in the first quarter of 2015. The provision for income taxes in the first quarter of 2016 was due to income tax on our VIEs, as well as state and foreign tax in various jurisdictions.


34


LIQUIDITY AND CAPITAL RESOURCES
As of March 31, 2016, we had cash, cash equivalents and marketable securities of $1.03 billion, which represented a decrease of $17 million from $1.04 billion as of December 31, 2015. In the first quarter of 2016, we largely maintained our cash, cash equivalents and marketable securities balance due to increased cash receipts in the first quarter of 2016 from product sales, offset by increased cash expenditures in the first quarter of 2016 related to, among other things, research and development expenses and sales, general and administrative expenses.
Our future cash flows will be substantially dependent on product sales of KALYDECO and ORKAMBI.
Sources of Liquidity
We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity. We are receiving cash flows from sales of ORKAMBI and KALYDECO from the United States and ex-U.S. markets. We expect ORKAMBI net product revenues to continue to increase during the remainder of 2016. Initially, we expect that our ex-U.S. ORKAMBI net product revenues will be primarily from Germany due to the time it will take to complete the reimbursement discussions in other European countries.
We borrowed $300.0 million under a credit agreement that we entered into in July 2014 and, subject to certain conditions, we may request up to an additional $200.0 million pursuant to that credit agreement. In recent periods, we also have received significant proceeds from the issuance of common stock under our employee benefit plans, but the amount and timing of future proceeds from employee benefits plans is uncertain. Other possible sources of liquidity include strategic collaborative agreements that include research and/or development funding, commercial debt, public and private offerings of our equity and debt securities, development milestones and royalties on sales of products, software and equipment leases, strategic sales of assets or businesses and financial transactions. Negative covenants in our credit agreement may prohibit or limit our ability to access these sources of liquidity.
Future Capital Requirements
We incur substantial operating expenses to conduct research and development activities and to operate our organization. Under the terms of our credit agreement, we are required to repay the principal amount on the $300.0 million we borrowed in July 2014 in installments of $75 million on each of October 1, 2016, January 1, 2017, April 1, 2017 and July 9, 2017. We also have substantial facility and capital lease obligations, including leases for two buildings in Boston, Massachusetts that continue through 2028. In addition, we have entered into certain collaboration agreements with third parties that include the funding of certain research, development and commercialization efforts with the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets.
We expect that cash flows from KALYDECO and ORKAMBI, together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by KALYDECO and ORKAMBI and the potential introduction of one or more of our other drug candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.
Financing Strategy
In July 2014, we borrowed $300.0 million pursuant to a credit agreement. In addition, subject to certain conditions, we may request that the lenders loan us up to an additional $200.0 million under the credit agreement. We may raise additional capital through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
CONTRACTUAL COMMITMENTS AND OBLIGATIONS
Our commitments and obligations were reported in our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission, or SEC, on February 16, 2016. There have been no material changes from the contractual commitments and obligations previously disclosed in that Annual Report on Form 10-K.


35

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the three months ended March 31, 2016, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the SEC on February 16, 2016.
RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2015 Annual Report on Form 10-K. There were no new accounting pronouncements adopted during the three months ended March 31, 2016 that had a material effect on our financial statements.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes.
Interest Rate Risk
As of March 31, 2016, we invest our cash in a variety of financial instruments, principally money market funds, short-term government-sponsored enterprise securities, U.S. Treasury securities, investment-grade corporate bonds and commercial paper. These investments are denominated in U.S. dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative nature of these instruments, we do not believe that we have a material exposure to interest rate risk.
Foreign Exchange Market Risk
As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Euro, Swiss Franc, British Pound, Australian Dollar and Canadian Dollar against the U.S. dollar. The current exposures arise primarily from cash, accounts receivable, intercompany receivables, payables and inventories. Both positive and negative affects to our net revenues from international product sales from movements in foreign currency exchange rates are partially mitigated by the natural, opposite affect that foreign currency exchange rates have on our international operating costs and expenses.
We maintain a foreign currency management program with the objective of reducing the impact of exchange rate fluctuations on our operating results and forecasted revenues and expenses denominated in foreign currencies.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our chief executive officer and chief financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the


36


end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, as of March 31, 2016 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended March 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting other than the implementation of a new equity administrative and accounting system, together with related adjustments to our systems controls, in the first quarter of 2016.
PART II. Other Information
Item 1.     Legal Proceedings
Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al.
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming us and certain of our current and former officers and directors as defendants. The lawsuit alleged that we made material misrepresentations and/or omissions of material fact in our disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased our common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of our stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. We filed a motion to dismiss the complaint on December 8, 2014 and the plaintiffs filed their opposition to our motion to dismiss on January 22, 2015. On February 23, 2015, we filed a reply to the plaintiffs’ opposition to our motion to dismiss.  The court heard oral argument on our motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted our motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The First Circuit Court of Appeals issued a scheduling order on December 24, 2015. On February 2, 2016, the Plaintiff filed their opening brief and we filed our opposition brief on March 7, 2016. On March 24, 2016, the plaintiff filed their reply brief. We believe the claims to be without merit and intend to vigorously defend the litigation.
DOJ Subpoena
In the third quarter of 2015, we received a subpoena from the United States Department of Justice related to our marketed medicines. This subpoena requests documents relating primarily to our Good Laboratory Practices in a bioanalytical laboratory. We are in the process of responding to the subpoena and intend to continue to cooperate.
Item 1A. Risk Factors
Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the SEC on February 16, 2016. There have been no material changes from the risk factors previously disclosed in that Annual Report on Form 10-K.



37

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I-Item 2, contain or incorporate a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding:
•
our expectations regarding the amount of, timing of and trends with respect to our revenues, costs and expenses and other gains and losses, including those related to net product revenues from KALYDECO and ORKAMBI;
•
our expectations regarding clinical trials, development timelines and regulatory authority filings and submissions for ivacaftor, lumacaftor, VX-661, VX-371 (formerly P-1037), VX-152, VX-440, VX-970, VX-803, VX-984, VX-150, VX-241 and VX-210, as well as the sNDA for ORKAMBI for the treatment of patients with CF six to eleven years of age who are homozygous for the F508del mutation in their CFTR gene;
•
our expectations regarding planned clinical trials for next-generation correctors based upon pre-clinical data;
•
our ability to successfully market KALYDECO and ORKAMBI or any of our other drug candidates for which we obtain regulatory approval;
•
our expectations regarding the timing and structure of clinical trials of our drugs and drug candidates, including ivacaftor, lumacaftor, VX-661, VX-371 (formerly P-1037), VX-152, VX-440, VX-970, VX-803, VX-984, VX-150, VX-241 and VX-210, and the expected timing of our receipt of data from our ongoing and planned clinical trial;
•
the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•
our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our drug candidates for further investigation, clinical trials or potential use as a treatment;
•
our plan to continue investing in our research and development programs and our strategy to develop our drug candidates, alone or with third party-collaborators;
•
the establishment, development and maintenance of collaborative relationships;
•
potential business development activities;
•
potential fluctuations in foreign currency exchange rates;
•
our ability to use our research programs to identify and develop new drug candidates to address serious diseases and significant unmet medical needs; and
•
our liquidity and our expectations regarding the possibility of raising additional capital.
Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results. We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the SEC on February 16, 2016. These are factors and uncertainties that we think could cause our actual results to differ materially from expected results. Other factors and uncertainties besides those listed there could also adversely affect us.
Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “intends,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these


38

forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
The table set forth below shows all repurchases of securities by us during the three months ended March 31, 2016:
Period
 
Total Number
of Shares Purchased
Average Price
Paid per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares that May Yet
be Purchased Under
the Plans or Programs
January 1, 2016 to January 31, 2016
13,645
$0.01
—
—
February 1, 2016 to February 29, 2016
9,930
$0.01
—
—
March 1, 2016 to March 31, 2016
66,312
$0.01
—
—
The repurchases were made under the terms of our Amended and Restated 2006 Stock and Option Plan and our Amended and Restated 2013 Stock and Option Plan. Under these plans, we award shares of restricted stock to our employees that typically are subject to a lapsing right of repurchase by us. We may exercise this right of repurchase if a restricted stock recipient’s service to us is terminated. If we exercise this right, we are required to repay the purchase price paid by or on behalf of the recipient for the repurchased restricted shares, which typically is the par value per share of $0.01. Repurchased shares are returned and are available for future awards under the terms of our Amended and Restated 2013 Stock and Option Plan.
Item 6.    Exhibits
Exhibit Number
Exhibit Description
3.1
Amended and Restated By-Laws of Vertex Pharmaceuticals Incorporated, as subsequently amended on April 26, 2016.
31.1
Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of the Chief Executive Officer and the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
XBRL Instance
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation
101.LAB
XBRL Taxonomy Extension Labels
101.PRE
XBRL Taxonomy Extension Presentation
101.DEF
XBRL Taxonomy Extension Definition




39

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Vertex Pharmaceuticals Incorporated
 
 
 
May 3, 2016
By:
/s/ Ian F. Smith
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer
(principal financial officer and
duly authorized officer)



40
 EX-3.1 2 a2016q110-q_exhibit31.htm EXHIBIT 3.1 Exhibit


Exhibit 3.1

AMENDED AND RESTATED
BY-LAWS
of
VERTEX PHARMACEUTICALS INCORPORATED

ARTICLE I

STOCKHOLDERS

Section 1. Annual Meeting. The annual meeting of the stockholders shall be held on the second Monday of May in each year, or on such other date within six months after the end of the fiscal year of the Corporation as the Board of Directors shall fix, at such time as shall be fixed by the Board of Directors in the call of the meeting. Purposes for which an annual meeting is to be held, in addition to those prescribed by law, by the Articles of Organization, or by these By-Laws, may be specified by the Board of Directors in the notice of the meeting.

Section 2. Special Meeting in Lieu of Annual Meeting. If no annual meeting has been held in accordance with the foregoing provisions, a special meeting of the stockholders may be held in lieu thereof. Any action taken at such special meeting shall have the same force and effect as if taken at the annual meeting, and in such case all references in these By-Laws to the annual meeting of the stockholders shall be deemed to refer to such special meeting. Any such special meeting shall be called as provided in Section 3 of this Article 1.

Section 3. Special Meetings. A special meeting of the stockholders may be called at any time by the Chairman of the Board, the President, or by the Board of Directors. A special meeting of the stockholders shall also be called by the Clerk (or, in the case of the death, absence, incapacity, or refusal of the Clerk, by any other officer) upon written application of one or more stockholders who hold at least forty percent in interest of the capital stock entitled to vote at the meeting. Each call of a meeting shall state the place, date, hour, and purposes of the meeting.

Section 4. Place of the Meetings. All meetings of the stockholders shall be held at such place, either within or without The Commonwealth of Massachusetts, within the United States as shall be fixed by the Board of Directors in the notice of the meeting. Any adjourned session of any meeting of the stockholders shall be held within the United States at the place designated in the vote of adjournment.

Section 5. Notice of Meeting. A written notice of each meeting of stockholders, stating the place, date, hour and purposes of the meeting, shall be given at least seven days before the meeting to each stockholder entitled to vote thereat and to each stockholder who, by law, by the Articles of Organization, or by these By-Laws, is entitled to notice. Such notice shall be given by the Clerk or an Assistant Clerk or by an officer designated by the Board of Directors. Whenever notice of a meeting is required to be given to a stockholder under any provision of the Business Corporation Law of the Commonwealth of Massachusetts or of the Articles of Organization or these By-Laws, a written waiver thereof, executed before or after the meeting by such stockholder or his attorney thereunto authorized and filed with the records of the meeting, shall be deemed equivalent to such notice.





Section 6. Quorum of Stockholders. At any meeting of the stockholders, a quorum shall consist of a majority in interest of all stock issued and outstanding and entitled to vote at the meeting, except when a larger quorum is required by law, by the Articles of Organization, or by these By-Laws. Stock owned directly or indirectly by the Corporation, if any, shall not be deemed outstanding for this purpose.

Section 7. Adjournment of Meetings. Any meeting of the stockholders may be adjourned (a) prior to the time the meeting has been convened, by the Board of Directors, or (b) after the meeting has been convened, by a majority of the votes properly cast upon the question, whether or not a quorum is present at the meeting, and the meeting may be held as adjourned without further notice.

Section 8. Action by Vote. When a quorum is present at any meeting, (a) upon any question other than an election of a director, a majority of the votes properly cast shall decide the question, except when a larger vote is required by law, by the Articles of Organization, or by these By-Laws, (b) in an uncontested election, votes properly cast in favor of election of a director exceeding the votes properly withheld in such election shall effect the election of a director, and (c) in a contested election, a plurality of the votes properly cast for election shall effect the election of a director. An election of directors shall be considered contested if, as of the record date for the applicable meeting, there are more nominees for election than positions on the board of directors to be filled by election at the meeting. All other elections of directors shall be considered uncontested.

Section 9. Voting. Stockholders entitled to vote shall have one vote for each share of stock held by them of record according to the records of the Corporation, unless otherwise provided by the Articles of Organization. No ballot shall be required for any vote for election to any office unless requested by a stockholder present or represented at the meeting and entitled to vote in such election. The Corporation shall not, directly or indirectly, vote any share of its own stock.

Section 10. Proxies. To the extent permitted by law, stockholders entitled to vote may vote either in person or by written proxy. Unless otherwise specified or limited by their terms, such proxies shall entitle the holders thereof to vote at any adjournment of such meeting but shall not be valid after the final adjournment of such meeting.

Section 11. Action by Consent. Any action required or permitted to be taken at any meeting of the stockholders may be taken without a meeting, but only if all stockholders entitled to vote on the matter consent to the action in writing and the written consents are filed with the records of meetings of stockholders. Such consents shall be treated for all purposes as a vote taken at a meeting.


ARTICLE II

BOARD OF DIRECTORS

Section 1. Number, Elections and Terms. Subject to the rights of the holders of Preferred Stock to elect one or more additional directors under specified circumstances as provided in Article 4 of the Articles of Organization, the Board of Directors shall consist of not less than three nor more than eleven persons, the exact number to be fixed from time to time by the Board of Directors pursuant to a resolution adopted by a majority vote of the directors then in office. The Board of Directions shall be classified with respect to the time for which they shall severally hold office




by dividing them into three classes, as nearly equal in number as possible, with the term of office of one class expiring at the annual meeting of stockholders each year. At each annual meeting of the stockholders of the Corporation, the successors to the class of directors whose terms expire at that meeting shall be elected to hold office for terms expiring at the annual meeting of stockholders held in the third year following the year of their election. If the number of directors is changed, any increase or decrease shall be apportioned by the Board of Directors among the classes so as to maintain the number of directors in each class as nearly equal as possible. Each director shall hold office until the annual meeting for the year in which such director's term expires and until such director's successor shall be elected and shall qualify. No director need be a stockholder.

Section 2. Nomination. Nominations for the election of directors may be made by the Board of Directors or a committee appointed by the Board of Directors or by any stockholder entitled to vote in the election of directors generally. However, any stockholder entitled to vote in the election of directors generally may nominate one of more persons for election as directors at a meeting only if written notice of such stockholder's intent to make such nomination or nominations has been given, either by personal delivery or by mailing it, postage prepaid, to the Clerk of the Corporation not later than (a) with respect to an election to be held at an annual meeting of stockholders, ninety (90) days prior to the anniversary date of the immediately preceding annual meeting, and (b) with respect to an election to be held at a special meeting of stockholders for the election of directors, the close of business on the tenth day following the date on which notice of such meeting is first given to stockholders. Each such notice shall set forth (i) the name and address of the stockholder who intends to make the nomination and of the person or persons to be nominated; (ii) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice; (iii) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be made by the stockholder; (iv) such other information regarding each nominee proposed by such stockholder as would be required to be included in a proxy statement filed pursuant to the proxy rules of the Securities and Exchange Commission; and (v) the consent of each nominee to serve as a director of the Corporation if so elected. The presiding officer of the meeting may refuse to acknowledge the nomination of any person not made in compliance with the foregoing procedure.

Section 3. Newly Created Directorships and Vacancies. Newly created directorships resulting from any increase in the number of directors and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal, or other cause shall be filled only by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board of Directors. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the class of directors in which the new directorship was created or the vacancy occurred and until such director's successor shall have been elected and qualified. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

Section 4. Removal of Directors. Any director may be removed from office by stockholder vote at any time, but only for cause, by the affirmative vote of the holders of at least a majority of the voting power of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class. Any director may also be removed from office for cause by vote of a majority of the directors then in office.

Section 5. Directors Elected by Holders of Preferred Stock. Whenever the holders of any class or series or Preferred Stock or of any other class or series of shares issued by the Corporation shall have the right, voting separately as a




class or series, to elect one or more directors under specified circumstances, the election, term of office, filling of vacancies, and other features of such directorships shall be governed by the terms of the Articles of Organization applicable thereto, and none of the provisions of Sections 1 to 4 of this Article II shall apply with respect to directors so elected.

Section 6. Resignations. Any director, member of a committee, or officer may resign at any time by delivering his resignation in writing to the Chairman of the Board, the President, the Clerk, or to a meeting of the Board of Directors. Such resignation shall be effective upon receipt unless specified to be effective at some other time.

Section 7. Powers. Except as reserved to the stockholders by law, by the Articles of Organization, or by these By-Laws, the business of the Corporation shall be managed by the Board of Directors who shall have and may exercise all the powers of the Corporation.

Section 8. [Intentionally Omitted]

Section 9. Other Committees. The Board of Directors may, by vote of a majority of the directors then in office, elect from their number other committees and may delegate to any such committee or committees some or all of the powers of the Board of Directors except those powers which by law, by the Articles of Organization, or by these By-Laws they are prohibited from delegating. Except as the Board of Directors may otherwise determine, each committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or such rules, its business shall be conducted as nearly as may be in the same manner as is provided by these By-Laws for the conduct of business by the Board of Directors. The Board of Directors shall have the power to rescind any vote, resolution, or other action of any committee, provided that the rights of third parties shall not be impaired by such rescission.

Section 10. Regular Meetings. A regular meeting of the Board of Directors shall be held without call or notice immediately after and at the same place as the annual meeting of the stockholders. Other regular meetings of the Board of Directors may be held without call or notice at such places and at such times as the Board of Directors may, from time to time, determine, provided that notice of the first regular meeting following any such determination shall be given to absent directors.

Section 11. Special Meetings. Special meetings of the Board of Directors may be held at any time and at any place designated in the call of the meeting, when called by the Chairman of the Board, the President, or by two or more directors.

Section 12. Notice of the Meetings. It shall be sufficient notice to a director of a meeting of the Board of Directors (i) to send notice by mail at least forty-eight (48) hours before the meeting, addressed to such directors at his usual or last known business or residence address, (ii) to send notice by electronic mail (to the electronic mail address designated by such director) at least twenty-four (24) hours before the meeting, or (iii) to give notice to such director in person or by telephone at least twenty-four (24) hours before the meeting. A director may waive any notice before or after the date and time of the meeting. The waiver shall be in writing, signed by the director entitled to the notice, or in the form of an electronic transmission by the director to a representative of the Corporation, and filed with the minutes or corporate records. A director's attendance at or participation in a meeting waives any required notice to him or her of the meeting unless the director at the beginning of the meeting, or promptly upon his or her arrival, objects to holding




the meeting or transacting business at the meeting and does not thereafter vote for or assent to action taken at the meeting. Neither notice of a meeting nor a waiver of a notice need specify the purposes of the meeting.

Section 13. Quorum of Directors. At any meeting of the Board of Directors, a majority of the directors then in office shall constitute a quorum. Any meeting may be adjourned from time to time by a majority of the votes cast upon the question, whether or not a quorum is present, and the meeting may be held as adjourned without further notice.

Section 14. Action by Vote. When a quorum is present at any meeting, a majority of the directors present may take any action, except when a larger vote is required by law, by the Articles of Organization, or by these By-Laws.

Section 15. Action by Written Consent. Unless the Articles of Organization otherwise provide, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all the directors or members of the committee as the case may be, consent to the action. The action must be evidenced by one or more consents describing the action taken, in writing, signed by each director or delivered to the Corporation by electronic transmission, and included in the minutes or filed with the corporate records reflecting the action taken. Such consents shall be treated for all purposes as a vote taken at a meeting.

Section 16. Participation Through Communications Equipment. Unless otherwise provided by law or the Articles of Organization, members of the Board of Directors or of any committee thereof may participate in a meeting of such Board or committee, as the case may be, through conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other at the same time, and participation by such means shall constitute presence in person at a meeting.

Section 17. Compensation of Directors. The Board of Directors may provide for the payment to any of the directors, other than officers or employees of the Corporation, of a specified amount for services as a director or member of a committee of the Board, or of a specified amount for attendance at each regular or special Board or committee meeting or of both, and all directors shall be reimbursed for expenses of attendance at any such meeting; provided, however, that nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity and receiving compensation therefor.


ARTICLE III

OFFICERS AND AGENTS

Section 1. Enumeration; Qualification. The officers of the Corporation shall be a President, a Treasurer, a Secretary, who may also be referred to in these By-Laws as the Clerk, and such other officers, including, without limitation, a Chairman of the Board, one or more Vice Presidents, Assistant Treasurers, and Assistant Clerks as the Board of Directors from time to time may in their discretion elect or appoint. In addition, the Corporation shall have such other agents as may be appointed by management in accordance with these By-Laws. The Chairman of the Board shall be a director. The President need not be a director. Any two or more offices may be held by the same person.





Section 2. Powers. Subject to law, to the Articles of Organization, and to the other provisions of these By-Laws, each officer shall have, in addition to the duties and powers herein set forth, such duties and powers as are commonly incident to his office and such duties and powers as the Board of Directors may from time to time designate.

Section 3. Election. The Chairman of the Board, if any, the President, the Treasurer, and the Clerk shall be elected annually by the Board of Directors at their first meeting following the annual meeting of the stockholders. Other officers, if any, may be elected or appointed by the Board of Directors at said meeting or at any other time.

Section 4. Tenure. Except as otherwise provided by law, by the Articles of Organization, or by these By-Laws, the Chairman of the Board, if any, the President, the Treasurer, and the Clerk shall hold office until the first meeting of the Board of Directors following the next annual meeting of the stockholders and until their respective successors are chosen and qualified, and each other officer shall hold office for such term as may be designated in the vote electing or appointing him, or in each case until such officer sooner dies, resigns, is removed, or becomes disqualified.

Section 5. Chief Executive Officer. The Chief Executive Officer of the Corporation shall be the Chairman of the Board, the President, or such other officer as may from time to time be designated by the Board of Directors. If no such designation is made, the President shall be the Chief Executive Officer. The Chief Executive Officer shall, subject to the control of the Board of Directors, have general charge and supervision of the business of the Corporation and, except as the Board of Directors shall otherwise determine, shall preside at all meetings of the stockholders and of the Executive Committee. Unless otherwise determined by the Board of Directors, the Chief Executive Officer shall have the authority to appoint such agents, in addition to those officers enumerated in Section 2 of this Article III as being elected or appointed by the Board of Directors, as he shall deem appropriate and to define their respective duties and powers.

Section 6. Chairman of the Board. If a Chairman of the Board of Directors is elected, he shall preside at all meetings of the Board of Directors and shall have the duties and powers specified in these By-Laws and such other duties and powers as may be determined by the Board of Directors.

Section 7. President and Vice Presidents. The President shall have the duties and powers specified in these By-Laws and shall have such other duties and powers as may be determined by the Board of Directors.

The Vice Presidents shall have such duties and powers as shall be designated from time to time by the Board of Directors. Unless the Board of Directors otherwise determines, one Vice President shall be designated as the Chief Financial officer of the Corporation and, as such, shall be the chief financial and accounting officer of the Corporation and shall have the duties and powers commonly incident thereto.

Section 8. Treasurer and Assistant Treasurers. The Treasurer shall have general responsibility for the corporate treasury function, shall be in charge of its funds and valuable papers, books of account, and accounting records, and shall have such other duties and powers as may be designated from time to time by the Board of Directors.

Any Assistant Treasurer shall have such duties and powers as shall be designated from time to time by the Board of Directors or the Treasurer.





Section 9. Clerk and Assistant Clerks. The Clerk shall record all proceedings of the stockholders and Board of Directors in a book or series of books to be kept for that purpose, which book or books shall be kept as the principal office of the Corporation and shall be open at all reasonable times to the inspection of any stockholder. In the absence of the Clerk from any meeting of the stockholders or Board of Directors, an Assistant Clerk, or if there be none or he is absent, a temporary clerk chosen at the meeting, shall record the proceedings thereof in the aforesaid book.

Any Assistant Clerks shall have such other duties and powers as shall be designated from time by the Board of Directors or the Clerk.


ARTICLE IV

CAPITAL STOCK

Section 1. Stock Certificates. The Board of Directors may authorize the issue without certificates of some or all of the shares of any or all of the Corporation’s classes or series of stock.  Except to the extent the Board of Directors has determined to issue shares without certificates, a stockholder shall be entitled to a certificate stating the number and the class and the designation of the series, if any, of the shares held by him, in such form as shall, in conformity to law, be prescribed from time to time by the Board of Directors. Such certificate shall be signed by the President or a Vice President and by the Treasurer or an Assistant Treasurer. Such signatures may be facsimile if the certificate is signed by a transfer agent, or by a registrar, other than a director, officer, or employee of the Corporation. In case any officer who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer at the time of its issue.

Every certificate for shares of stock which are subject to any restriction on transfer pursuant to the Articles of Organization, these By-Laws, or any agreement to which the Corporation is a party shall have the existence of the restriction noted conspicuously on the certificate and shall also set forth on the face or back either a summary of the restriction or a statement of the existence of such restriction and a statement that the Corporation will, upon written request, furnish a copy thereof to the holder of such certificate without charge.

Every certificate issued when the Corporation is authorized to issue more that one class or series of stock shall set forth on its face or back either a summary of the preferences, voting powers, qualifications, and special and relative rights of the shares of each class and series authorized to be issued or a statement of the existence of such preferences, powers, qualifications, and rights and a statement that the Corporation will, upon written request, furnish a copy thereof to the holder of such certificate without charge.

Section 2. Lost Certificates. In the case of the alleged loss, destruction, or mutilation of a certificate of stock, a duplicate certificate may be issued in place thereof, upon such conditions as the Board of Directors may prescribe. When authorizing such issue of a new certificate, the Board may in its discretion require the owner of such lost, destroyed, or mutilated certificate, or his legal representative, to give the Corporation a bond, with or without surety, sufficient in the Board's opinion to indemnify the Corporation against any loss or claim that may be made against it with request to the certificate alleged to have been lost, destroyed, or mutilated.





Section 3. Transfer of Shares. Subject to the restrictions, if any, stated or noted on the stock certificates, shares of stock may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate therefor properly endorsed or accompanied by a written assignment and power of attorney properly executed with necessary transfer stamps affixed, and with such proof of the authenticity of signature as the Board of Directors or the transfer agent of the Corporation may reasonably require. Except as may be otherwise required by law, by the Articles of Organization, or by these By-Laws, the Corporation shall be entitled to treat the record holder of stock as shown on its on its books as the owner of such stock for all purposes, including the payment of dividends and the right to receive notice and to vote with respect thereto, regardless of any transfer, pledge, or other disposition of such stock, until the shares have been transferred on the books of the stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these By-Laws.

Section 4. Record Date and Closing Transfer Books. The Board of Directors may fix in advance a time, which shall not be more than sixty (60) days before the date of any meeting of stockholders or the date for the payment of any dividend or making of any distribution to stockholders or the last day on which the consent or dissent of stockholders may be effectively expressed for any purpose, as the record date for determining the stockholders having the right to notice of and to vote at such meeting and any adjournment thereof or the right to receive such dividend or distribution or the right to give such consent or dissent, and in such case only stockholders of record on such record date shall have such right, notwithstanding any transfer of stock on the books of the Corporation after the record date; or without fixing such record date the Board of Directors may for any such purposes close the transfer books for all or any part of such period.

If no record date is fixed and the transfer books are not closed, the record date for determining stockholders having the right to notice of or to vote at a meeting of stockholders shall be at the close of business on the date next preceding the day on which notice is given, and the record date for determining stockholders for any other purpose shall be at the close of business on the date on which the Board of Directors acts with respect thereto.


ARTICLE V

INDEMNIFICATION

Section 1. Directors and Officers. The Corporation shall indemnify, and advance funds to pay for or reimburse the reasonable expenses incurred by, its directors and the officers that have been appointed by the Board of Directors (including persons who serve at its request as directors, officers, or trustees of another organization in which it has any interest, direct or indirect, as a shareholder, creditor, or otherwise or who serve at its request in any capacity with respect to any employee benefit plan) to the fullest extent permitted by law, and may indemnify, and advance funds to pay for or reimburse the reasonable expenses incurred by, such other employees and agents as are identified by the Board of Directors.

The right of indemnification hereby provided shall not be exclusive of or affect any other rights to which any director or officer may be entitled. As used in this section, the terms "director" and "officer" include their respective heirs, executors, and administrators, an "interested" director or officer is one against whom in such capacity the proceedings in question or another proceeding on the same or similar grounds is then pending or threatened, and a "disinterested" director is one against whom no such proceeding is then pending or threatened. Nothing contained in




this section shall affect any rights to indemnification to which corporate personnel other than directors and officers may be entitled by contract or otherwise under law.

The Board of Directors may authorize the purchase and maintenance of insurance, in such amounts as the Board of Directors may from time to time deem appropriate, on behalf of any person who is or was a director or officer or agent of the Corporation, or who is or was serving at the request of the Corporation as a director, officer, or agent of another organization in which it has any interest, direct or indirect, as a shareholder, creditor, or otherwise, or with respect to any employee benefit plan, against any liability incurred by him in any such capacity, or arising out of his status as such, whether or not such person is entitled to indemnification by the Corporation pursuant to this Article V or otherwise and whether or not the Corporation would have the power to indemnify him against such liability.

ARTICLE VI

MISCELLANEOUS

Section 1. Corporate Seal. The seal of the Corporation shall be in such form as the Board of Directors may from time to time determine.

Section 2. Fiscal Year. The fiscal year of the Corporation shall be such period as shall from time to time be determined by the Board of Directors.

Section 3. [Intentionally Omitted]

Section 4. Execution of Documents. Except as the Board of Directors may generally or in specific instances authorize the execution thereof in some other manner, all deeds, leases, transfers, contracts, checks, drafts, and other orders for the payment of money out of the funds of the Corporation, and all bonds, notes, debentures, guarantees, and other obligations or evidences or indebtedness of the Corporation shall be executed by the Chairman of the Board, the President, any Vice President, or the Treasurer.

Section 5. Voting of Securities. Except as the Board of Directors may generally or in specific instances direct otherwise, the Chairman of the Board, the President, any Vice President, or the Treasurer shall have the power, in the name and on behalf of the Corporation, to waive notice of, appoint any person or persons to act as proxy or attorney-in-fact of the Corporation (with or without power of substitution) to vote at, or attend and act for the Corporation at, any meeting of holders of shares or other securities of any other organization of which the Corporation holds shares or securities.

Section 6. Appointment of Auditor. The Board of Directors, or a committee thereof, shall each year select independent public accountants to report to the stockholders on the financial statements of the Corporation for such year. The selection of such accountants shall be presented to the stockholders for their approval at the annual meeting each year; provided, however, that if the shareholders shall not approve the selection made by the Board, the Board shall appoint other independent public accountants for such year.

ARTICLE VII





AMENDMENTS

Except as provided in the second paragraph of this Article VII, these By-Laws may be altered, amended, or repealed, and new By-Laws not inconsistent with any provision of the Articles of organization or applicable statute may be made either by the affirmative vote of a majority of the voting power of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, at any annual or special meeting of the stockholders called for the purpose, or (except with respect to any provision hereof which by law, the Articles of Organization, or these By-Laws requires action by the stockholders) by the affirmative vote of a majority of the Board of Directors then in office. Not later that the time of giving notice of the meeting of stockholders next following the making, amending, or repealing by the Board of Directors of any By-Law, notice thereof stating the substance of such change shall be given to all stockholders entitled to vote on amending the By-Laws. Any By-Law made, amended, or repealed by the Board of Directors may be altered, amended, repealed, or reinstated by the stockholders.

Notwithstanding anything contained in these By-Laws to the contrary, the affirmative vote of the holders of 80% of the voting power of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend, adopt any provision inconsistent with, or repeal any provision of Section 1, 2, 3, or 4 of Article II of these By-Laws or this Article VII.




AMENDMENT
TO
AMENDED AND RESTATED
BY-LAWS OF VERTEX PHARMACEUTICALS INCORPORATED

A new Article II Section 8 is hereby inserted, as follows:
Section 8.    Proxy Access for Director Nominations.
(a)Information to be Included in the Corporation’s Proxy Materials. Whenever the Board of Directors solicits proxies with respect to the election of directors at an annual meeting of stockholders (following the 2016 annual meeting of stockholders), subject to the provisions of this Section 8, the Corporation shall include in its proxy statement for such annual meeting, in addition to any persons nominated for election by the Board of Directors or a committee appointed by the Board of Directors, the name, together with the Required Information (as defined below), of any person to be nominated for election to the Board of Directors by a stockholder pursuant to Section 2 of this Article II (a “Stockholder Nominee”) if (i) the stockholder of record who intends to make the nomination qualifies as, or is acting on behalf of, an Eligible Stockholder (as defined in Section 8(c) of this Article II), (ii) the Eligible Stockholder expressly elects, in a written statement accompanying the notice required by Section 2 of this Article II (a “Nomination Notice”), to have its Stockholder Nominee included in the Corporation’s proxy materials pursuant to this Section 8 and (iii) all of the other requirements set forth in this Section 8 and in Section 2 of this Article II are satisfied. For purposes of this Section 8, the “Required Information” that the Corporation will include in its proxy statement is (A) the information provided to the Clerk of the Corporation concerning the Stockholder Nominee and the Eligible Stockholder that is required to be disclosed in the Corporation’s proxy statement pursuant to Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, and (B) if the Eligible Stockholder so elects, a Supporting Statement (as defined in Section 8(g) of this Article II). For the avoidance of doubt, nothing in this Section 8 shall limit the Corporation’s ability to solicit against any Stockholder Nominee or include in its proxy materials the Corporation’s own statements or other information relating to any Eligible Stockholder or Stockholder Nominee, including any information provided to the Corporation pursuant to this Section 8. Subject to the provisions of this Section 8, the name of any Stockholder Nominee included in the Corporation’s proxy statement for an annual meeting of stockholders shall also be set forth on the form of proxy distributed by the Corporation in connection with such annual meeting.
(b)Permitted Number of Stockholder Nominees. The maximum number of Stockholder Nominees that will be included in the Corporation’s proxy materials with respect to an annual meeting of stockholders shall not exceed the greater of (i) two or (ii) 20% of the number of directors in office as of the last day on which a Nomination Notice may be delivered pursuant to Section 2 of this Article II (the “Final Proxy Access Date”) or, if such amount is not a whole number, the closest whole number below 20% (such greater number, as it may be adjusted pursuant to this Section 8(b)), the “Permitted Number”). In the event that one or more vacancies for any reason occurs on the Board of Directors after the Final




Proxy Access Date but before the date of the annual meeting and the Board of Directors resolves to reduce the size of the Board of Directors in connection therewith, the Permitted Number shall be calculated based on the number of directors in office as so reduced. In addition, the Permitted Number shall be reduced by (i) the number of individuals who will be included in the Corporation’s proxy materials as nominees recommended by the Board of Directors pursuant to an agreement, arrangement or other understanding with a stockholder or group of stockholders (other than any such agreement, arrangement or understanding entered into in connection with an acquisition of stock from the Corporation by such stockholder or group of stockholders), together with the number of directors in office as of the Final Proxy Access Date who were either elected by the Board of Directors to fill a vacancy pursuant to such an agreement, arrangement or other understanding, or included in the Corporation’s proxy materials as nominees recommended by the Board of Directors pursuant to such an agreement, arrangement or other understanding for any of the two preceding annual meetings of stockholders, and whose remaining terms extend beyond the upcoming annual meeting, and (ii) the number of directors in office as of the Final Proxy Access Date who were included in the Corporation’s proxy materials as Stockholder Nominees for any of the two preceding annual meetings of stockholders (including any persons counted as Stockholder Nominees pursuant to the immediately succeeding sentence) and whose remaining terms extend beyond the upcoming annual meeting. For purposes of determining when the Permitted Number has been reached, any individual requested by an Eligible Stockholder to be included in the Corporation’s proxy materials pursuant to this Section 8 whose nomination is subsequently withdrawn or whom the Board of Directors decides to nominate for election to the Board of Directors shall be counted as one of the Stockholder Nominees. Any Eligible Stockholder requesting that more than one Stockholder Nominee be included in the Corporation’s proxy materials pursuant to this Section 8 shall rank such Stockholder Nominees based on the order in which the Eligible Stockholder desires such Stockholder Nominees to be selected for inclusion in the Corporation’s proxy materials in the event that the total number of Stockholder Nominees requested by Eligible Stockholders to be included in the Corporation’s proxy materials pursuant to this Section 8 exceeds the Permitted Number. In the event that the number of Stockholder Nominees requested by Eligible Stockholders to be included in the Corporation’s proxy materials pursuant to this Section 8 exceeds the Permitted Number, the highest ranking Stockholder Nominee who meets the requirements of this Section 8 from each Eligible Stockholder will be selected for inclusion in the Corporation’s proxy materials until the Permitted Number is reached, going in order of the amount (largest to smallest) of shares of stock of the Corporation each Eligible Stockholder disclosed as owned in its Nomination Notice. If the Permitted Number is not reached after the highest ranking Stockholder Nominee who meets the requirements of this Section 8 from each Eligible Stockholder has been selected, then the next highest ranking Stockholder Nominee who meets the requirements of this Section 8 from each Eligible Stockholder will be selected for inclusion in the Corporation’s proxy materials, and this process will continue as many times as necessary, following the same order each time, until the Permitted Number is reached. Notwithstanding anything to the contrary contained in this Section 8, the Corporation shall not be required to include any Stockholder Nominees in its proxy materials pursuant to this Section 8 for any meeting of stockholders for which the Corporation receives a Nomination Notice (whether or not subsequently withdrawn) and the stockholder by whom or on whose behalf the nomination is to be made does not expressly elect, in a written statement accompanying the




Nomination Notice, to have its Stockholder Nominee included in the Corporation’s proxy materials pursuant to this Section 8.
(c)Eligible Stockholder. An “Eligible Stockholder” is a stockholder or a group of no more than 20 stockholders (counting as one stockholder, for this purpose, any two or more funds that are part of the same Qualifying Fund Group (as defined below)) that (i) has Owned (as defined in Section 8(d) of this Article II) continuously for at least three years (the “Minimum Holding Period”) a number of shares of stock of the Corporation that represents at least three percent of the voting power of the outstanding shares of stock as of the date the Nomination Notice is delivered to or mailed and received by the Clerk of the Corporation in accordance with Section 2 of this Article II (the “Required Shares”) and (ii) continues to Own the Required Shares through the date of the annual meeting. A “Qualifying Fund Group” is any two or more funds that are (A) under common management and investment control, (B) under common management and funded primarily by the same employer or (C) a “group of investment companies” as such term is defined in Section 12(d)(1)(G)(ii) of the Investment Company Act of 1940, as amended. Whenever the Eligible Stockholder consists of a group of stockholders (including a group of funds that are part of the same Qualifying Fund Group), (1) each provision in this Section 8 that requires the Eligible Stockholder to provide any written statements, representations, undertakings, agreements or other instruments or to meet any other conditions shall be deemed to require each stockholder (including each individual fund within a Qualifying Fund Group) that is a member of such group to provide such statements, representations, undertakings, agreements or other instruments and to meet such other conditions (except that the members of such group may aggregate the shares that each member has Owned continuously for the Minimum Holding Period in order to meet the three percent Ownership requirement of the “Required Shares” definition) and (2) a breach of any obligation, agreement or representation under this Section 8 by any member of such group shall be deemed a breach by the Eligible Stockholder. No person may be a member of more than one group of stockholders constituting an Eligible Stockholder with respect to any annual meeting.
(d)Definition of Ownership. For purposes of this Section 8, a stockholder shall be deemed to “Own” only those outstanding shares of stock of the Corporation as to which the stockholder possesses both (i) the full voting and investment rights pertaining to the shares and (ii) the full economic interest in (including the opportunity for profit from and risk of loss on) such shares; provided that the number of shares calculated in accordance with clauses (i) and (ii) shall not include any shares (A) sold by such stockholder or any of its affiliates in any transaction that has not been settled or closed, (B) borrowed by such stockholder or any of its affiliates for any purposes or purchased by such stockholder or any of its affiliates pursuant to an agreement to resell, or (C) subject to any option, warrant, forward contract, swap, contract of sale, or other derivative or similar instrument or agreement entered into by such stockholder or any of its affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of shares of outstanding capital stock of the Corporation, in any such case which instrument or agreement has, or is intended to have, the purpose or effect of (1) reducing in any manner, to any extent or at any time in the future, such stockholder’s or its affiliates’ full right to vote or direct the voting of any such shares or (2) hedging, offsetting or altering to any degree any gain or




loss realized or realizable from maintaining the full economic ownership of such shares by such stockholder or affiliate. For purposes of this Section 8, a beneficial owner shall be considered a “stockholder” and shall “Own” shares held in the name of a nominee or other intermediary so long as such person retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares. A stockholder’s Ownership of shares shall be deemed to continue during any period in which (i) the stockholder has loaned such shares, provided that the stockholder has the power to recall such loaned shares on five business days’ notice and includes with its Nomination Notice an agreement that it (A) will promptly recall such loaned shares upon being notified that any of its Stockholder Nominees will be included in the Corporation’s proxy materials and (B) will continue to hold such shares through the date of the annual meeting, or (ii) the stockholder has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement that is revocable at any time by the stockholder. The terms “Owned,” “Owning” and other variations of the word “Own” shall have correlative meanings. Whether outstanding shares of stock of the Corporation are “Owned” for these purposes shall be determined by the Board of Directors. For purposes of this Section 8, the term “affiliate” or “affiliates” shall have the meaning ascribed thereto under the General Rules and Regulations under the Exchange Act.
(e)Information to be Included with a Nomination Notice. In addition to containing the information, representations and other documents required to be set forth in a Nomination Notice pursuant to Section 2 of this Article II, in order for a Stockholder Nominee to be eligible for inclusion in the Corporation’s proxy materials pursuant to this Section 8, the Nomination Notice must also set forth or be accompanied by the following:
(i)A written statement by the Eligible Stockholder setting forth and certifying as to the number of shares of stock it Owns and has Owned continuously for the Minimum Holding Period;
(ii)one or more written statements from the record holder of the Required Shares (and from each intermediary through which the Required Shares are or have been held during the Minimum Holding Period) verifying that, as of a date within seven calendar days prior to the date the Nomination Notice is delivered to or mailed and received by the Clerk of the Corporation in accordance with Section 2 of this Article II, the Eligible Stockholder Owns, and has Owned continuously for the Minimum Holding Period, the Required Shares, and the Eligible Stockholder’s agreement to provide, within five business days following the later of the record date for the determination of stockholders certified to vote at the annual meeting and the date notice of the record date is first publicly disclosed, one or more written statements from the record holder and such intermediaries verifying the Eligible Stockholder’s continuous Ownership of the Required Shares through the record date;
(iii)a copy of the Schedule 14N that has been or is concurrently being filed with the Securities and Exchange Commission as required by Rule 14a-18 under the Exchange Act;




(iv)a representation and agreement that the Eligible Stockholder (A) will continue to hold the Required Shares through the date of the annual meeting, (B) acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control of the Corporation, and does not presently have such intent, (C) has not nominated and will not nominate for election to the Board of Directors at the annual meeting any person whom it has not requested be included in the Corporation’s proxy materials pursuant to this Section 8, (D) has not engaged and will not engage in, and has not and will not be a “participant” in another person’s, “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting other than its Stockholder Nominee(s) or a nominee of the Board of Directors, (E) has not distributed and will not distribute to any stockholder of the Corporation any form of proxy for the annual meeting other than the form distributed by the Corporation, (F) has complied and will comply with all laws and regulations applicable to solicitations and the use, if any, of soliciting material in connection with the annual meeting and (G) has provided and will provide facts, statements and other information in all communications with the Corporation and its stockholders that are or will be true and correct in all material respects and do not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading;
(v)an undertaking that the Eligible Stockholder agrees to (A) assume all liability stemming from any legal or regulatory violation arising out of the Eligible Stockholder’s communications with the stockholders of the Corporation or out of the information provided to the Corporation by or on behalf of the Eligible Stockholder, (B) indemnify and hold harmless the Corporation and each of its directors, officers and employees individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the Corporation or any of its directors, officers or employees arising out of any nomination of any person for election to the Board of Directors submitted by or on behalf of the Eligible Stockholder or any solicitation or other activity in connection therewith, and (C) file with the Securities and Exchange Commission any solicitation or other communication with the stockholders of the Corporation relating to the meeting at which its Stockholder Nominee(s) will be nominated, regardless of whether any such filing is required under Regulation 14A of the Exchange Act or whether any exemption from filing is available for such solicitation or other communication under Regulation 14A of the Exchange Act;
(vi)a written representation and agreement from each Stockholder Nominee that such Stockholder Nominee (A) is not and will not become a party to (1) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such Stockholder Nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation in such representation and agreement or (2) any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law, (B) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation,




reimbursement or indemnification in connection with such person’s nomination or service or action as a director that has not been disclosed to the Corporation in such representation and agreement, (C) would be in compliance, if elected as a director of the Corporation, and will comply with the Corporation’s code of business conduct and ethics, corporate governance guidelines, stock ownership and trading policies and guidelines and any other policies or guidelines of the Corporation applicable to directors and (D) will make such other acknowledgments, enter into such agreements and provide such information as the Board of Directors requires of all directors, including promptly submitting all completed and signed questionnaires required of the Corporation’s directors;
(vii)if the Eligible Stockholder consists of a group of stockholders, the designation by all group members of one member of the group that is authorized to receive communications, notices and inquiries from the Corporation and to act on behalf of all members of the group with respect to all matters relating to the request under this Section 8 (including withdrawal of the nomination); and
(viii)if two or more funds that are part of the same Qualifying Fund Group are intended to be counted as one stockholder for purposes of qualifying as an Eligible Stockholder, documentation reasonably satisfactory to the Corporation that demonstrates that the funds are part of the same Qualifying Fund Group.
(f)Additional Required Information. In addition to the information required pursuant to Section 8(e) of this Article II or any other provision of these By-Laws, the Corporation may require (i) any proposed Stockholder Nominee requested to be included in the Corporation’s proxy materials to furnish any other information (A) that may reasonably be requested by the Corporation to determine whether the Stockholder Nominee would be independent under the Independence Standards (as defined in Section 8(i) of this Article II), (B) that could be material to a reasonable stockholder’s understanding of the independence, or lack thereof, of such Stockholder Nominee or (C) that may reasonably be requested by the Corporation to determine the eligibility of such Stockholder Nominee to be included in the Corporation’s proxy materials pursuant to this Section 8 or to serve as a director of the Corporation, and (ii) any Eligible Stockholder to furnish any other information that may reasonably be requested by the Corporation to verify the Eligible Stockholder’s continuous ownership of the Required Shares for the Minimum Holding Period and through the date of the annual meeting.
(g)Supporting Statement. The Eligible Stockholder may, at its option, provide to the Clerk of the Corporation, at the time the Nomination Notice is provided, a written statement, not to exceed 500 words, in support of its Stockholder Nominee(s)’ candidacy (a “Supporting Statement”). Only one Supporting Statement may be submitted by an Eligible Stockholder (including any group of stockholders together constituting an Eligible Stockholder) in support of its Stockholder Nominee(s). Notwithstanding anything to the contrary contained in this Section 8, the Corporation may omit from its proxy materials any information or Supporting Statement (or portion thereof) that it, in good faith, believes would violate any applicable law, rule or regulation.




(h)Correction of Defects; Updates and Supplements. In the event that any information or communications provided by or on behalf of an Eligible Stockholder or a Stockholder Nominee to the Corporation or its stockholders ceases to be true and correct in all material respects or omits to state a material fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading, such Eligible Stockholder or Stockholder Nominee, as the case may be, shall promptly notify the Clerk of the Corporation of any such defect and of the information that is required to correct any such defect. Without limiting the forgoing, an Eligible Stockholder must provide immediate notice to the Corporation if the Eligible Stockholder ceases to Own any of the Required Shares prior to the date of the annual meeting. For the avoidance of doubt, no notification, update or supplement provided pursuant to this Section 8(h) shall be deemed to cure any defect in any previously provided information or communications or limit the remedies available to the Corporation relating to any such defect (including the right to omit a Stockholder Nominee from its proxy materials pursuant to this Section 8).
(i)Stockholder Nominee Eligibility. Notwithstanding anything to the contrary contained in this Section 8, the Corporation shall not be required to include in its proxy materials, pursuant to this Section 8, a Stockholder Nominee (i) who would not be an independent director under the rules and listing standards of the United States securities exchanges upon which the capital stock of the Corporation is listed or traded, any applicable rules of the Securities and Exchange Commission, or any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the Corporation’s directors (collectively, the “Independence Standards”), (ii) whose election as a member of the Board of Directors would cause the Corporation to be in violation of these By-Laws, the Articles of Organization, the rules and listing standards of the United States securities exchanges upon which the capital stock of the Corporation is listed or traded, or any applicable law, rule or regulation, (iii) who is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, (iv) who is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted in such a criminal proceeding within the past 10 years, (v) who is subject to any order of the type specified in Rule 506(d) of Regulation D promulgated under the Securities Act of 1933, as amended, or (vi) who shall have provided any information to the Corporation or its stockholders that was untrue in any material respect or that omitted to state a material fact necessary to make the statements made, in light of the circumstances in which they were made, not misleading.
(j)Omission and Removal of Stockholder Nominees. Notwithstanding anything to the contrary set forth herein, if (i) a Stockholder Nominee and/or the applicable Eligible Stockholder breaches any of its representations, agreements or undertakings or fails to comply with any of its obligations under this Section 8 or Section 2 of this Article II, or (ii) a Stockholder Nominee otherwise becomes ineligible for inclusion in the Corporation’s proxy materials pursuant to this Section 8 or dies, becomes disabled or otherwise becomes ineligible or unavailable for election at the annual meeting, in each case as determined by the Board of Directors or the presiding officer of the annual meeting, then (A) the Corporation may omit or, to the extent feasible, remove the information concerning such Stockholder Nominee and the related Supporting Statement from its proxy materials and otherwise communicate to its stockholders that




such Stockholder Nominee will not be eligible for election at the annual meeting and, (B) the Corporation shall not be required to include in its proxy materials any successor or replacement nominee proposed by the applicable Eligible Stockholder or any other Eligible Stockholder.
(k)Restrictions on Re-Nominations. Any Stockholder Nominee who is included in the Corporation’s proxy materials for a particular annual meeting of stockholders but either (i) withdraws from or becomes ineligible or unavailable for election at the annual meeting, or (ii) does not receive at least 10% of the votes cast in favor of such Stockholder Nominee’s election, will be ineligible to be included in the Corporation’s proxy materials pursuant to this Section 8 for the next two annual meetings of stockholders.
(l)General. This Section 8 provides the exclusive method for a stockholder to include nominees for election to the Board of Directors in the Corporation’s proxy materials.




 EX-31.1 3 a2016q110-q_exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, Jeffrey M. Leiden, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
May 3, 2016
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President




 EX-31.2 4 a2016q110-q_exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Ian F. Smith, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
May 3, 2016
/s/ Ian F. Smith
 
 
 
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer



 EX-32.1 5 a2016q110-q_exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
May 3, 2016
 
 
 
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President
 
 
 
Date:
May 3, 2016
 
 
 
/s/ Ian F. Smith
 
 
 
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 





 EX-101.INS 6 vrtx-20160331.xml XBRL INSTANCE DOCUMENT 0000875320 2016-01-01 2016-03-31 0000875320 2016-04-20 0000875320 2015-01-01 2015-03-31 0000875320 2016-03-31 0000875320 2015-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-03-31 0000875320 us-gaap:ParentMember 2016-01-01 2016-03-31 0000875320 us-gaap:NoncontrollingInterestMember 2015-12-31 0000875320 us-gaap:ParentMember 2015-01-01 2015-03-31 0000875320 us-gaap:NoncontrollingInterestMember 2016-03-31 0000875320 us-gaap:CommonStockMember 2015-03-31 0000875320 us-gaap:NoncontrollingInterestMember 2015-03-31 0000875320 us-gaap:ParentMember 2015-12-31 0000875320 us-gaap:ParentMember 2015-03-31 0000875320 us-gaap:RetainedEarningsMember 2016-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-03-31 0000875320 us-gaap:CommonStockMember 2015-01-01 2015-03-31 0000875320 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-03-31 0000875320 us-gaap:NoncontrollingInterestMember 2014-12-31 0000875320 us-gaap:ParentMember 2016-03-31 0000875320 us-gaap:CommonStockMember 2015-12-31 0000875320 us-gaap:RetainedEarningsMember 2015-01-01 2015-03-31 0000875320 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0000875320 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0000875320 2014-12-31 0000875320 us-gaap:CommonStockMember 2016-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000875320 us-gaap:CommonStockMember 2014-12-31 0000875320 us-gaap:RetainedEarningsMember 2014-12-31 0000875320 2015-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-03-31 0000875320 us-gaap:RetainedEarningsMember 2015-12-31 0000875320 us-gaap:ParentMember 2014-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000875320 us-gaap:RetainedEarningsMember 2015-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-03-31 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2016-01-01 2016-03-31 0000875320 vrtx:CopayMitigationRebatesMember 2016-01-01 2016-03-31 0000875320 us-gaap:AllowanceForSalesReturnsMember 2016-01-01 2016-03-31 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2015-12-31 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2016-01-01 2016-03-31 0000875320 us-gaap:AllowanceForSalesReturnsMember 2015-12-31 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2015-12-31 0000875320 vrtx:CopayMitigationRebatesMember 2015-12-31 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2016-03-31 0000875320 vrtx:CopayMitigationRebatesMember 2016-03-31 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2016-03-31 0000875320 us-gaap:AllowanceForSalesReturnsMember 2016-03-31 0000875320 vrtx:ParionSciencesIncMember vrtx:EnacInhibitorsinCfMember 2015-06-04 2015-06-04 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2011-04-01 2011-04-30 0000875320 vrtx:BioAxoneBiosciencesIncMember 2015-12-31 0000875320 vrtx:BioAxoneBiosciencesIncMember 2016-01-01 2016-03-31 0000875320 vrtx:BioAxoneBiosciencesIncMember 2014-12-31 0000875320 vrtx:CRISPRTherapeuticsMember 2015-10-26 2015-10-26 0000875320 vrtx:JanssenCollaborativeAgreementMember 2016-01-01 2016-03-31 0000875320 vrtx:ParionSciencesIncMember 2015-06-04 2015-06-04 0000875320 vrtx:ParionSciencesIncMember 2016-01-01 2016-03-31 0000875320 vrtx:ParionSciencesIncMember 2016-03-31 0000875320 vrtx:BioAxoneBiosciencesIncMember 2016-03-31 0000875320 vrtx:ParionSciencesIncMember 2015-12-31 0000875320 2015-06-04 0000875320 vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-10-31 0000875320 vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-12-31 0000875320 vrtx:BioAxoneBiosciencesIncMember 2015-01-01 2015-03-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2012-01-01 2012-12-31 0000875320 vrtx:ParionSciencesIncMember vrtx:EnacInhibitorsinNonCfMember 2015-06-04 2015-06-04 0000875320 vrtx:CRISPRTherapeuticsMember 2015-10-26 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2015-10-01 2015-12-31 0000875320 vrtx:JanssenCollaborativeAgreementMember 2014-01-01 2014-12-31 0000875320 vrtx:ParionSciencesIncMember 2015-06-04 0000875320 vrtx:JanssenCollaborativeAgreementMember 2015-01-01 2015-03-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2016-01-01 2016-03-31 0000875320 vrtx:ParionSciencesIncMember vrtx:AdditionalEnacInhibitorsMember 2015-06-04 2015-06-04 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-01-01 2015-03-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-01-01 2016-03-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-03-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2015-01-01 2015-03-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2013-01-01 2013-12-31 0000875320 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 0000875320 us-gaap:RestrictedStockMember 2015-01-01 2015-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2016-03-31 0000875320 us-gaap:FairValueInputsLevel3Member 2016-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2015-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2016-03-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2015-12-31 0000875320 us-gaap:CommercialPaperMember 2015-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2015-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:USTreasurySecuritiesMember 2016-03-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2016-03-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2016-03-31 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2015-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2016-03-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2015-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2016-03-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2016-03-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2015-12-31 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2016-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-03-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-01-01 2016-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-03-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-01-01 2015-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-03-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2015-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember 2015-12-31 0000875320 us-gaap:OtherAssetsMember 2015-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember 2015-12-31 0000875320 us-gaap:OtherAssetsMember 2016-03-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember 2016-03-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember 2016-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2016-03-31 0000875320 us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-10-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2014-10-31 0000875320 us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesIncMember 2014-10-01 2014-10-31 0000875320 us-gaap:SeniorLoansMember 2014-07-01 2014-07-31 0000875320 us-gaap:SeniorLoansMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2014-07-01 2014-07-31 0000875320 us-gaap:BuildingMember vrtx:FanPierLeasesMember 2015-12-31 0000875320 us-gaap:ConstructionInProgressMember vrtx:FanPierLeasesMember 2015-12-31 0000875320 us-gaap:BuildingMember vrtx:FanPierLeasesMember 2016-03-31 0000875320 us-gaap:SecuredDebtMember 2014-07-31 0000875320 us-gaap:SeniorLoansMember 2015-12-31 0000875320 us-gaap:SeniorLoansMember 2014-07-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-02 0000875320 vrtx:FanPierLeasesMember 2011-12-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-02 2015-12-02 0000875320 vrtx:FanPierLeasesMember 2011-01-01 2011-12-31 0000875320 us-gaap:SeniorLoansMember 2015-10-01 2015-10-31 0000875320 us-gaap:SeniorLoansMember 2016-03-31 0000875320 us-gaap:ConstructionInProgressMember vrtx:FanPierLeasesMember 2016-03-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2016-01-01 2016-03-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2016-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2016-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2016-01-01 2016-03-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2016-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars134.69Member 2016-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars18.93toDollars20.00Member 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars20.01toDollars40.00Member 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars20.01toDollars40.00Member 2016-01-01 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2016-01-01 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2016-01-01 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2016-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars134.69Member 2016-01-01 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2016-01-01 2016-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars18.93toDollars20.00Member 2016-01-01 2016-03-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2016-01-01 2016-03-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2015-01-01 2015-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0000875320 vrtx:FanPierMoveMember 2016-01-01 2016-03-31 0000875320 us-gaap:OtherRestructuringMember 2016-01-01 2016-03-31 0000875320 vrtx:KendallRestructuringMember 2016-01-01 2016-03-31 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2015-01-01 2015-03-31 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0000875320 2008-01-01 2008-12-31 0000875320 2015-01-01 2015-12-31 0000875320 vrtx:KendallRestructuringMember 2003-01-01 2003-12-31 0000875320 vrtx:FanPierMoveMember 2014-07-01 2014-09-30 0000875320 vrtx:FanPierMoveMember 2015-01-01 2015-03-31 0000875320 vrtx:FanPierMoveMember 2015-03-31 0000875320 us-gaap:OtherRestructuringMember 2016-03-31 0000875320 us-gaap:OtherRestructuringMember 2015-01-01 2015-03-31 0000875320 us-gaap:OtherRestructuringMember 2015-03-31 0000875320 us-gaap:OtherRestructuringMember 2015-12-31 0000875320 us-gaap:OtherRestructuringMember 2014-12-31 0000875320 vrtx:KendallRestructuringMember 2015-03-31 0000875320 vrtx:KendallRestructuringMember 2015-12-31 0000875320 vrtx:KendallRestructuringMember 2015-01-01 2015-03-31 0000875320 vrtx:KendallRestructuringMember 2016-03-31 0000875320 vrtx:KendallRestructuringMember 2014-12-31 0000875320 vrtx:FanPierMoveMember 2015-12-31 0000875320 vrtx:FanPierMoveMember 2014-12-31 0000875320 vrtx:FanPierMoveMember 2016-03-31 xbrli:shares vrtx:term_extension vrtx:lease utreg:sqft iso4217:USD xbrli:shares vrtx:segment vrtx:target xbrli:pure vrtx:building iso4217:USD vrtx:facility false --12-31 Q1 2016 2016-03-31 10-Q 0000875320 247349864 Large Accelerated Filer VERTEX PHARMACEUTICALS INC / MA 27167000 103362000 78756000 209285000 28837000 215343000 76395000 320575000 74942000 676000 75221000 1569000 177639000 181878000 305820000 7100000 272665000 6595000 917000 2011000 -123000 -971000 791000 2317000 53000 -1579000 1824000 3778000 126000 -2080000 -4899000 -1434000 355000 -3820000 6197500000 6262964000 58268000 58268000 0 58268000 56246000 56317000 -71000 56317000 57384000 38217000 19167000 55472000 34448000 21024000 12682000 3474000 12619000 3565000 1100000 120000 170000 2498587000 2487906000 1407153000 1402835000 372663000 292720000 0 665383000 350183000 279184000 0 629367000 327694000 421373000 255340000 125000 100000 9430000 400000 9000000 28000000 179000000 28400000 188000000 175340000 164317000 15545000 17292000 42923000 38886000 625259000 664879000 714768000 604245000 0 0 199507000 85994000 34889000 11533000 0 0 0 0 0 0 34889000 11533000 199507000 85994000 0 190601000 13557000 0 0 0 13557000 190601000 39620000 -110523000 0.01 0.01 500000000 500000000 246306818 247286705 246306818 247286705 2427000 2429000 -198732000 -48354000 -98000 5529000 -198830000 -42825000 964000 593000 0 30138000 9381000 49789000 310494000 412410000 0.05 300000000 0.072 0.062 75000000 4600000 4000000 5300000 16296000 14705000 9714000 8490000 110439000 110438000 112259000 112259000 91023000 16363000 16415000 901000 3836000 5766000 3836000 5766000 3836000 4865000 0 901000 4422000 0 586000 901000 4422000 0 769000 0 769000 0 132000 0 132000 901000 3836000 P18M P1M 2926000 860000 -0.83 -0.17 -0.83 -0.17 -2596000 2620000 884000 845000 206783000 223184000 3143000 P2Y9M29D P2Y9M11D P5M27D 0.075 0.071 0 901000 0 901000 0 4422000 0 4422000 605000 5161000 182000 3654000 0 605000 0 605000 0 5161000 0 5161000 0 182000 0 182000 0 -3765000 0 -3765000 0 -657000 0 -657000 0 3654000 0 3654000 769000 132000 3765000 657000 50384000 19391000 50384000 19391000 10468000 -287000 -839000 -198405000 -30617000 299000 -64000 5485000 3062000 3100000 60000 581000 -23556000 -343000 5863000 2512000 -20921000 -29922000 -5333000 -2815000 2635000 4771000 0 2060000 15233000 7325000 21971000 3000 0 -2637000 -21307000 -20698000 21538000 20603000 7816000 15365000 57207000 63200000 8696000 9936000 40695000 37899000 1404959000 1371708000 2498587000 2487906000 506167000 552041000 200000000 295800000 0 0 87162000 141409000 99123000 0 0 0 0 141409000 99123000 87162000 0 0 126478000 33104000 141562000 120229000 0 0 0 0 0 0 141562000 120229000 126478000 33104000 153661000 153661000 159119000 159119000 50414000 4702000 214038000 -102708000 -222236000 -15137000 -198606000 -41631000 -98000 -98000 5529000 5529000 30000000 0 1 -171985000 -14330000 6912000 455000 7600000 434000 1572000 2004000 176000 -608000 -5338000 -3827000 229000 -1740000 -608000 -1740000 -126000 306000 176000 -126000 -608000 -126000 -6723000 -5212000 229000 -6723000 -1740000 -6723000 306000 -5212000 176000 229000 284340000 284340000 284340000 284340000 255340000 14374000 18117000 31778000 300000 31822000 310000 -629000 3835000 -5113000 4411000 -799000 -83000 19256000 330000 3985000 439000 3156000 3931000 4497000 4041000 125655000 224624000 10558000 11974000 0.01 0.01 1000000 1000000 0 0 0 0 0 0 50935000 3138000 55866000 2818000 41616000 8846000 13386000 0 371423000 131173000 -198704000 -98000 -198606000 -198606000 -36102000 5529000 -41631000 -41631000 697715000 502300000 690521000 499000000 1698000 1698000 0 0 1385000 1385000 0 0 7600000 3500000 91000 103000 215599000 255860000 21900000 78910000 78910000 76273000 76273000 22083000 22088000 -2997000 -3272000 306000 -581000 687000 251000 233000 203000 869000 33390000 11596000 845000 11137000 9506000 1450000 5964000 7944000 1262000 5449000 7224000 7894000 7790000 7464000 6145000 -24367000 -1459000 -5261784000 -5303415000 138509000 2167000 398080000 78000 6792000 1525000 3596000 78000 130875000 394410000 85860000 105214000 223863000 149571000 71296000 146251000 57384000 55472000 120.01 18.93 100.01 20.01 40.01 60.01 80.01 6057000 339000 138000 402000 2119000 1590000 654000 815000 12619000 1524000 138000 1677000 2124000 2210000 1396000 3550000 134.69 20.00 120 40 60 80 100 28959000 27169000 2140000 26260000 27533000 2524000 59.71 129.57 18.93 109.26 34.29 48.77 75.31 88.04 78.61 130.63 18.93 109.32 34.30 48.09 75.92 90.65 P7Y4M10D P9Y3M11D P1Y10M6D P8Y9M18D P3Y6M22D P6Y3M29D P7Y9M29D P8Y9M22D 241764000 243580000 246307000 247287000 1816000 980000 41916000 41902000 14000 0 41916000 9149000 9147000 2000 9149000 939967000 957079000 1096183000 917000 5777154000 2385000 21177000 1075006000 -4705450000 997537000 791000 5877324000 2399000 21079000 976458000 -4904056000 1093628000 1824000 6197500000 2427000 153661000 939967000 -5261784000 1116198000 -4899000 6262964000 2429000 159119000 957079000 -5303415000 24554000 24512000 400000 400000 0 0 0 -2294000 -75000 -38000 0 -2181000 49296000 1228000 2089000 1310000 44669000 59680000 1817000 2060000 1309000 54494000 239493000 243831000 239493000 243831000 2 10200000 0.066 0.059 0.041 1042462000 327694000 714768000 34889000 99123000 11533000 85994000 582352000 141409000 87162000 1025618000 421373000 604245000 141562000 13557000 33104000 590688000 120229000 126478000 1042336000 327568000 714768000 34889000 98877000 11533000 85994000 582352000 141515000 87176000 1025263000 421018000 604245000 141243000 13557000 33108000 590688000 120206000 126461000 246000 246000 0 0 246000 0 0 0 0 0 359000 359000 0 319000 0 0 0 23000 17000 120000 120000 0 0 0 0 0 0 106000 14000 4000 4000 0 0 0 4000 0 0 0 P30D 230000000 490000000 370000000 420000000 30000000 P90D P90D 360000000 75000000 75000000 6 P180D P270D P10Y P6M 80000000 75000000 10000000 35000000 P1Y 842000 0 642000 74000 0 0 472611000 472494000 473000000 472900000 P2Y 23200000 0 0 0 0 2 2 0.09 P15Y P5Y P16Y 90000000.0 9300000 9300000 13900000 2 P5Y P10Y 10468000 160000000.0 0 2476000 2408000 3008000 0.5 3 400000 40049000 924000 4707000 3280000 31138000 27371000 260000 4698000 3281000 19132000 76000000 11300000 29000000 29000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP"). </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which are contained in the Company's Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">February&#160;16, 2016</font><font style="font-family:inherit;font-size:10pt;"> (the "</font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K").</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">590,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">590,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">604,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">604,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,478</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">421,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">421,373</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,025,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,025,618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">582,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">582,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">327,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">327,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,042,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,042,462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a limited number of marketable securities in insignificant loss positions as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cystic Fibrosis Foundation Therapeutics Incorporated</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2011, the Company entered into an amendment (the &#8220;April 2011 Amendment&#8221;) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (&#8220;CFFT&#8221;) pursuant to which CFFT agreed to provide financial support for (i)&#160;development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii)&#160;additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the April 2011 Amendment, CFFT agreed to provide the Company with up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in funding over approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> years for corrector compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor and VX-661. The Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> collaborative revenues from this collaboration during </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs first synthesized or tested during the research term that ended in 2008, including ivacaftor, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds first synthesized or tested during the research term that ended in February 2014. In each of 2012 and 2013, CFFT earned a commercial milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$9.3 million</font><font style="font-family:inherit;font-size:10pt;"> from the Company upon achievement of certain sales levels for KALYDECO. In each of the fourth quarter of 2015 and first quarter of 2016, CFFT earned a commercial milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;"> from the Company upon achievement of certain sales levels of lumacaftor. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO or ORKAMBI. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in 2015. The Company received approval for ORKAMBI in the European Union in 2015 and in Canada and Australia in 2016. The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and VX-661 until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of VX-661 that expire in 2027 and 2028, respectively, subject to potential extension.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CRISPR Therapeutics AG</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> to research and development, and the </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment was recorded at cost and is classified as a long-term asset on the Company&#8217;s condensed consolidated balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development, regulatory and commercial milestones and royalties on net product sales. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the CRISPR Agreement upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice to CRISPR prior to any product receiving marketing approval or upon </font><font style="font-family:inherit;font-size:10pt;">270</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Janssen Pharmaceutica&#160;NV</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a collaboration agreement (the &#8220;Janssen HCV Agreement&#8221;) with Janssen Pharmaceutica NV (&#8220;Janssen NV&#8221;) for the development, manufacture and commercialization of telaprevir, which Janssen NV began marketing under the brand name INCIVO in certain of its territories in September 2011. Pursuant to the Janssen HCV Agreement, as amended, Janssen NV has a fully-paid license to manufacture and commercialize INCIVO in its territories including Europe, South America, the Middle East, Africa and Australia, subject to the payment of third-party royalties on net sales of INCIVO. In addition to the collaborative revenues, the Company recorded royalty revenues and corresponding royalty expenses related to third-party royalties that Janssen NV remains responsible for based on INCIVO net sales. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following revenues attributable to the Janssen NV collaboration:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.57142857142857%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty revenues (INCIVO)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Collaborative revenues (telaprevir)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Total revenues attributable to the Janssen NV collaboration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Interest Entities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the Company's condensed consolidated financial statements as VIEs. In order to account for </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop the drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are reflected in the Company's financial statements as consolidated VIEs:</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Parion Sciences,&#160;Inc.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License and Collaboration Agreement</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (&#8220;Parion&#8221;).&#160; Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (&#8220;ENaC&#8221;) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.&#160; The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion&#8217;s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion&#8217;s research program.&#160; Parion received an </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front payment and has the potential to receive up to an additional (i) </font><font style="font-family:inherit;font-size:10pt;">$490.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestone payments for development of ENaC inhibitors in CF, including </font><font style="font-family:inherit;font-size:10pt;">$360.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to global filing and approval milestones, (ii) </font><font style="font-family:inherit;font-size:10pt;">$370.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii)&#160;</font><font style="font-family:inherit;font-size:10pt;">$230.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion&#8217;s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the Parion Agreement upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice to Parion prior to any licensed product receiving marketing approval or upon </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i)&#160;the date the last-to-expire patent covering a licensed product expires or (ii)&#160;</font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years after the first commercial sale in the country.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly affect the economic performance of Parion. &#160;Accordingly, the Company consolidated Parion's financial statements beginning on June&#160;4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement. In particular, the Company did not acquire any equity interest in Parion, any interest in Parion's cash and cash equivalents or any control over Parion's activities that do not relate to the Parion Agreement.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consideration for the Parion Agreement</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the fair value of the consideration from the Company to Parion was </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of June 4, 2015, which consisted of (i)&#160;an </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front payment, (ii)&#160;the estimated fair value of the contingent research and development milestones potentially payable by the Company to Parion and (iii)&#160;the estimated fair value of potential royalty payments payable by the Company to Parion. The Company valued the contingent milestone and royalty payments using (a)&#160;discount rates ranging from </font><font style="font-family:inherit;font-size:10pt;">4.1%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">5.9%</font><font style="font-family:inherit;font-size:10pt;"> for the development milestones and (b)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;">6.6%</font><font style="font-family:inherit;font-size:10pt;"> for royalties. The consideration paid and the fair value of the contingent milestone and royalty payments payable by the Company pursuant to the Parion Agreement are set forth in the table below:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.49206349206349%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 4, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Up-front payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Allocation of Assets and Liabilities</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the purposes of the condensed consolidated balance sheets at June&#160;4, 2015 and </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company allocated the total consideration, which is comprised of the up-front payment and the fair value of the contingent milestone and royalty payments, intangible assets, goodwill, deferred tax liability, net and net other assets and liabilities. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The difference between the fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values of the assets and liabilities recorded on the effective date of the Parion Agreement:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.49206349206349%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 4, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(91,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other assets (liabilities)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,468</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net assets attributable to noncontrolling interests</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BioAxone Biosciences, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company entered into a license and collaboration agreement (the &#8220;BioAxone Agreement&#8221;) with BioAxone Biosciences, Inc. (&#8220;BioAxone&#8221;), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the fourth quarter of 2014. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BioAxone has the potential to receive up to </font><font style="font-family:inherit;font-size:10pt;">$90.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> for VX-210 and a corresponding deferred tax liability of </font><font style="font-family:inherit;font-size:10pt;">$11.3 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company&#8217;s option to extend this date by </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year. </font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Aggregate VIE Financial Information</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015 is as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.10317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss attributable to noncontrolling interest before provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for (benefit from) income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,062</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(64</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase in fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net (income) loss attributable to noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to the BioAxone Agreement increased by </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to the Parion Agreement increased by </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;">. The changes in </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> were primarily due to the changes in market interest rates and the time value of money. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the contingent milestone and royalty payments related to the BioAxone Agreement and the Parion Agreement was </font><font style="font-family:inherit;font-size:10pt;">$28.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$188.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the contingent milestone and royalty payments related to the BioAxone collaboration and the Parion collaboration was </font><font style="font-family:inherit;font-size:10pt;">$28.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$179.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (VIE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,818</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">676</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">112,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">159,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i)&#160;the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii)&#160;the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company's VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Outlicense Arrangements</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Janssen Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the Company entered into an agreement (the &#8220;Janssen Influenza Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen Inc.&#8221;), which was amended in October 2014 to clarify certain roles and responsibilities of the parties. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of </font><font style="font-family:inherit;font-size:10pt;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded reimbursement for these development activities of </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The reimbursements are recorded as a reduction to development expense in the Company's </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;"> primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months' notice.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling </font><font style="font-family:inherit;font-size:10pt;">$21.9 million</font><font style="font-family:inherit;font-size:10pt;"> that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, on the Company's condensed consolidated balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 28, 2014, a purported shareholder class action </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Local No. 8 IBEW Retirement Plan &amp; Trust v. Vertex Pharmaceuticals Incorporated, et al.</font><font style="font-family:inherit;font-size:10pt;"> was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company&#8217;s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys&#8217; fees as well as disgorgement of the proceeds from certain individual defendants&#8217; sales of the Company&#8217;s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs&#8217; opposition to its motion to dismiss.&#160; The court heard oral argument on the motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The First Circuit Court of Appeals issued a scheduling order on December 24, 2015. On February 2, 2016, the Plaintiff filed their opening brief and the Company filed its opposition brief on March 7, 2016. On March 24, 2016, the plaintiff filed their reply brief. The Company believes the claims to be without merit and intend to vigorously defend the litigation. </font><font style="font-family:inherit;font-size:10pt;">As of March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has not recorded any reserves for this purported class action.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Guaranties and Indemnifications</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As permitted under Massachusetts law, the Company&#8217;s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors&#8217; and officers&#8217; liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company&#8217;s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator&#8217;s institution relating to personal injury or property damage, violations of law or certain breaches of the Company&#8217;s contractual obligations arising out of the research or clinical testing of the Company&#8217;s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company&#8217;s contractual obligations. The indemnification provisions appearing in the Company&#8217;s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> material contingent liabilities accrued as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive (Loss) Income</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains (Losses) on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,740</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,827</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,338</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,385</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,385</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,740</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,723</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">355</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,434</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,899</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized (Losses) Gains on Foreign Currency Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,572</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,579</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">791</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term Obligations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> lease agreements, pursuant to which the Company leases approximately </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> buildings (the &#8220;Buildings&#8221;) at Fan Pier in Boston, Massachusetts (the &#8220;Fan Pier Leases&#8221;). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for &#8220;sale-leaseback&#8221; treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i)&#160;a portion that is allocated to the Buildings and (ii)&#160;a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, included </font><font style="font-family:inherit;font-size:10pt;">$499.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$502.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was </font><font style="font-family:inherit;font-size:10pt;">$472.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$473.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">San Diego Lease</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC. Pursuant to this agreement, the Company agreed to lease approximately </font><font style="font-family:inherit;font-size:10pt;">170,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the second half of 2017, and will extend for </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;"> years from the commencement date. Pursuant to the lease agreement, during the initial </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;">-year term, the Company will pay an average of approximately </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;"> per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year terms.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Term Loan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Term Loan initially bore interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">7.2%</font><font style="font-family:inherit;font-size:10pt;"> per annum, which was reduced to </font><font style="font-family:inherit;font-size:10pt;">6.2%</font><font style="font-family:inherit;font-size:10pt;"> per annum based on the FDA's approval of ORKAMBI. The Term Loan will bear interest at a rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum during the third year of the term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of </font><font style="font-family:inherit;font-size:10pt;">$75 million</font><font style="font-family:inherit;font-size:10pt;"> from October 1, 2016 through the maturity date. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years of interest payments over the life of the loan. The Company accounted for the amendment as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's obligations under the Term Loan are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the Term Loan, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;"> in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">As of March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the unamortized discount associated with the Term Loan that was included in the senior secured term loan caption on the Company&#8217;s condensed consolidated balance sheet was </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hedging</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company&#8217;s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> months. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge&#8217;s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the notional amount of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">215,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">320,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">209,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,765</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(657</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,836</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(586</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following stock-based compensation expense included in loss from continuing operations:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,959</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,524</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">55,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">55,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense,<br clear="none"/>Net of <br clear="none"/>Estimated Forfeitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition <br clear="none"/>Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">206,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.83</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">223,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.78</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.49</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$18.93&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.56</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,119</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$80.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.83</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01&#8211;$100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$100.01&#8211;$120.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$120.01&#8211;$134.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,524</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,619</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings Per Share</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.57142857142857%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,565</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,474</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:88%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company&#8217;s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s investments were in money market funds, short-term government-sponsored enterprise securities, U.S. Treasury securities, corporate debt securities and commercial paper.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s financial assets that were subject to fair value measurements were valued using observable inputs. The Company&#8217;s financial assets valued based on Level&#160;1 inputs consisted of money market funds, short-term government-sponsored enterprise securities and U.S. Treasury securities. The Company&#8217;s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as <br clear="none"/>of March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial assets carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">629,367</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">350,183</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">279,184</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial liabilities carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(657</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements as <br clear="none"/>of December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (asset position):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">665,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">372,663</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">292,720</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (liability position):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's VIEs invested in cash equivalents consisting of money market funds of </font><font style="font-family:inherit;font-size:10pt;">$76.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company&#8217;s noncontrolling interest related to VIEs includes </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;">, which are valued based on Level 3 inputs. Please refer to Note C, &#8220;Collaborative Arrangements,&#8221; for further information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value and carrying value of the Company's Term Loan was </font><font style="font-family:inherit;font-size:10pt;">$295.8 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current market rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, in-process research and development intangible assets of </font><font style="font-family:inherit;font-size:10pt;">$284.3 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded on the Company's condensed consolidated balance sheet. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> based on the Company&#8217;s estimate of the fair value of Parion&#8217;s lead investigational ENaC inhibitors, including VX-371 and VX-551, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on the Company&#8217;s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of </font><font style="font-family:inherit;font-size:10pt;">7.1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;"> in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also conducted an evaluation of Parion and BioAxone's other programs at the effective date of the Parion Agreement and BioAxone Agreement, respectively, and determined that market participants would not have ascribed value to those programs because of the stage of development of the assets in each program and uncertainties related to the potential development and commercialization of the programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, goodwill of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$50.4 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded on the Company's condensed consolidated balance sheet.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to United States federal, state, and foreign income taxes. For </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">provision for income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">. The provision for income taxes recorded in </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> included </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">, related to the Company's VIE's income tax provision. The Company has no liability for taxes payable by the Company's VIEs and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">provision for income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, related to state income taxes and income earned in various foreign jurisdictions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of each of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had unrecognized tax benefits of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. </font><font style="font-family:inherit;font-size:10pt;">As of March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. In 2016, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company&#8217;s effective tax rate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Delaware, Canada and Quebec for varying periods including the years ended December 31, 2011 through 2013. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Pennsylvania and Texas during 2016 and Massachusetts and New York during 2015 with no material adjustments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently intends to reinvest the total amount of its unremitted earnings. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,816</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of other recent accounting pronouncements please refer to Note&#160;A, &#8220;Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K. The Company did not adopt any new accounting pronouncements during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> that had a material effect on its condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP"). </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which are contained in the Company's Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">February&#160;16, 2016</font><font style="font-family:inherit;font-size:10pt;"> (the "</font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K").</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's significant accounting policies are described in Note&#160;A, "Nature of Business and Accounting Policies," in the </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of other recent accounting pronouncements please refer to Note&#160;A, &#8220;Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K. The Company did not adopt any new accounting pronouncements during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> that had a material effect on its condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sale of HIV Protease Inhibitor Royalty Stream</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline&#160;plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of </font><font style="font-family:inherit;font-size:10pt;">$160.0 million</font><font style="font-family:inherit;font-size:10pt;">. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline&#160;plc. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$23.2 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline&#160;plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease that terminates in 2018. The Company has not used more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,931</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,985</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(581</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Move Restructuring</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> facilities in Cambridge. During the first quarter of 2015, the Company terminated </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company&#8217;s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company&#8217;s landlord on the effective date of the termination. The third major facility included in this restructuring activity is </font><font style="font-family:inherit;font-size:10pt;">120,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;"> that the Company continued to use for its operations following its </font><font style="font-family:inherit;font-size:10pt;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;">. The rentable square footage in this portion of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;"> was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company&#8217;s estimated future cash flows related to this portion of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;">, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,156</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19,256</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,997</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,137</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Restructuring Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has engaged in several other restructuring activities that are unrelated to its </font><font style="font-family:inherit;font-size:10pt;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;"> and the </font><font style="font-family:inherit;font-size:10pt;">Fan Pier Move Restructuring</font><font style="font-family:inherit;font-size:10pt;">. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in CF and other research and development programs.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the Company's other restructuring liabilities for </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">251</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,262</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains (Losses) on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,740</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,827</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,338</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,385</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,385</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,740</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,723</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">355</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,434</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,899</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized (Losses) Gains on Foreign Currency Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,572</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,579</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">791</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.57142857142857%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,565</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,474</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">590,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">590,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">604,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">604,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,478</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">421,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">421,373</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,025,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,025,618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">582,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">582,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">714,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">327,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">327,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,042,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,042,462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following stock-based compensation expense included in loss from continuing operations:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,959</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,524</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">55,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">55,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as <br clear="none"/>of March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial assets carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">629,367</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">350,183</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">279,184</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial liabilities carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(657</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements as <br clear="none"/>of December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (asset position):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">141,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">665,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">372,663</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">292,720</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (liability position):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,765</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(657</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(769</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(132</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,816</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the notional amount of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">215,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">320,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">209,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values of the assets and liabilities recorded on the effective date of the Parion Agreement:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.49206349206349%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 4, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(91,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other assets (liabilities)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,468</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net assets attributable to noncontrolling interests</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,156</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19,256</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,997</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,137</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,931</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,985</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(581</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the Company's other restructuring liabilities for </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">251</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,262</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$18.93&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.56</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,119</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$80.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.83</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01&#8211;$100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$100.01&#8211;$120.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$120.01&#8211;$134.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,524</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,619</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,422</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,836</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(586</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration paid and the fair value of the contingent milestone and royalty payments payable by the Company pursuant to the Parion Agreement are set forth in the table below:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.49206349206349%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 4, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Up-front payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenues, Net </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its &#8220;Customers&#8221;). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i)&#160;there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii)&#160;collectibility is reasonably assured and (iii)&#160;the price is fixed or determinable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to conclude that the price is fixed or determinable, the Company must be able to (i)&#160;calculate its gross product revenues from sales to Customers and (ii)&#160;reasonably estimate its net product revenues upon delivery to its Customers' locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a)&#160;trade allowances, such as invoice discounts for prompt payment and Customer fees, (b)&#160;estimated government and private payor rebates, chargebacks and discounts, (c)&#160;estimated reserves for expected product returns and (d)&#160;estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,707</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">924</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,280</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,049</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,698</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19,132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,281</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015 is as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.10317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss attributable to noncontrolling interest before provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for (benefit from) income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,062</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(64</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase in fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net (income) loss attributable to noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (VIE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,818</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">676</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">112,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">159,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following revenues attributable to the Janssen NV collaboration:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.57142857142857%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty revenues (INCIVO)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Collaborative revenues (telaprevir)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Total revenues attributable to the Janssen NV collaboration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,707</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">924</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,280</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,049</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,698</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19,132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,281</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense,<br clear="none"/>Net of <br clear="none"/>Estimated Forfeitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition <br clear="none"/>Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">206,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.83</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">223,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.78</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.49</font></div></td></tr></table></div></div></div> EX-101.SCH 7 vrtx-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2108100 - Disclosure - Accumulated Other Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Collaborative Arrangement - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2404407 - Disclosure - Collaborative Arrangements - Aggregate VIE Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Collaborative Arrangements Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2404408 - Disclosure - Collaborative Arrangements Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Collaborative Arrangements - CRISPR Therapeutics AG (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Collaborative Arrangements - Janssen Pharmaceutica NV (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Collaborative Arrangements - Parion Sciences, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Hedging (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Long-term Obligations link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Long-term Obligations - Fan Pier Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Long-term Obligations - San Diego Lease (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Long-term Obligations - Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Other Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Product Revenues, Net link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Product Revenues, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Product Revenues, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Restructuring Liabilities link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Restructuring Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Restructuring Liabilities (Details 2) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Restructuring Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-based Compensation Expense (Details 2) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vrtx-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 vrtx-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 vrtx-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Derivatives Offsetting Derivatives Offsetting [Table Text Block] [Table Text Block] for Derivatives Offsetting [Table] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Inventory Disclosure [Abstract] Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Collaborative Arrangement Agreement [Domain] Collaborative Arrangement Agreement [Domain] Listing of significant collaboration agreements. Janssen Janssen Collaborative Agreement [Member] Collaboration agreement entered into with Janssen Pharmaceutical, N.V. for the development, manufacture and commercialization of a product of the entity. Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Royalty revenues (INCIVO) Royalty Revenue Collaborative revenues (telaprevir) Collaborative Revenues The aggregate revenue from collaborative revenues. It includes the revenues earned by the entity from nonrefundable, up-front license fees; net reimbursements of research and/or development efforts, including manufacturing services; and milestone payments. Total revenues Revenues Long-term Debt and Capital Lease Obligations [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] San Diego Lease San Diego Lease [Member] San Diego Lease [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Area of real estate property (in square feet) Area of Real Estate Property Length of lease Lessee Leasing Arrangements, Capital Leases, Term of Contract Lessee Leasing Arrangements, Capital Leases, Term of Contract Average yearly aggregate rent Average Yearly Aggregate Rent, Exclusive of Operating Expenses Average Yearly Aggregate Rent, Exclusive of Operating Expenses Amount of optional renewal terms Amount of Optional Renewal Terms Amount of Optional Renewal Terms Optional renewal term length Lessee Leasing Arrangements, Capital Leases, Renewal Term Lessee Leasing Arrangements, Capital Leases, Renewal Term Fan Pier Leases Fan Pier Leases [Member] Represents the fan pier leases. Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Buildings Building [Member] Construction in progress Construction in Progress [Member] Number of leases Lease Agreement, Number of Leases Represents the number of leases entered by the reporting entity. Number of buildings under lease agreement Lease Agreements Number of Buildings Represents number of buildings under lease agreements. Optional term of lease agreement (in years) Optional Term of Lease Agreement Represents additional period to extend term of lease agreement. Property and equipment, net Property, Plant and Equipment, Net Construction financing lease obligation, current and noncurrent Construction financing lease obligation, current and noncurrent Represents the current noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Schedule of Collaborative Arrangement Agreements [Table] Schedule of Collaborative Arrangement Agreements [Table] A schedule reflecting significant collaboration agreements in which the entity is a participant. Parion Sciences, Inc Parion Sciences, Inc [Member] Parion Sciences, Inc Schedule of Collaborative Arrangement Agreements [Line Items] Schedule of Collaborative Arrangement Agreements [Line Items] -- None. No documentation exists for this element. -- Provision for income taxes Income Tax Expense (Benefit) Up-front payment Collaborative Arrangement Up-front License Fee The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement. Unrecognized tax benefits Unrecognized Tax Benefits Income taxes, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Income taxes, material interest or penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Estimated reduction in unrecognized tax benefits in next fiscal year Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations and Settlements with Taxing Authorities, Estimated in Next Fiscal Year Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations and Settlements with Taxing Authorities, Estimated in Next Fiscal Year Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Kendall Restructuring Kendall Restructuring [Member] Kendall Restructuring [Member] Fan Pier Move Restructuring Fan Pier Move [Member] Fan Pier Move [Member] Other Restructuring Other Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring activities Restructuring Reserve [Roll Forward] Liability, beginning of the period Restructuring Reserve Cash payments Payments for Restructuring Cash received from subleases Restructuring Reserve Settled with Cash Receipt from Sublease Amount of cash received in the period to fully or partially offset a specified, previously accrued type of restructuring cost. Restructuring expense (income) Restructuring Charges Liability, end of the period Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Cash and Cash Equivalents [Abstract] Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Reimbursement for development and commercialization of compounds Reimbursement Revenue Time period of notice required to terminate Collaborative Arrangement, Time Period of Notice Required to Terminate Collaborative Arrangement, Time Period of Notice Required to Terminate Commitments and Contingencies Disclosure [Abstract] Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Fair Value Disclosures [Abstract] Financial assets subject to fair value measurements (excluding restricted cash and cash equivalents (Alios)) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Product Revenues [Abstract] Product Revenues [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Trade Allowances Allowance for Trade Receivables [Member] Rebates, Chargebacks and Discounts Rebates Chargebacks and Discounts [Member] A valuation allowance for amounts due to the entity for rebates, chargebacks and discounts in the normal course of business that are expected to be uncollectible. Product Returns Allowance for Sales Returns [Member] Other Incentives Copay Mitigation Rebates [Member] A valuation allowance for amounts due to the entity for copay mitigation rebates in the normal course of business that are expected to be uncollectible. Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Product Revenue Allowance and Reserve [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at December 31, 2015 Valuation Allowances and Reserves, Balance Provision related to current period sales Valuation Allowances and Reserves Provision Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to product revenues. Adjustments related to prior period sales Valuation Allowances and Reserves, Adjustments Credits/payments made Valuation Allowances and Reserves, Sales Credits or Payments, Current Represents the credits or payments to allowances and reserves. Balance at March 31, 2016 Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Indefinite-Lived Intangible Assets by Major Class [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Indefinite-lived Intangible Assets Indefinite-lived Intangible Assets [Member] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] BioAxone Biosciences Inc BioAxone Biosciences Inc [Member] BioAxone Biosciences Inc [Member] Indefinite-Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Intangible assets Other Indefinite-lived Intangible Assets In-process research and development intangible asset Variable Interest Entity, Consolidated, Carrying Amount, In-Process Research and Development Intangible Asset Variable Interest Entity, Consolidated, Carrying Amount, In-Process Research and Development Intangible Asset Fair value inputs, discount rate (percent) Fair Value Inputs, Discount Rate Goodwill Goodwill Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Senior Secured Term Loan Facility Secured Debt [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Secured Term Loan Senior Loans [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Face amount of term loan Debt Instrument, Face Amount Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Contingent interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Amount of principal repayment on quarterly installment payments from October 1, 2016 through maturity Debt Instrument, Periodic Payment, Principal Debt instrument, repayment provision, period over which present value of interest payments is determined (in years) Debt Instrument, Repayment Provision, Period Over Which Present Value of Interest Payments is Determined Debt Instrument, Repayment Provision, Period Over Which Present Value of Interest Payments is Determined Unamortized discount on term loan Debt Instrument, Unamortized Discount Activity related to the restructuring liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Changes in other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized holding gains on marketable securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized (losses) gains on foreign currency forward contracts, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total changes in other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive (income) loss attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to Vertex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Lease term (in years) Lease Term Total length of time of a real estate lease, stated in years. Restructuring and related activities, leased office space, maximum percentage used - not more than Restructuring and Related Activities, Leased Office Space, Maximum Percentage Used Maximum of percentage used of leased office space. Number of facilities decommissioned Restructuring and Related Activities, Number of Facilities Decommissioned Restructuring and Related Activities, Number of Facilities Decommissioned Number of leases terminated Number Of Lease Terminated Number Of Lease Terminated Discount rate related to leases (percent) Lease Restructuring Liability Accrual Discount Rate The credit-adjusted risk-free discount rate applied to the undiscounted amount of projected cash inflows and/or outflows to arrive at the present value of the lease restructuring liability recorded as of the balance sheet date. Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities, available for sale Available-for-sale Securities, Current Restricted cash and cash equivalents (VIE) Restricted Cash and Cash Equivalents, Current Accounts receivable, net Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Cost Method Investment in CRISPR Cost Method Investments Notes Receivable Notes, Loans and Financing Receivable, Net, Noncurrent Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Deferred revenues, current portion Deferred Revenue, Current Accrued restructuring expenses, current portion Restructuring Reserve, Current Capital lease obligations, current portion Capital Lease Obligations, Current Senior secured term loan, current portion Senior Notes, Current Other liabilities, current portion Other Liabilities, Current Total current liabilities Liabilities, Current Deferred revenues, excluding current portion Deferred Revenue, Noncurrent Accrued restructuring expenses, excluding current portion Restructuring Reserve, Noncurrent Capital lease obligations, excluding current portion Capital Lease Obligations, Noncurrent Deferred tax liability Deferred Tax Liabilities, Net, Noncurrent Construction financing lease obligation, excluding current portion Construction Financing Obligation, Noncurrent Represents the noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Senior secured term loan, net of current portion and discount Senior Notes, Noncurrent Other liabilities, excluding current portion Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at March 31, 2016 and December 31, 2015 Preferred Stock, Value, Issued Common stock, $0.01 par value; 500,000,000 and 500,000,000 shares authorized at March 31, 2016 and December 31, 2015, respectively; 247,286,705 and 246,306,818 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total Vertex shareholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and shareholders’ equity Liabilities and Equity CRISPR Therapeutics CRISPRTherapeutics [Member] CRISPR Therapeutics AG collaboration. Right to license, number of targets (up to) Collaborative Arrangement, Right to License, Number of Targets Collaborative Arrangement, Right to License, Number of Targets Investment in collaborative partner, pursuant to convertible loan agreement Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative funding Collaborative Arrangement Research Development Funding This element represents the funding under collaborative agreement 2011 amendment for research and development. Collaborative arrangement development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Prior to marketing approval, time period of notice required to terminate (in days) Collaborative Arrangement, Prior to Marketing Approval, Time Period of Notice Required to Terminate Collaborative Arrangement, Prior to Marketing Approval, Time Period of Notice Required to Terminate Subsequent to marketing approval, time period of notice required to terminate (in days) Collaborative Arrangement, Subsequent to Marketing Approval, Time Period of Notice Required to Terminate Collaborative Arrangement, Subsequent to Marketing Approval, Time Period of Notice Required to Terminate Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Accounting Policies [Abstract] Number of operating segments Number of Operating Segments Income Statement [Abstract] Revenues: Revenues [Abstract] Product revenues, net Sales Revenue, Goods, Net Royalty revenues Collaborative revenues Costs and expenses: Costs and Expenses [Abstract] Cost of product revenues Cost of Goods Sold Royalty expenses Direct Operating Cost, Royalty Expense Research and development expenses Research and Development Expense Sales, general and administrative expenses Selling, General and Administrative Expense Restructuring expenses (income), net Total costs and expenses Costs and Expenses Loss from operations Operating Income (Loss) Interest expense, net Interest Income (Expense), Net Other income (expenses), net Other Nonoperating Income (Expense) Loss from continuing operations before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Net loss (Income) loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to Vertex Net Income (Loss) Attributable to Parent Net loss: Earnings Per Share [Abstract] Basic (usd per share) Earnings Per Share, Basic Diluted (usd per share) Earnings Per Share, Diluted Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Other Income and Expenses [Abstract] Other Arrangements Other Nonoperating Income and Expense [Text Block] Maximum license fees and milestone payments Maximum license fees and milestone payments Maximum license fees and milestone payments Deferred tax liability attributable to BioAxone Variable Interest Entity, Consolidated, Carrying Amount, Deferred Tax Liability Variable Interest Entity, Consolidated, Carrying Amount, Deferred Tax Liability Purchase option, term of extension of expiration date (in years) Collaborative Arrangements, Purchase Option, Term of Extension of Expiration Date Collaborative Arrangements, Purchase Option, Term of Extension of Expiration Date Long-term Obligations Debt Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-based compensation expense by line item Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Unrecognized stock-based compensation expense, net of estimated forfeitures Schedule of Unrecognized Share-based Compensation Expense [Table Text Block] Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported. Stock options outstanding and exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Equity [Abstract] Accumulated Other Comprehensive (Loss) Income Comprehensive Income (Loss) Note [Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] This element represents a number of concepts which capture the categories of financial instruments classified as cash and cash equivalents and available-for-sale investments. Types of Financial Instruments [Domain] Types of Financial Instruments [Domain] Provides general categories of financial instruments included as cash, cash equivalents and available-for-sale investments. Total cash and cash equivalents Cash and Cash Equivalents [Member] Cash and money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Commercial paper Commercial Paper [Member] Corporate debt securities Corporate Debt Securities [Member] Total marketable securities Available-for-sale Securities [Member] U.S. Treasury securities (due within 1 year) US Treasury Securities [Member] Government-sponsored enterprise securities (due within 1 year) U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] Commercial paper (due within 1 year) Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Corporate debt securities (due within 1 year) Corporate Debt Securities, Due Within One Year [Member] Corporate Debt Securities, Due Within One Year [Member] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Amortized Cost Cash, Cash Equivalents, Available-for-sale Securities, Amortized Cost This item represents the cost of cash and cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any. Gross Unrealized Gains Cash, Cash Equivalents, Available-for-sale Securities, Gross Unrealized Gain This item represents the gross unrealized gains for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized gains are the excess of the fair value over the carrying value as of the reporting date. Gross Unrealized Losses Cash, Cash Equivalents, Available-for-sale Securities, Unrealized Loss, Gross This item represents the gross unrealized losses for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized losses are the excess of the carrying value over the fair value as of the reporting date. Fair Value Cash, Cash Equivalents and Available-for-sale Securities, Fair Value This item represents the fair value of cash, cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading. Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract] Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract] Loss attributable to noncontrolling interest before provision for income taxes Income (Loss) from Continuing Operations Attributable to Noncontrolling Interest Provision for (benefit from) income taxes Increase in fair value of contingent milestone and royalty payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Net (income) loss attributable to noncontrolling interest Contingent consideration, liability Business Combination, Contingent Consideration, Liability Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net: Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net [Abstract] Intangible assets Other assets Accounts payable Taxes payable Taxes Payable, Current Other current liabilities Deferred tax liability, net Other liabilities Noncontrolling interest Fair Value Measurements Fair Value Disclosures [Text Block] Product Revenues, Net Product Revenues Disclosure [Text Block] Product Revenues Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $18.93–$20.00 Exercise Price Range From Dollars 18.93 to Dollars 20.00 [Member] Represents the range of exercise prices from $18.93 to $20.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $20.01–$40.00 Exercise Price Range from Dollars 20.01 to Dollars 40.00 [Member] Represents the range of exercise prices from $20.01 to $40.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $40.01–$60.00 Exercise Price Range from Dollars 40.01 to Dollars 60.00 [Member] Represents the range of exercise prices from $40.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $60.01–$80.00 Exercise Price Range from Dollars 60.01 to Dollars 80.00 [Member] Represents the range of exercise prices from $60.01 to $80.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $80.01–$100.00 Exercise Price Range from Dollars 80.01 to Dollars 100.00 [Member] Represents the range of exercise prices from $80.01 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $100.01–$120.00 Exercise Price Range from Dollars 100.01 to Dollars 120.00 [Member] Represents the range of exercise prices from $100.01 to $120.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $120.01–$134.69 Exercise Price Range From Dollars 120.01 to Dollars 134.69 [Member] Represents the range of exercise prices from $120.01 to $134.69 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Exercise price, low end of range (usd per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise price, high end of range (usd per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Exercise price range, options outstanding (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Exercise price range, options outstanding, weighted-average remaining contractual life (in years) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Exercise price range, options exercisable (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Sale of HIV Protease Inhibitor Royalty Stream Sale of HIV Protease Inhibitor Royalty Stream Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline Proceeds from Sale of Royalty Rights The cash inflow from the sale of the entity's right to receive future royalty payments. Deferred revenue royalty purchase agreement Deferred Revenue Royalty Purchase Agreement This element represents the carrying value of deferred revenue recorded with regard to agreement to sell rights to receive royalty payments, as on the balance sheet date. Drug Candidate [Axis] Drug Candidate [Axis] Potential drug candidate that milestone payments are based upon Drug Candidate [Domain] Drug Candidate [Domain] [Domain] for Potential drug candidate that milestone payments are based upon ENaC Inhibitors in CF Enac Inhibitors in Cf [Member] ENaC Inhibitors in CF Enac Inhibitors in Non Cf Enac Inhibitors in Non Cf [Member] ENaC Inhibitors in Non-CF Additional Enac Inhibitors Additional Enac Inhibitors [Member] Additional ENaC Inhibitors Commercial milestones and royalties discount rate (percentage) Business Acquisition Contingent Consideration Commercial Milestones And Royalties Discount Rate The discount rate used to estimate the fair value of the contingent consideration related to commercial milestones and royalties in a business combination. Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval Collaborative Arrangement Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are commercialized. Change of control prior to clinical trial, time period of notice required to terminate (in days) Collaborative Arrangement, Change of Control Prior to Clinical Trial, Time Period of Notice Required to Terminate Collaborative Arrangement, Change of Control Prior to Clinical Trial, Time Period of Notice Required to Terminate Term of agreement following first commercial sale (in years) Collaborative Arrangement, Term of Agreement Following First Commercial Sale Collaborative Arrangement, Term of Agreement Following First Commercial Sale Development milestones discount rate low end of range (percentage) Business Acquisition Contingent Consideration Development Milestones Discount Rate Low End Of Range The low end of the range of discount rates used to estimate the fair value of the contingent consideration related to development milestones in a business combination. Development milestones discount rate high end of range (percentage) Business Acquisition Contingent Consideration Development Milestones Discount Rate High End Of Range The high end of the range of discount rates used to estimate the fair value of the contingent consideration related to development milestones in a business combination. Consideration Paid Business Combination, Consideration Transferred [Abstract] Fair value of contingent milestone and royalty payments Business Combination, Liabilities Arising from Contingencies, Amount Recognized Total consideration paid Business Combination, Consideration Transferred Deferred tax liability Net other assets (liabilities) Other Liabilities (Assets), Net Other Liabilities (Assets), Net Net assets attributable to noncontrolling interests Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Earnings Per Share Earnings Per Share [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Employee Stock Option [Member] Unvested restricted stock and restricted stock units Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cystic Fibrosis Foundation Therapeutics Incorporated Cystic Fibrosis Foundation Therapeutics Incorporated Agreement [Member] Collaboration agreement entered into with Cystic Fibrosis Foundation Therapeutics Inc., for the development, manufacture and commercialization of a product of the entity. Number of years over which funding will be made (in years) Number of Years over which Research Development Funding will be Made This element represents the number of years over which research and development funding will be made as per the collaboration agreement 2011 amendment. Milestone Revenues Milestone Revenues This element represents the revenues recorded for milestone payments received. Derivative [Table] Derivative [Table] Maximum Maximum [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Prepaid and other current assets Prepaid Expenses and Other Current Assets [Member] Other liabilities, current portion Other Current Liabilities [Member] Other assets Other Assets [Member] Other liabilities, excluding current portion Other Noncurrent Liabilities [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Euro Member Countries, Euro British pound sterling United Kingdom, Pounds Australian dollar Australia, Dollars Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign Currency Forward Contract Foreign Exchange Forward [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Derivative [Line Items] Derivative [Line Items] Derivative term Derivative, Term of Contract Notional amount of foreign currency forward contract Derivative, Notional Amount Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract] Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net [Abstract] Fair Value - assets Foreign Currency Cash Flow Hedge Asset at Fair Value Fair Value - liabilities Foreign Currency Cash Flow Hedge Liability at Fair Value Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Gross Amounts Recognized Derivative Asset, Fair Value, Gross Asset Gross Amounts Offset Derivative Asset Fair Value Gross Asset Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Derivative, Asset Fair Value, Gross Asset, Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Gross Amounts Presented Derivative Asset Gross Amounts Not Offset Derivative Asset, Not Offset, Policy Election Deduction Legal Offset Derivative Asset, Fair Value, Amount Offset Against Collateral Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Gross Amounts Recognized Derivative Liability, Fair Value, Gross Liability Gross Amounts Offset Derivative Liability Fair Value Gross Liability Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Derivative Liability, Fair Value, Gross Liability, Collateral and Other Set Off Against Gross Assets Subject to Offsetting Enforceable Master Netting Arrangement or Similar Agreement Gross Amounts Presented Derivative Liability Gross Amounts Not Offset Derivative Liability, Not Offset, Policy Election Deduction Legal Offset Derivative Liability, Fair Value, Amount Offset Against Collateral Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense Share-based Compensation Depreciation and amortization expense Depreciation, Depletion and Amortization Deferred income taxes Increase (Decrease) in Other Deferred Liability Other non-cash items, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued restructuring expense Restructuring Reserve, Period Increase (Decrease) Deferred revenues Increase (Decrease) in Deferred Revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities Maturities of marketable securities Proceeds from Sale and Maturity of Available-for-sale Securities Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment Increase in restricted cash and cash equivalents Increase (Decrease) in Restricted Cash Decrease in restricted cash and cash equivalents (VIE) Increase (Decrease) in Restricted Cash and Investments Decrease in other assets Payments for (Proceeds from) Other Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Issuances of common stock under benefit plans Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payments on capital lease obligations Payments of Financing Costs Proceeds from capital lease financing Proceeds from Long-term Capital Lease Obligations Payments on construction financing lease obligation Repayments of Long-term Capital Lease Obligations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents—beginning of period Cash and cash equivalents—end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Cash paid for income taxes Income Taxes Paid Issuances of common stock exercises from employee benefit plans receivable Conversion of Stock, Amount Issued Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Potential gross common equivalent shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Stock-based Compensation Expense Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Other Assets Foreign currency forward contracts Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring basis Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Investment Type [Axis] Investment Type [Axis] Investment Type Categorization [Domain] Investments [Domain] Money market funds Money Market Funds [Member] U.S. Treasury securities Corporate debt securities Fair value of financial assets and liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets carried at fair value: Assets, Fair Value Disclosure [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Marketable securities Marketable Securities Foreign currency forward contracts Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net Total financial assets Assets, Fair Value Disclosure Financial instruments carried at fair value (liability position): Liabilities, Fair Value Disclosure [Abstract] Derivative liability current Derivative Liability, Current Derivative liability noncurrent Derivative Liability, Noncurrent Total financial liabilities Financial Liabilities Fair Value Disclosure Cash and cash equivalents Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents Term loan fair value Loans Payable, Fair Value Disclosure Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventories Inventory Disclosure [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Income Statement Location [Domain] Research and development expenses Research and Development Expense [Member] Sales, general and administrative expenses Selling General and Administrative Expense [Member] The allocation (or location) of expense to (in) selling, general and administrative expense. Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock options Restricted stock and restricted stock units Employee Restricted Stock Option [Member] An arrangement whereby certain members of senior management are entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. ESPP share issuances Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Stock-based compensation expense by type of award: Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Less stock-based compensation expense capitalized to inventories Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Total stock-based compensation included in costs and expenses Allocated Share-based Compensation Expense Type of award: Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Unrecognized Expense, Net of Estimated Forfeitures Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted-average recognition period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates and Summary of Significant Accounting Policies Use of Estimates, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of product revenue allowances and reserve categories Schedule of Valuation and Qualifying Accounts [Table Text Block] Tabular disclosure of product revenues allowances and reserve accounts (their beginning and ending balances, as well as reconciliation by type of activity during the period). Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Total Vertex Shareholders’ Equity Parent [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Noncontrolling Interest Noncontrolling Interest [Member] Statement Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (shares) Shares, Outstanding Balance Other comprehensive loss, net of tax Issuance of common stock under benefit plans (shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Balance (shares) Balance Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrealized Holding Gains (Losses) on Marketable Securities Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Unrealized Gains (Losses) on Foreign Currency Forward Contracts, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Balance at balance sheet date Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Balance at balance sheet date Schedule of Recognized Collaborative Revenue Schedule of Recognized Collaborative Revenue [Table Text Block] This element represents the revenues related to the collaboration recognized by the entity during the period. Fair Value Of Consideration Transferred Fair Value Of Consideration Transferred [Table Text Block] [Table Text Block] for Fair Value Of Consideration Transferred [Table] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest [Table Text Block] Represents the summary of activity related to the Alios Collaboration. Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities [Table Text Block] Represents details pertaining to Variable Interest Entities assets and liabilities included in the company's condensed consolidated balance sheets. Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Other Comprehensive (Loss) Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Restructuring Liabilities Restructuring and Related Activities Disclosure [Text Block] Summary of cash, cash equivalents and marketable securities Cash, Cash Equivalents and Investments [Table Text Block] EX-101.PRE 11 vrtx-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2016
Apr. 20, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Mar. 31, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   247,349,864
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenues:    
Product revenues, net $ 394,410 $ 130,875
Royalty revenues 3,596 6,792
Collaborative revenues 74 842
Total revenues 398,080 138,509
Costs and expenses:    
Cost of product revenues 49,789 9,381
Royalty expenses 860 2,926
Research and development expenses 255,860 215,599
Sales, general and administrative expenses 105,214 85,860
Restructuring expenses (income), net 687 (3,272)
Total costs and expenses 412,410 310,494
Loss from operations (14,330) (171,985)
Interest expense, net (20,698) (21,307)
Other income (expenses), net 4,411 (5,113)
Loss from continuing operations before provision for income taxes (30,617) (198,405)
Provision for income taxes 5,485 299
Net loss (36,102) (198,704)
(Income) loss attributable to noncontrolling interest (5,529) 98
Net loss attributable to Vertex $ (41,631) $ (198,606)
Net loss:    
Basic (usd per share) $ (0.17) $ (0.83)
Diluted (usd per share) $ (0.17) $ (0.83)
Shares used in per share calculations:    
Basic (in shares) 243,831 239,493
Diluted (in shares) 243,831 239,493
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]    
Net loss $ (36,102) $ (198,704)
Changes in other comprehensive loss:    
Unrealized holding gains on marketable securities 229 176
Unrealized (losses) gains on foreign currency forward contracts, net of tax (5,212) 306
Foreign currency translation adjustment (1,740) (608)
Total changes in other comprehensive loss (6,723) (126)
Comprehensive loss (42,825) (198,830)
Comprehensive (income) loss attributable to noncontrolling interest (5,529) 98
Comprehensive loss attributable to Vertex $ (48,354) $ (198,732)
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 604,245 $ 714,768
Marketable securities, available for sale 421,373 327,694
Restricted cash and cash equivalents (VIE) 76,273 78,910
Accounts receivable, net 181,878 177,639
Inventories 63,200 57,207
Prepaid expenses and other current assets 55,866 50,935
Total current assets 1,402,835 1,407,153
Property and equipment, net 690,521 697,715
Intangible assets 284,340 284,340
Goodwill 50,384 50,384
Cost Method Investment in CRISPR 30,138 0
Notes Receivable 0 30,000
Restricted cash 22,088 22,083
Other assets 7,600 6,912
Total assets 2,487,906 2,498,587
Current liabilities:    
Accounts payable 75,221 74,942
Accrued expenses 272,665 305,820
Deferred revenues, current portion 14,705 16,296
Accrued restructuring expenses, current portion 7,790 7,894
Capital lease obligations, current portion 17,292 15,545
Senior secured term loan, current portion 146,251 71,296
Other liabilities, current portion 18,117 14,374
Total current liabilities 552,041 506,167
Deferred revenues, excluding current portion 8,490 9,714
Accrued restructuring expenses, excluding current portion 6,145 7,464
Capital lease obligations, excluding current portion 38,886 42,923
Deferred tax liability 112,259 110,439
Construction financing lease obligation, excluding current portion 472,494 472,611
Senior secured term loan, net of current portion and discount 149,571 223,863
Other liabilities, excluding current portion 31,822 31,778
Total liabilities $ 1,371,708 $ 1,404,959
Commitments and contingencies
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at March 31, 2016 and December 31, 2015 $ 0 $ 0
Common stock, $0.01 par value; 500,000,000 and 500,000,000 shares authorized at March 31, 2016 and December 31, 2015, respectively; 247,286,705 and 246,306,818 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively 2,429 2,427
Additional paid-in capital 6,262,964 6,197,500
Accumulated other comprehensive (loss) income (4,899) 1,824
Accumulated deficit (5,303,415) (5,261,784)
Total Vertex shareholders' equity 957,079 939,967
Noncontrolling interest 159,119 153,661
Total shareholders’ equity 1,116,198 1,093,628
Total liabilities and shareholders’ equity $ 2,487,906 $ 2,498,587
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred stock, par value (usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (usd per share) $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 247,286,705 246,306,818
Common stock, shares outstanding 247,286,705 246,306,818
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Total Vertex Shareholders’ Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Noncontrolling Interest
Balance (shares) at Dec. 31, 2014     241,764        
Balance at Dec. 31, 2014 $ 1,096,183 $ 1,075,006 $ 2,385 $ 5,777,154 $ 917 $ (4,705,450) $ 21,177
Increase (Decrease) in Stockholders' Equity              
Other comprehensive loss, net of tax (126) (126)     (126)    
Net loss (198,704) (198,606)       (198,606) (98)
Issuance of common stock under benefit plans (shares)     1,816        
Issuance of common stock under benefit plans 41,916 41,916 $ 14 41,902     0
Stock-based compensation expense 58,268 58,268   58,268     0
Balance (shares) at Mar. 31, 2015     243,580        
Balance at Mar. 31, 2015 997,537 976,458 $ 2,399 5,877,324 791 (4,904,056) 21,079
Balance (shares) at Dec. 31, 2015     246,307        
Balance at Dec. 31, 2015 1,093,628 939,967 $ 2,427 6,197,500 1,824 (5,261,784) 153,661
Increase (Decrease) in Stockholders' Equity              
Other comprehensive loss, net of tax (6,723) (6,723)     (6,723)    
Net loss (36,102) (41,631)       (41,631) 5,529
Issuance of common stock under benefit plans (shares)     980        
Issuance of common stock under benefit plans 9,149 9,149 $ 2 9,147      
Stock-based compensation expense 56,246 56,317   56,317     (71)
Balance (shares) at Mar. 31, 2016     247,287        
Balance at Mar. 31, 2016 $ 1,116,198 $ 957,079 $ 2,429 $ 6,262,964 $ (4,899) $ (5,303,415) $ 159,119
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net loss $ (36,102) $ (198,704)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 55,472 57,384
Depreciation and amortization expense 16,415 16,363
Deferred income taxes 2,060 0
Other non-cash items, net (3,835) 629
Changes in operating assets and liabilities:    
Accounts receivable, net (2,512) (5,863)
Inventories (4,771) (2,635)
Prepaid expenses and other assets (7,325) (15,233)
Accounts payable (343) (23,556)
Accrued expenses and other liabilities (29,922) (20,921)
Accrued restructuring expense (1,459) (24,367)
Deferred revenues (2,815) (5,333)
Net cash used in operating activities (15,137) (222,236)
Cash flows from investing activities:    
Purchases of marketable securities (224,624) (125,655)
Maturities of marketable securities 131,173 371,423
Expenditures for property and equipment (11,974) (10,558)
Increase in restricted cash and cash equivalents (3) (21,971)
Decrease in restricted cash and cash equivalents (VIE) 2,637 0
Decrease in other assets 83 799
Net cash (used in) provided by investing activities (102,708) 214,038
Cash flows from financing activities:    
Issuances of common stock under benefit plans 8,846 41,616
Payments on capital lease obligations (4,041) (4,497)
Proceeds from capital lease financing 0 13,386
Payments on construction financing lease obligation (103) (91)
Net cash provided by financing activities 4,702 50,414
Effect of changes in exchange rates on cash 2,620 (2,596)
Net increase in cash and cash equivalents (110,523) 39,620
Cash and cash equivalents—beginning of period 714,768 625,259
Cash and cash equivalents—end of period 604,245 664,879
Supplemental disclosure of cash flow information:    
Cash paid for interest 20,603 21,538
Cash paid for income taxes 581 60
Issuances of common stock exercises from employee benefit plans receivable $ 593 $ 964
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
Basis of Presentation and Accounting Policies
 3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies
Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2016 and 2015.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2016 (the "2015 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2015 Annual Report on Form 10-K.
Recent Accounting Pronouncements
In 2016, the Financial Accounting Standards Board (“FASB”) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2015 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the three months ended March 31, 2016 that had a material effect on its condensed consolidated financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
Product Revenues, Net
 3 Months Ended
Mar. 31, 2016
Product Revenues [Abstract]  
Product Revenues, Net
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its “Customers”). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customers' locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and Customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.
The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2016:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2015
$
2,089

 
$
44,669

 
$
1,228

 
$
1,310

 
$
49,296

Provision related to current period sales
4,707

 
31,138

 
924

 
3,280

 
40,049

Adjustments related to prior period sales
(38
)
 
(2,181
)
 
(75
)
 
—

 
(2,294
)
Credits/payments made
(4,698
)
 
(19,132
)
 
(260
)
 
(3,281
)
 
(27,371
)
Balance at March 31, 2016
$
2,060

 
$
54,494

 
$
1,817

 
$
1,309

 
$
59,680
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements
 3 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative Arrangements
Collaborative Arrangements
Cystic Fibrosis Foundation Therapeutics Incorporated
In April 2011, the Company entered into an amendment (the “April 2011 Amendment”) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) pursuant to which CFFT agreed to provide financial support for (i) development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii) additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein.
Under the April 2011 Amendment, CFFT agreed to provide the Company with up to $75.0 million in funding over approximately five years for corrector compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor and VX-661. The Company recognized no collaborative revenues from this collaboration during the three months ended March 31, 2016 and 2015.
In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs first synthesized or tested during the research term that ended in 2008, including ivacaftor, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds first synthesized or tested during the research term that ended in February 2014. In each of 2012 and 2013, CFFT earned a commercial milestone payment of $9.3 million from the Company upon achievement of certain sales levels for KALYDECO. In each of the fourth quarter of 2015 and first quarter of 2016, CFFT earned a commercial milestone payment of $13.9 million from the Company upon achievement of certain sales levels of lumacaftor. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO or ORKAMBI.
The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in 2015. The Company received approval for ORKAMBI in the European Union in 2015 and in Canada and Australia in 2016. The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and VX-661 until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of VX-661 that expire in 2027 and 2028, respectively, subject to potential extension.
CRISPR Therapeutics AG
On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to six CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of $75.0 million and a $30.0 million investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed $75.0 million to research and development, and the $30.0 million investment was recorded at cost and is classified as a long-term asset on the Company’s condensed consolidated balance sheet.
The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to six targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net product sales.
The Company may terminate the CRISPR Agreement upon 90 days’ notice to CRISPR prior to any product receiving marketing approval or upon 270 days’ notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.
Janssen Pharmaceutica NV
The Company has a collaboration agreement (the “Janssen HCV Agreement”) with Janssen Pharmaceutica NV (“Janssen NV”) for the development, manufacture and commercialization of telaprevir, which Janssen NV began marketing under the brand name INCIVO in certain of its territories in September 2011. Pursuant to the Janssen HCV Agreement, as amended, Janssen NV has a fully-paid license to manufacture and commercialize INCIVO in its territories including Europe, South America, the Middle East, Africa and Australia, subject to the payment of third-party royalties on net sales of INCIVO. In addition to the collaborative revenues, the Company recorded royalty revenues and corresponding royalty expenses related to third-party royalties that Janssen NV remains responsible for based on INCIVO net sales.
During the three months ended March 31, 2016 and 2015, the Company recognized the following revenues attributable to the Janssen NV collaboration:
 
Three Months Ended March 31,
 
2016
 
2015
 
(in thousands)
Royalty revenues (INCIVO)
$
78

 
$
1,525

Collaborative revenues (telaprevir)
—

 
642

  Total revenues attributable to the Janssen NV collaboration
$
78

 
$
2,167



Variable Interest Entities
The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the Company's condensed consolidated financial statements as VIEs. In order to account for the fair value of the contingent milestone and royalty payments related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop the drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are reflected in the Company's financial statements as consolidated VIEs:
Parion Sciences, Inc.
License and Collaboration Agreement

On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (“Parion”).  Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.  The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.

Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion’s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion’s research program.  Parion received an $80.0 million up-front payment and has the potential to receive up to an additional (i) $490.0 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360.0 million related to global filing and approval milestones, (ii) $370.0 million in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii) $230.0 million in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion’s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.

The Company may terminate the Parion Agreement upon 90 days’ notice to Parion prior to any licensed product receiving marketing approval or upon 180 days’ notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon 30 days’ notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i) the date the last-to-expire patent covering a licensed product expires or (ii) ten years after the first commercial sale in the country.

The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly affect the economic performance of Parion.  Accordingly, the Company consolidated Parion's financial statements beginning on June 4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement. In particular, the Company did not acquire any equity interest in Parion, any interest in Parion's cash and cash equivalents or any control over Parion's activities that do not relate to the Parion Agreement.
Consideration for the Parion Agreement

The Company determined that the fair value of the consideration from the Company to Parion was $255.3 million as of June 4, 2015, which consisted of (i) an $80.0 million up-front payment, (ii) the estimated fair value of the contingent research and development milestones potentially payable by the Company to Parion and (iii) the estimated fair value of potential royalty payments payable by the Company to Parion. The Company valued the contingent milestone and royalty payments using (a) discount rates ranging from 4.1% to 5.9% for the development milestones and (b) a discount rate of 6.6% for royalties. The consideration paid and the fair value of the contingent milestone and royalty payments payable by the Company pursuant to the Parion Agreement are set forth in the table below:
 
June 4, 2015
 
(in thousands)
Up-front payment
$
80,000

Fair value of contingent milestone and royalty payments
175,340

Total
$
255,340


Allocation of Assets and Liabilities

For the purposes of the condensed consolidated balance sheets at June 4, 2015 and March 31, 2016, the Company allocated the total consideration, which is comprised of the up-front payment and the fair value of the contingent milestone and royalty payments, intangible assets, goodwill, deferred tax liability, net and net other assets and liabilities.

The Company recorded $255.3 million of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The difference between the fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill.

The following table summarizes the fair values of the assets and liabilities recorded on the effective date of the Parion Agreement:
 
June 4, 2015
 
(in thousands)
Intangible assets
$
255,340

Goodwill
10,468

Deferred tax liability
(91,023
)
Net other assets (liabilities)
(10,468
)
Net assets attributable to noncontrolling interests
$
164,317


BioAxone Biosciences, Inc.
In October 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone Biosciences, Inc. (“BioAxone”), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of $10.0 million in the fourth quarter of 2014.
BioAxone has the potential to receive up to $90.0 million in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of $29.0 million for VX-210 and a corresponding deferred tax liability of $11.3 million attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company’s option to extend this date by one year.
Aggregate VIE Financial Information

An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three months ended March 31, 2016 and 2015 is as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
839

 
$
287

Provision for (benefit from) income taxes
3,062

 
(64
)
Increase in fair value of contingent milestone and royalty payments
(9,430
)
 
(125
)
Net (income) loss attributable to noncontrolling interest
$
(5,529
)
 
$
98



During the three months ended March 31, 2016 and 2015, the fair value of the contingent milestone and royalty payments related to the BioAxone Agreement increased by $0.4 million and $0.1 million, respectively. During the three months ended March 31, 2016 the fair value of the contingent milestone and royalty payments related to the Parion Agreement increased by $9.0 million. The changes in the fair value of the contingent milestone and royalty payments were primarily due to the changes in market interest rates and the time value of money. As of March 31, 2016, the fair value of the contingent milestone and royalty payments related to the BioAxone Agreement and the Parion Agreement was $28.4 million and $188.0 million, respectively. As of December 31, 2015, the fair value of the contingent milestone and royalty payments related to the BioAxone collaboration and the Parion collaboration was $28.0 million and $179.0 million, respectively.

The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:
 
March 31, 2016
 
December 31, 2015
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
76,273

 
$
78,910

Prepaid expenses and other current assets
2,818

 
3,138

Intangible assets
284,340

 
284,340

Goodwill
19,391

 
19,391

Other assets
434

 
455

Accounts payable
1,569

 
676

Taxes payable
24,512

 
24,554

Other current liabilities
6,595

 
7,100

Deferred tax liability, net
112,259

 
110,438

Other liabilities
310

 
300

Noncontrolling interest
159,119

 
153,661



The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i) the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii) the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company's VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets.
Outlicense Arrangements
In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration.

Janssen Pharmaceuticals, Inc.
In June 2014, the Company entered into an agreement (the “Janssen Influenza Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen Inc.”), which was amended in October 2014 to clarify certain roles and responsibilities of the parties.

Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of $35.0 million from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any.
Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During the three months ended March 31, 2016 and 2015, the Company recorded reimbursement for these development activities of $3.5 million and $7.6 million, respectively. The reimbursements are recorded as a reduction to development expense in the Company's condensed consolidated statements of operations primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon six months' notice.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
Earnings Per Share
 3 Months Ended
Mar. 31, 2016
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Stock options
12,619

 
12,682

Unvested restricted stock and restricted stock units
3,565

 
3,474
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair Value Measurements
 3 Months Ended
Mar. 31, 2016
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of March 31, 2016, the Company’s investments were in money market funds, short-term government-sponsored enterprise securities, U.S. Treasury securities, corporate debt securities and commercial paper.
As of March 31, 2016, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, short-term government-sponsored enterprise securities and U.S. Treasury securities. The Company’s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations.
The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:
 
Fair Value Measurements as
of March 31, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
190,601

 
$
190,601

 
$
—

 
$
—

Corporate debt securities
13,557

 
—

 
13,557

 
—

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities
33,104

 
33,104

 
—

 
—

Government-sponsored enterprise securities
126,478

 
126,478

 
—

 
—

Corporate debt securities
120,229

 
—

 
120,229

 
—

Commercial paper
141,562

 
—

 
141,562

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
3,654

 
—

 
3,654

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
182

 
—

 
182

 
—

Total financial assets
$
629,367


$
350,183

 
$
279,184

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(3,765
)
 
$
—

 
$
(3,765
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(657
)
 
—

 
(657
)
 
—

Total financial liabilities
$
(4,422
)
 
$
—

 
$
(4,422
)
 
$
—


 
Fair Value Measurements as
of December 31, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
199,507

 
$
199,507

 
$
—

 
$
—

Government-sponsored enterprise securities
85,994

 
85,994

 
—

 
—

Commercial paper
34,889

 
—

 
34,889

 
—

Corporate debt securities
11,533

 
—

 
11,533

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
87,162

 
87,162

 
—

 
—

Commercial paper
141,409

 
—

 
141,409

 
—

Corporate debt securities
99,123

 
—

 
99,123

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
5,161

 
—

 
5,161

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
605

 
$
—

 
605

 
$
—

Total financial assets
$
665,383

 
$
372,663

 
$
292,720

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(769
)
 
$
—

 
$
(769
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(132
)
 
—

 
(132
)
 
—

Total financial liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
—


The Company's VIEs invested in cash equivalents consisting of money market funds of $76.0 million as of March 31, 2016, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company’s noncontrolling interest related to VIEs includes the fair value of the contingent milestone and royalty payments, which are valued based on Level 3 inputs. Please refer to Note C, “Collaborative Arrangements,” for further information.
As of March 31, 2016, the fair value and carrying value of the Company's Term Loan was $295.8 million. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current market rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
Marketable Securities
 3 Months Ended
Mar. 31, 2016
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of March 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
590,688

 
$
—

 
$
—

 
$
590,688

Corporate debt securities
13,557

 
—

 
—

 
13,557

Total cash and cash equivalents
$
604,245

 
$
—

 
$
—

 
$
604,245

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
33,108

 
$
—

 
$
(4
)
 
$
33,104

Government-sponsored enterprise securities (due within 1 year)
126,461

 
17

 
—

 
126,478

Commercial paper (due within 1 year)
141,243

 
319

 
—

 
141,562

Corporate debt securities (due within 1 year)
120,206

 
23

 
—

 
120,229

Total marketable securities
$
421,018

 
$
359

 
$
(4
)
 
$
421,373

Total cash, cash equivalents and marketable securities
$
1,025,263

 
$
359

 
$
(4
)
 
$
1,025,618

 
 
 
 
 
 
 
 
As of December 31, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
582,352

 
$
—

 
$
—

 
$
582,352

Government-sponsored enterprise securities
85,994

 
—

 
—

 
85,994

Commercial paper
34,889

 
—

 
—

 
34,889

Corporate debt securities
11,533

 
—

 
—

 
11,533

Total cash and cash equivalents
$
714,768

 
$
—

 
$
—

 
$
714,768

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
87,176

 
$
—

 
$
(14
)
 
$
87,162

Commercial paper (due within 1 year)
98,877

 
246

 
—

 
99,123

Corporate debt securities (due within 1 year)
141,515

 
—

 
(106
)
 
141,409

Total marketable securities
$
327,568

 
$
246

 
$
(120
)
 
$
327,694

Total cash, cash equivalents and marketable securities
$
1,042,336

 
$
246

 
$
(120
)
 
$
1,042,462


The Company has a limited number of marketable securities in insignificant loss positions as of March 31, 2016, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three months ended March 31, 2016 and 2015.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
Accumulated Other Comprehensive (Loss) Income
 3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, net of tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(1,740
)
 
229

 
(3,827
)
 
(5,338
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(1,385
)
 
(1,385
)
Net current period other comprehensive (loss) income
$
(1,740
)
 
$
229

 
$
(5,212
)
 
$
(6,723
)
Balance at March 31, 2016
$
(3,820
)
 
$
355

 
$
(1,434
)
 
$
(4,899
)

 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized (Losses) Gains on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
(608
)
 
176

 
2,004

 
1,572

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(1,698
)
 
(1,698
)
Net current period other comprehensive (loss) income
$
(608
)
 
$
176

 
$
306

 
$
(126
)
Balance at March 31, 2015
$
(1,579
)
 
$
53

 
$
2,317

 
$
791
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
Hedging
 3 Months Ended
Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging
Hedging
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2016, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:
 
As of March 31, 2016
 
As of December 31, 2015
Foreign Currency
(in thousands)
Euro
$
215,343

 
$
103,362

British pound sterling
76,395

 
78,756

Australian dollar
28,837

 
27,167

Total foreign currency forward contracts
$
320,575

 
$
209,285


The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of March 31, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
3,654

 
Other liabilities, current portion
 
$
(3,765
)
Other assets
 
182

 
Other liabilities, excluding current portion
 
(657
)
Total assets
 
$
3,836

 
Total liabilities
 
$
(4,422
)
As of December 31, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
5,161

 
Other liabilities, current portion
 
$
(769
)
Other assets
 
605

 
Other liabilities, excluding current portion
 
(132
)
Total assets
 
$
5,766

 
Total liabilities
 
$
(901
)
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:
 
As of March 31, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
3,836

 
$
—

 
$
3,836

 
$
(3,836
)
 
$
—

Total liabilities
$
(4,422
)
 
$
—

 
$
(4,422
)
 
$
3,836

 
$
(586
)
 
As of December 31, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
5,766

 
$
—

 
$
5,766

 
$
(901
)
 
$
4,865

Total liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
901

 
$
—
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventories
 3 Months Ended
Mar. 31, 2016
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following:
 
As of March 31, 2016
 
As of December 31, 2015
 
(in thousands)
Raw materials
$
9,936

 
$
8,696

Work-in-process
37,899

 
40,695

Finished goods
15,365

 
7,816

Total
$
63,200

 
$
57,207
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
Intangible Assets and Goodwill
 3 Months Ended
Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
Intangible Assets and Goodwill
Intangible Assets
As of March 31, 2016 and December 31, 2015, in-process research and development intangible assets of $284.3 million were recorded on the Company's condensed consolidated balance sheet.
In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of $255.3 million based on the Company’s estimate of the fair value of Parion’s lead investigational ENaC inhibitors, including VX-371 and VX-551, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of $29.0 million based on the Company’s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of 7.1% and 7.5% in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively.
The Company also conducted an evaluation of Parion and BioAxone's other programs at the effective date of the Parion Agreement and BioAxone Agreement, respectively, and determined that market participants would not have ascribed value to those programs because of the stage of development of the assets in each program and uncertainties related to the potential development and commercialization of the programs.
Goodwill
As of March 31, 2016 and December 31, 2015, goodwill of $50.4 million was recorded on the Company's condensed consolidated balance sheet.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
Long-term Obligations
 3 Months Ended
Mar. 31, 2016
Long-term Debt and Capital Lease Obligations [Abstract]  
Long-term Obligations
Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings (the “Buildings”) at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.
Property and equipment, net, included $499.0 million and $502.3 million as of March 31, 2016 and December 31, 2015, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was $472.9 million and $473.0 million as of March 31, 2016 and December 31, 2015, respectively.
San Diego Lease
On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC. Pursuant to this agreement, the Company agreed to lease approximately 170,000 square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the second half of 2017, and will extend for 16 years from the commencement date. Pursuant to the lease agreement, during the initial 16-year term, the Company will pay an average of approximately $10.2 million per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to two additional five-year terms.

Term Loan
In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a $300.0 million senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed $200.0 million.
The Term Loan initially bore interest at a rate of 7.2% per annum, which was reduced to 6.2% per annum based on the FDA's approval of ORKAMBI. The Term Loan will bear interest at a rate of LIBOR plus 5.0% per annum during the third year of the term.
The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of $75 million from October 1, 2016 through the maturity date.
The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of two years of interest payments over the life of the loan. The Company accounted for the amendment as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.
The Company's obligations under the Term Loan are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the Term Loan, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries.
The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended March 31, 2016.
Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.
The Company incurred $5.3 million in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company’s condensed consolidated statements of operations. As of March 31, 2016 and December 31, 2015, the unamortized discount associated with the Term Loan that was included in the senior secured term loan caption on the Company’s condensed consolidated balance sheet was $4.0 million and $4.6 million, respectively.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-based Compensation Expense
 3 Months Ended
Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based Compensation Expense
Stock-based Compensation Expense
During the three months ended March 31, 2016 and 2015, the Company recognized the following stock-based compensation expense included in loss from continuing operations:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Stock-based compensation expense by type of award:
 
 
 
Stock options
$
26,260

 
$
28,959

Restricted stock and restricted stock units
27,533

 
27,169

ESPP share issuances
2,524

 
2,140

Less stock-based compensation expense capitalized to inventories
(845
)
 
(884
)
Total stock-based compensation included in costs and expenses
$
55,472

 
$
57,384

 
 
 


Stock-based compensation expense by line item:
 
 
 
Research and development expenses
$
34,448

 
$
38,217

Sales, general and administrative expenses
21,024

 
19,167

Total stock-based compensation included in costs and expenses
$
55,472

 
$
57,384


The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of March 31, 2016
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
206,783

 
2.83
Restricted stock and restricted stock units
$
223,184

 
2.78
ESPP share issuances
$
3,143

 
0.49

The following table summarizes information about stock options outstanding and exercisable at March 31, 2016:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
138

 
1.85
 
$
18.93

 
138

 
$
18.93

$20.01–$40.00
 
2,124

 
3.56
 
$
34.30

 
2,119

 
$
34.29

$40.01–$60.00
 
2,210

 
6.33
 
$
48.09

 
1,590

 
$
48.77

$60.01–$80.00
 
1,396

 
7.83
 
$
75.92

 
654

 
$
75.31

$80.01–$100.00
 
3,550

 
8.81
 
$
90.65

 
815

 
$
88.04

$100.01–$120.00
 
1,677

 
8.80
 
$
109.32

 
402

 
$
109.26

$120.01–$134.69
 
1,524

 
9.28
 
$
130.63

 
339

 
$
129.57

Total
 
12,619

 
7.36
 
$
78.61

 
6,057

 
$
59.71
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
Other Arrangements
 3 Months Ended
Mar. 31, 2016
Other Income and Expenses [Abstract]  
Other Arrangements
Other Arrangements
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of March 31, 2016, the Company had $23.2 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Income Taxes
 3 Months Ended
Mar. 31, 2016
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The Company is subject to United States federal, state, and foreign income taxes. For the three months ended March 31, 2016, the Company recorded a provision for income taxes of $5.5 million. The provision for income taxes recorded in the three months ended March 31, 2016 included $3.1 million, related to the Company's VIE's income tax provision. The Company has no liability for taxes payable by the Company's VIEs and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For the three months ended March 31, 2015, the Company recorded a provision for income taxes of $0.3 million, related to state income taxes and income earned in various foreign jurisdictions.
As of each of March 31, 2016 and December 31, 2015, the Company had unrecognized tax benefits of $0.4 million. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. As of March 31, 2016, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of March 31, 2016 and December 31, 2015. In 2016, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately $0.4 million due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company’s effective tax rate.
The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses.
The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Delaware, Canada and Quebec for varying periods including the years ended December 31, 2011 through 2013. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Pennsylvania and Texas during 2016 and Massachusetts and New York during 2015 with no material adjustments.
The Company currently intends to reinvest the total amount of its unremitted earnings. At March 31, 2016, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
Restructuring Liabilities
 3 Months Ended
Mar. 31, 2016
Restructuring and Related Activities [Abstract]  
Restructuring Liabilities
Restructuring Liabilities
2003 Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018. The Company has not used more than 50% of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties.
The activities related to the restructuring liability for the three months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
7,944

 
$
11,596

Cash payments
(3,931
)
 
(3,985
)
Cash received from subleases
3,008

 
2,476

Restructuring expense (income)
203

 
(581
)
Liability, end of the period
$
7,224

 
$
9,506



Fan Pier Move Restructuring
In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning three facilities in Cambridge. During the first quarter of 2015, the Company terminated two of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company’s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company’s landlord on the effective date of the termination. The third major facility included in this restructuring activity is 120,000 square feet of the Kendall Square Facility that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the Kendall Square Facility was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company’s estimated future cash flows related to this portion of the Kendall Square Facility, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of 9%.
The activities related to the restructuring liability for the three months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
5,964

 
$
33,390

Cash payments
(3,156
)
 
(19,256
)
Cash received from subleases
2,408

 
—

Restructuring expense (income)
233

 
(2,997
)
Liability, end of the period
$
5,449

 
$
11,137


Other Restructuring Activities
The Company has engaged in several other restructuring activities that are unrelated to its 2003 Kendall Restructuring and the Fan Pier Move Restructuring. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in CF and other research and development programs.
The activities related to the Company's other restructuring liabilities for the three months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
1,450

 
$
869

Cash payments
(439
)
 
(330
)
Restructuring expense
251

 
306

Liability, end of the period
$
1,262

 
$
845
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Financing Arrangements
As of March 31, 2016, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling $21.9 million that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of March 31, 2016, on the Company's condensed consolidated balance sheet.
Litigation
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company’s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of the Company’s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs’ opposition to its motion to dismiss.  The court heard oral argument on the motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The First Circuit Court of Appeals issued a scheduling order on December 24, 2015. On February 2, 2016, the Plaintiff filed their opening brief and the Company filed its opposition brief on March 7, 2016. On March 24, 2016, the plaintiff filed their reply brief. The Company believes the claims to be without merit and intend to vigorously defend the litigation. As of March 31, 2016, the Company has not recorded any reserves for this purported class action.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of March 31, 2016 or December 31, 2015.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
Basis of Presentation and Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2016 and 2015.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2016 (the "2015 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In 2016, the Financial Accounting Standards Board (“FASB”) issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This update requires an entity to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that will be effective for the year ending December 31, 2017. Early adoption is permitted. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is in the process of evaluating the new guidance and determining the expected effect on its consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2015 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the three months ended March 31, 2016 that had a material effect on its condensed consolidated financial statements.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
Product Revenues, Net (Tables)
 3 Months Ended
Mar. 31, 2016
Product Revenues [Abstract]  
Schedule of product revenue allowances and reserve categories
The following table summarizes activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2016:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2015
$
2,089

 
$
44,669

 
$
1,228

 
$
1,310

 
$
49,296

Provision related to current period sales
4,707

 
31,138

 
924

 
3,280

 
40,049

Adjustments related to prior period sales
(38
)
 
(2,181
)
 
(75
)
 
—

 
(2,294
)
Credits/payments made
(4,698
)
 
(19,132
)
 
(260
)
 
(3,281
)
 
(27,371
)
Balance at March 31, 2016
$
2,060

 
$
54,494

 
$
1,817

 
$
1,309

 
$
59,680
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements (Tables)
 3 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Recognized Collaborative Revenue
During the three months ended March 31, 2016 and 2015, the Company recognized the following revenues attributable to the Janssen NV collaboration:
 
Three Months Ended March 31,
 
2016
 
2015
 
(in thousands)
Royalty revenues (INCIVO)
$
78

 
$
1,525

Collaborative revenues (telaprevir)
—

 
642

  Total revenues attributable to the Janssen NV collaboration
$
78

 
$
2,167
Fair Value Of Consideration Transferred
The consideration paid and the fair value of the contingent milestone and royalty payments payable by the Company pursuant to the Parion Agreement are set forth in the table below:
 
June 4, 2015
 
(in thousands)
Up-front payment
$
80,000

Fair value of contingent milestone and royalty payments
175,340

Total
$
255,340
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the fair values of the assets and liabilities recorded on the effective date of the Parion Agreement:
 
June 4, 2015
 
(in thousands)
Intangible assets
$
255,340

Goodwill
10,468

Deferred tax liability
(91,023
)
Net other assets (liabilities)
(10,468
)
Net assets attributable to noncontrolling interests
$
164,317
Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest
n aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three months ended March 31, 2016 and 2015 is as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
839

 
$
287

Provision for (benefit from) income taxes
3,062

 
(64
)
Increase in fair value of contingent milestone and royalty payments
(9,430
)
 
(125
)
Net (income) loss attributable to noncontrolling interest
$
(5,529
)
 
$
98
Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities
The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:
 
March 31, 2016
 
December 31, 2015
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
76,273

 
$
78,910

Prepaid expenses and other current assets
2,818

 
3,138

Intangible assets
284,340

 
284,340

Goodwill
19,391

 
19,391

Other assets
434

 
455

Accounts payable
1,569

 
676

Taxes payable
24,512

 
24,554

Other current liabilities
6,595

 
7,100

Deferred tax liability, net
112,259

 
110,438

Other liabilities
310

 
300

Noncontrolling interest
159,119

 
153,661
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2016
Earnings Per Share [Abstract]  
Potential gross common equivalent shares
The Company did not include the securities in the following table in the computation of the net loss per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Stock options
12,619

 
12,682

Unvested restricted stock and restricted stock units
3,565

 
3,474
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2016
Fair Value Disclosures [Abstract]  
Financial assets subject to fair value measurements (excluding restricted cash and cash equivalents (Alios))
The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents) and liabilities subject to fair value measurements:
 
Fair Value Measurements as
of March 31, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
190,601

 
$
190,601

 
$
—

 
$
—

Corporate debt securities
13,557

 
—

 
13,557

 
—

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities
33,104

 
33,104

 
—

 
—

Government-sponsored enterprise securities
126,478

 
126,478

 
—

 
—

Corporate debt securities
120,229

 
—

 
120,229

 
—

Commercial paper
141,562

 
—

 
141,562

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
3,654

 
—

 
3,654

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
182

 
—

 
182

 
—

Total financial assets
$
629,367


$
350,183

 
$
279,184

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(3,765
)
 
$
—

 
$
(3,765
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(657
)
 
—

 
(657
)
 
—

Total financial liabilities
$
(4,422
)
 
$
—

 
$
(4,422
)
 
$
—


 
Fair Value Measurements as
of December 31, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
199,507

 
$
199,507

 
$
—

 
$
—

Government-sponsored enterprise securities
85,994

 
85,994

 
—

 
—

Commercial paper
34,889

 
—

 
34,889

 
—

Corporate debt securities
11,533

 
—

 
11,533

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
87,162

 
87,162

 
—

 
—

Commercial paper
141,409

 
—

 
141,409

 
—

Corporate debt securities
99,123

 
—

 
99,123

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
5,161

 
—

 
5,161

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
605

 
$
—

 
605

 
$
—

Total financial assets
$
665,383

 
$
372,663

 
$
292,720

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(769
)
 
$
—

 
$
(769
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(132
)
 
—

 
(132
)
 
—

Total financial liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
—
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
Marketable Securities (Tables)
 3 Months Ended
Mar. 31, 2016
Cash and Cash Equivalents [Abstract]  
Summary of cash, cash equivalents and marketable securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of March 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
590,688

 
$
—

 
$
—

 
$
590,688

Corporate debt securities
13,557

 
—

 
—

 
13,557

Total cash and cash equivalents
$
604,245

 
$
—

 
$
—

 
$
604,245

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
33,108

 
$
—

 
$
(4
)
 
$
33,104

Government-sponsored enterprise securities (due within 1 year)
126,461

 
17

 
—

 
126,478

Commercial paper (due within 1 year)
141,243

 
319

 
—

 
141,562

Corporate debt securities (due within 1 year)
120,206

 
23

 
—

 
120,229

Total marketable securities
$
421,018

 
$
359

 
$
(4
)
 
$
421,373

Total cash, cash equivalents and marketable securities
$
1,025,263

 
$
359

 
$
(4
)
 
$
1,025,618

 
 
 
 
 
 
 
 
As of December 31, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
582,352

 
$
—

 
$
—

 
$
582,352

Government-sponsored enterprise securities
85,994

 
—

 
—

 
85,994

Commercial paper
34,889

 
—

 
—

 
34,889

Corporate debt securities
11,533

 
—

 
—

 
11,533

Total cash and cash equivalents
$
714,768

 
$
—

 
$
—

 
$
714,768

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
87,176

 
$
—

 
$
(14
)
 
$
87,162

Commercial paper (due within 1 year)
98,877

 
246

 
—

 
99,123

Corporate debt securities (due within 1 year)
141,515

 
—

 
(106
)
 
141,409

Total marketable securities
$
327,568

 
$
246

 
$
(120
)
 
$
327,694

Total cash, cash equivalents and marketable securities
$
1,042,336

 
$
246

 
$
(120
)
 
$
1,042,462
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
Accumulated Other Comprehensive (Loss) Income (Tables)
 3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, net of tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(1,740
)
 
229

 
(3,827
)
 
(5,338
)
Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(1,385
)
 
(1,385
)
Net current period other comprehensive (loss) income
$
(1,740
)
 
$
229

 
$
(5,212
)
 
$
(6,723
)
Balance at March 31, 2016
$
(3,820
)
 
$
355

 
$
(1,434
)
 
$
(4,899
)

 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized (Losses) Gains on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
(608
)
 
176

 
2,004

 
1,572

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(1,698
)
 
(1,698
)
Net current period other comprehensive (loss) income
$
(608
)
 
$
176

 
$
306

 
$
(126
)
Balance at March 31, 2015
$
(1,579
)
 
$
53

 
$
2,317

 
$
791
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
Hedging (Tables)
 3 Months Ended
Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:
 
As of March 31, 2016
 
As of December 31, 2015
Foreign Currency
(in thousands)
Euro
$
215,343

 
$
103,362

British pound sterling
76,395

 
78,756

Australian dollar
28,837

 
27,167

Total foreign currency forward contracts
$
320,575

 
$
209,285
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of March 31, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
3,654

 
Other liabilities, current portion
 
$
(3,765
)
Other assets
 
182

 
Other liabilities, excluding current portion
 
(657
)
Total assets
 
$
3,836

 
Total liabilities
 
$
(4,422
)
As of December 31, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
5,161

 
Other liabilities, current portion
 
$
(769
)
Other assets
 
605

 
Other liabilities, excluding current portion
 
(132
)
Total assets
 
$
5,766

 
Total liabilities
 
$
(901
)
Derivatives Offsetting
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:
 
As of March 31, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
3,836

 
$
—

 
$
3,836

 
$
(3,836
)
 
$
—

Total liabilities
$
(4,422
)
 
$
—

 
$
(4,422
)
 
$
3,836

 
$
(586
)
 
As of December 31, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
5,766

 
$
—

 
$
5,766

 
$
(901
)
 
$
4,865

Total liabilities
$
(901
)
 
$
—

 
$
(901
)
 
$
901

 
$
—
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventories (Tables)
 3 Months Ended
Mar. 31, 2016
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
 
As of March 31, 2016
 
As of December 31, 2015
 
(in thousands)
Raw materials
$
9,936

 
$
8,696

Work-in-process
37,899

 
40,695

Finished goods
15,365

 
7,816

Total
$
63,200

 
$
57,207
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-based Compensation Expense (Tables)
 3 Months Ended
Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based compensation expense by line item
During the three months ended March 31, 2016 and 2015, the Company recognized the following stock-based compensation expense included in loss from continuing operations:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Stock-based compensation expense by type of award:
 
 
 
Stock options
$
26,260

 
$
28,959

Restricted stock and restricted stock units
27,533

 
27,169

ESPP share issuances
2,524

 
2,140

Less stock-based compensation expense capitalized to inventories
(845
)
 
(884
)
Total stock-based compensation included in costs and expenses
$
55,472

 
$
57,384

 
 
 


Stock-based compensation expense by line item:
 
 
 
Research and development expenses
$
34,448

 
$
38,217

Sales, general and administrative expenses
21,024

 
19,167

Total stock-based compensation included in costs and expenses
$
55,472

 
$
57,384
Unrecognized stock-based compensation expense, net of estimated forfeitures
The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of March 31, 2016
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
206,783

 
2.83
Restricted stock and restricted stock units
$
223,184

 
2.78
ESPP share issuances
$
3,143

 
0.49
Stock options outstanding and exercisable
The following table summarizes information about stock options outstanding and exercisable at March 31, 2016:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
138

 
1.85
 
$
18.93

 
138

 
$
18.93

$20.01–$40.00
 
2,124

 
3.56
 
$
34.30

 
2,119

 
$
34.29

$40.01–$60.00
 
2,210

 
6.33
 
$
48.09

 
1,590

 
$
48.77

$60.01–$80.00
 
1,396

 
7.83
 
$
75.92

 
654

 
$
75.31

$80.01–$100.00
 
3,550

 
8.81
 
$
90.65

 
815

 
$
88.04

$100.01–$120.00
 
1,677

 
8.80
 
$
109.32

 
402

 
$
109.26

$120.01–$134.69
 
1,524

 
9.28
 
$
130.63

 
339

 
$
129.57

Total
 
12,619

 
7.36
 
$
78.61

 
6,057

 
$
59.71
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.4.0.3
Restructuring Liabilities (Tables)
 3 Months Ended
Mar. 31, 2016
Kendall Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to the restructuring liability
The activities related to the restructuring liability for the three months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
7,944

 
$
11,596

Cash payments
(3,931
)
 
(3,985
)
Cash received from subleases
3,008

 
2,476

Restructuring expense (income)
203

 
(581
)
Liability, end of the period
$
7,224

 
$
9,506
Fan Pier Move Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to the restructuring liability
The activities related to the restructuring liability for the three months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
5,964

 
$
33,390

Cash payments
(3,156
)
 
(19,256
)
Cash received from subleases
2,408

 
—

Restructuring expense (income)
233

 
(2,997
)
Liability, end of the period
$
5,449

 
$
11,137
Other Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to the restructuring liability
The activities related to the Company's other restructuring liabilities for the three months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
 
 
Liability, beginning of the period
$
1,450

 
$
869

Cash payments
(439
)
 
(330
)
Restructuring expense
251

 
306

Liability, end of the period
$
1,262

 
$
845
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
Basis of Presentation and Accounting Policies (Details)
 3 Months Ended
Mar. 31, 2016
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.4.0.3
Product Revenues, Net (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
USD ($)
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 $ 49,296
Provision related to current period sales 40,049
Adjustments related to prior period sales (2,294)
Credits/payments made (27,371)
Balance at March 31, 2016 59,680
Trade Allowances  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 2,089
Provision related to current period sales 4,707
Adjustments related to prior period sales (38)
Credits/payments made (4,698)
Balance at March 31, 2016 2,060
Rebates, Chargebacks and Discounts  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 44,669
Provision related to current period sales 31,138
Adjustments related to prior period sales (2,181)
Credits/payments made (19,132)
Balance at March 31, 2016 54,494
Product Returns  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 1,228
Provision related to current period sales 924
Adjustments related to prior period sales (75)
Credits/payments made (260)
Balance at March 31, 2016 1,817
Other Incentives  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2015 1,310
Provision related to current period sales 3,280
Adjustments related to prior period sales 0
Credits/payments made (3,281)
Balance at March 31, 2016 $ 1,309
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangement - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2011
Mar. 31, 2016
Dec. 31, 2015
Mar. 31, 2015
Dec. 31, 2013
Dec. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Collaborative revenues   $ 74,000   $ 842,000    
Cystic Fibrosis Foundation Therapeutics Incorporated            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Collaborative funding $ 75,000,000          
Number of years over which funding will be made (in years) 5 years          
Collaborative revenues   $ 0   $ 0    
Milestone Revenues     $ 13,900,000   $ 9,300,000 $ 9,300,000
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements - CRISPR Therapeutics AG (Details) - CRISPR Therapeutics
Oct. 26, 2015
USD ($)
target
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Right to license, number of targets (up to) | target 6
Up-front payment $ 75,000,000
Investment in collaborative partner, pursuant to convertible loan agreement 30,000,000
Collaborative funding 75,000,000
Collaborative arrangement development and regulatory potential milestone payments maximum $ 420,000,000
Prior to marketing approval, time period of notice required to terminate (in days) 90 days
Subsequent to marketing approval, time period of notice required to terminate (in days) 270 days
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements - Janssen Pharmaceutica NV (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Royalty revenues (INCIVO) $ 3,596 $ 6,792
Collaborative revenues (telaprevir) 74 842
Total revenues 398,080 138,509
Janssen    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Royalty revenues (INCIVO) 78 1,525
Collaborative revenues (telaprevir) 0 642
Total revenues $ 78 $ 2,167
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements - Parion Sciences, Inc. (Details) - USD ($)
Jun. 04, 2015
Mar. 31, 2016
Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Commercial milestones and royalties discount rate (percentage) 6.60%    
Development milestones discount rate low end of range (percentage) 4.10%    
Development milestones discount rate high end of range (percentage) 5.90%    
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:      
Intangible assets   $ 284,340,000 $ 284,340,000
Goodwill   50,384,000 50,384,000
Deferred tax liability   $ (112,259,000) $ (110,439,000)
Parion Sciences, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Prior to marketing approval, time period of notice required to terminate (in days) 90 days    
Subsequent to marketing approval, time period of notice required to terminate (in days) 180 days    
Change of control prior to clinical trial, time period of notice required to terminate (in days) 30 days    
Term of agreement following first commercial sale (in years) 10 years    
Consideration Paid      
Up-front payment $ 80,000,000    
Fair value of contingent milestone and royalty payments 175,340,000    
Total consideration paid 255,340,000    
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:      
Intangible assets 255,340,000    
Goodwill 10,468,000    
Deferred tax liability (91,023,000)    
Net other assets (liabilities) (10,468,000)    
Net assets attributable to noncontrolling interests 164,317,000    
ENaC Inhibitors in CF | Parion Sciences, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Collaborative arrangement development and regulatory potential milestone payments maximum 490,000,000    
Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval 360,000,000    
Enac Inhibitors in Non Cf | Parion Sciences, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Collaborative arrangement development and regulatory potential milestone payments maximum 370,000,000    
Additional Enac Inhibitors | Parion Sciences, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Collaborative arrangement development and regulatory potential milestone payments maximum $ 230,000,000    
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) - BioAxone Biosciences Inc - USD ($)
 1 Months Ended 3 Months Ended
Oct. 31, 2014
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Up-front payment   $ 10,000,000
Maximum license fees and milestone payments $ 90,000,000.0  
In-process research and development intangible asset   29,000,000
Deferred tax liability attributable to BioAxone   $ 11,300,000
Purchase option, term of extension of expiration date (in years) 1 year  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements - Aggregate VIE Financial Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Jun. 04, 2015
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]        
Provision for (benefit from) income taxes $ 5,485 $ 299    
Net (income) loss attributable to noncontrolling interest (5,529) 98    
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:        
Restricted cash and cash equivalents (VIE) 76,273   $ 78,910  
Prepaid expenses and other current assets 55,866   50,935  
Intangible assets 284,340   284,340  
Goodwill 50,384   50,384  
Other assets 7,600   6,912  
Accounts payable 75,221   74,942  
Other current liabilities 272,665   305,820  
Deferred tax liability, net 112,259   110,439  
Other liabilities 31,822   31,778  
Noncontrolling interest 159,119   153,661  
BioAxone Biosciences Inc        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]        
Increase in fair value of contingent milestone and royalty payments 400 100    
Contingent consideration, liability 28,400   28,000  
Parion Sciences, Inc        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]        
Provision for (benefit from) income taxes 3,100      
Increase in fair value of contingent milestone and royalty payments 9,000      
Contingent consideration, liability 188,000   179,000  
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:        
Intangible assets       $ 255,340
Goodwill       10,468
Deferred tax liability, net       $ 91,023
Variable Interest Entity, Primary Beneficiary        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]        
Loss attributable to noncontrolling interest before provision for income taxes 839 287    
Provision for (benefit from) income taxes 3,062 (64)    
Increase in fair value of contingent milestone and royalty payments 9,430 125    
Net (income) loss attributable to noncontrolling interest (5,529) $ 98    
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:        
Restricted cash and cash equivalents (VIE) 76,273   78,910  
Prepaid expenses and other current assets 2,818   3,138  
Intangible assets 284,340   284,340  
Goodwill 19,391   19,391  
Other assets 434   455  
Accounts payable 1,569   676  
Taxes payable 24,512   24,554  
Other current liabilities 6,595   7,100  
Deferred tax liability, net 112,259   110,438  
Other liabilities 310   300  
Noncontrolling interest $ 159,119   $ 153,661  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaborative Arrangements Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) - Janssen - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Up-front payment     $ 35.0
Reimbursement for development and commercialization of compounds $ 3.5 $ 7.6  
Time period of notice required to terminate 6 months    
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.4.0.3
Earnings Per Share (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 12,619 12,682
Unvested restricted stock and restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 3,565 3,474
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Level 3    
Financial instruments carried at fair value (liability position):    
Term loan fair value $ 295,800  
Recurring basis    
Financial assets carried at fair value:    
Total financial assets 629,367 $ 665,383
Financial instruments carried at fair value (liability position):    
Total financial liabilities (4,422) (901)
Recurring basis | Money market funds    
Financial assets carried at fair value:    
Cash equivalents 190,601 199,507
Recurring basis | Commercial paper    
Financial assets carried at fair value:    
Cash equivalents   34,889
Marketable securities 141,562 141,409
Recurring basis | U.S. Treasury securities    
Financial assets carried at fair value:    
Marketable securities 33,104  
Recurring basis | Government-sponsored enterprise securities    
Financial assets carried at fair value:    
Cash equivalents   85,994
Marketable securities 126,478 87,162
Recurring basis | Corporate debt securities    
Financial assets carried at fair value:    
Cash equivalents 13,557 11,533
Marketable securities 120,229 99,123
Recurring basis | Level 1    
Financial assets carried at fair value:    
Total financial assets 350,183 372,663
Financial instruments carried at fair value (liability position):    
Total financial liabilities 0 0
Recurring basis | Level 1 | Money market funds    
Financial assets carried at fair value:    
Cash equivalents 190,601 199,507
Recurring basis | Level 1 | Commercial paper    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 1 | U.S. Treasury securities    
Financial assets carried at fair value:    
Marketable securities 33,104  
Recurring basis | Level 1 | Government-sponsored enterprise securities    
Financial assets carried at fair value:    
Cash equivalents   85,994
Marketable securities 126,478 87,162
Recurring basis | Level 1 | Corporate debt securities    
Financial assets carried at fair value:    
Cash equivalents 0 0
Marketable securities 0 0
Recurring basis | Level 2    
Financial assets carried at fair value:    
Total financial assets 279,184 292,720
Financial instruments carried at fair value (liability position):    
Total financial liabilities (4,422) (901)
Recurring basis | Level 2 | Money market funds    
Financial assets carried at fair value:    
Cash equivalents 0 0
Recurring basis | Level 2 | Commercial paper    
Financial assets carried at fair value:    
Cash equivalents   34,889
Marketable securities 141,562 141,409
Recurring basis | Level 2 | U.S. Treasury securities    
Financial assets carried at fair value:    
Marketable securities 0  
Recurring basis | Level 2 | Government-sponsored enterprise securities    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 2 | Corporate debt securities    
Financial assets carried at fair value:    
Cash equivalents 13,557 11,533
Marketable securities 120,229 99,123
Recurring basis | Level 3    
Financial assets carried at fair value:    
Total financial assets 0 0
Financial instruments carried at fair value (liability position):    
Total financial liabilities 0 0
Recurring basis | Level 3 | Money market funds    
Financial assets carried at fair value:    
Cash equivalents 0 0
Recurring basis | Level 3 | Commercial paper    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 3 | U.S. Treasury securities    
Financial assets carried at fair value:    
Marketable securities 0  
Recurring basis | Level 3 | Government-sponsored enterprise securities    
Financial assets carried at fair value:    
Cash equivalents   0
Marketable securities 0 0
Recurring basis | Level 3 | Corporate debt securities    
Financial assets carried at fair value:    
Cash equivalents 0 0
Marketable securities 0 0
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis    
Financial assets carried at fair value:    
Foreign currency forward contracts 3,654 5,161
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 1    
Financial assets carried at fair value:    
Foreign currency forward contracts 0 0
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 2    
Financial assets carried at fair value:    
Foreign currency forward contracts 3,654 5,161
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 3    
Financial assets carried at fair value:    
Foreign currency forward contracts 0 0
Other Assets | Foreign currency forward contracts | Recurring basis    
Financial assets carried at fair value:    
Foreign currency forward contracts 182 605
Other Assets | Foreign currency forward contracts | Recurring basis | Level 1    
Financial assets carried at fair value:    
Foreign currency forward contracts 0 0
Other Assets | Foreign currency forward contracts | Recurring basis | Level 2    
Financial assets carried at fair value:    
Foreign currency forward contracts 182 605
Other Assets | Foreign currency forward contracts | Recurring basis | Level 3    
Financial assets carried at fair value:    
Foreign currency forward contracts 0 0
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis    
Financial assets carried at fair value:    
Foreign currency forward contracts (3,765)  
Financial instruments carried at fair value (liability position):    
Derivative liability current   (769)
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 1    
Financial assets carried at fair value:    
Foreign currency forward contracts 0  
Financial instruments carried at fair value (liability position):    
Derivative liability current   0
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 2    
Financial assets carried at fair value:    
Foreign currency forward contracts (3,765)  
Financial instruments carried at fair value (liability position):    
Derivative liability current   (769)
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 3    
Financial assets carried at fair value:    
Foreign currency forward contracts 0  
Financial instruments carried at fair value (liability position):    
Derivative liability current   0
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis    
Financial assets carried at fair value:    
Foreign currency forward contracts (657)  
Financial instruments carried at fair value (liability position):    
Derivative liability noncurrent   (132)
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 1    
Financial assets carried at fair value:    
Foreign currency forward contracts 0  
Financial instruments carried at fair value (liability position):    
Derivative liability noncurrent   0
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 2    
Financial assets carried at fair value:    
Foreign currency forward contracts (657)  
Financial instruments carried at fair value (liability position):    
Derivative liability noncurrent   (132)
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 3    
Financial assets carried at fair value:    
Foreign currency forward contracts 0  
Financial instruments carried at fair value (liability position):    
Derivative liability noncurrent   $ 0
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc | Level 1    
Financial instruments carried at fair value (liability position):    
Cash and cash equivalents $ 76,000  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.4.0.3
Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Summary of cash, cash equivalents and marketable securities    
Amortized Cost $ 1,025,263 $ 1,042,336
Gross Unrealized Gains 359 246
Gross Unrealized Losses (4) (120)
Fair Value 1,025,618 1,042,462
Total cash and cash equivalents    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 604,245 714,768
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 604,245 714,768
Cash and money market funds    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 590,688 582,352
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 590,688 582,352
Government-sponsored enterprise securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   85,994
Gross Unrealized Gains   0
Gross Unrealized Losses   0
Fair Value   85,994
Commercial paper    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   34,889
Gross Unrealized Gains   0
Gross Unrealized Losses   0
Fair Value   34,889
Corporate debt securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 13,557 11,533
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 13,557 11,533
Total marketable securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 421,018 327,568
Gross Unrealized Gains 359 246
Gross Unrealized Losses (4) (120)
Fair Value 421,373 327,694
U.S. Treasury securities (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 33,108  
Gross Unrealized Gains 0  
Gross Unrealized Losses (4)  
Fair Value 33,104  
Government-sponsored enterprise securities (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 126,461 87,176
Gross Unrealized Gains 17 0
Gross Unrealized Losses 0 (14)
Fair Value 126,478 87,162
Commercial paper (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 141,243 98,877
Gross Unrealized Gains 319 246
Gross Unrealized Losses 0 0
Fair Value 141,562 99,123
Corporate debt securities (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 120,206 141,515
Gross Unrealized Gains 23 0
Gross Unrealized Losses 0 (106)
Fair Value $ 120,229 $ 141,409
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.4.0.3
Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Balance at balance sheet date $ 1,824 $ 917
Other comprehensive (loss) income before reclassifications (5,338) 1,572
Amounts reclassified from accumulated other comprehensive loss (1,385) (1,698)
Total changes in other comprehensive loss (6,723) (126)
Balance at balance sheet date (4,899) 791
Foreign Currency Translation Adjustment    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Balance at balance sheet date (2,080) (971)
Other comprehensive (loss) income before reclassifications (1,740) (608)
Amounts reclassified from accumulated other comprehensive loss 0 0
Total changes in other comprehensive loss (1,740) (608)
Balance at balance sheet date (3,820) (1,579)
Unrealized Holding Gains (Losses) on Marketable Securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Balance at balance sheet date 126 (123)
Other comprehensive (loss) income before reclassifications 229 176
Amounts reclassified from accumulated other comprehensive loss 0 0
Total changes in other comprehensive loss 229 176
Balance at balance sheet date 355 53
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, net of tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Balance at balance sheet date 3,778 2,011
Other comprehensive (loss) income before reclassifications (3,827) 2,004
Amounts reclassified from accumulated other comprehensive loss (1,385) (1,698)
Total changes in other comprehensive loss (5,212) 306
Balance at balance sheet date $ (1,434) $ 2,317
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.4.0.3
Hedging (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized $ 3,836 $ 5,766
Gross Amounts Offset 0 0
Gross Amounts Presented 3,836 5,766
Gross Amounts Not Offset (3,836) (901)
Legal Offset 0 4,865
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (4,422) (901)
Gross Amounts Offset 0 0
Gross Amounts Presented (4,422) (901)
Gross Amounts Not Offset 3,836 901
Legal Offset (586) 0
Prepaid and other current assets    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets 3,654 5,161
Other liabilities, current portion    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - liabilities (3,765) (769)
Other assets    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets 182 605
Other liabilities, excluding current portion    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - liabilities (657) (132)
Designated as hedging instrument | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 320,575 209,285
Designated as hedging instrument | Euro | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 215,343 103,362
Designated as hedging instrument | British pound sterling | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 76,395 78,756
Designated as hedging instrument | Australian dollar | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 28,837 $ 27,167
Minimum | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Derivative term 1 month  
Maximum | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Derivative term 18 months  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 9,936 $ 8,696
Work-in-process 37,899 40,695
Finished goods 15,365 7,816
Total $ 63,200 $ 57,207
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.4.0.3
Intangible Assets and Goodwill (Details) - USD ($)
$ in Thousands
 1 Months Ended
Oct. 31, 2014
Mar. 31, 2016
Dec. 31, 2015
Jun. 04, 2015
Dec. 31, 2014
Indefinite-Lived Intangible Assets [Line Items]          
Intangible assets   $ 284,340 $ 284,340    
Goodwill   50,384 50,384    
Parion Sciences, Inc          
Indefinite-Lived Intangible Assets [Line Items]          
Intangible assets       $ 255,340  
Goodwill       $ 10,468  
BioAxone Biosciences Inc          
Indefinite-Lived Intangible Assets [Line Items]          
In-process research and development intangible asset         $ 29,000
Variable Interest Entity, Primary Beneficiary          
Indefinite-Lived Intangible Assets [Line Items]          
Intangible assets   284,340 284,340    
Goodwill   $ 19,391 $ 19,391    
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc          
Indefinite-Lived Intangible Assets [Line Items]          
In-process research and development intangible asset $ 29,000        
Indefinite-lived Intangible Assets | Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc          
Indefinite-Lived Intangible Assets [Line Items]          
Fair value inputs, discount rate (percent) 7.10%        
Indefinite-lived Intangible Assets | Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc          
Indefinite-Lived Intangible Assets [Line Items]          
Fair value inputs, discount rate (percent) 7.50%        
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.4.0.3
Long-term Obligations - Fan Pier Leases (Details)
$ in Thousands, ft² in Millions
 12 Months Ended
Dec. 31, 2011
ft²
lease
building
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Property, Plant and Equipment [Line Items]      
Property and equipment, net   $ 690,521 $ 697,715
Fan Pier Leases      
Property, Plant and Equipment [Line Items]      
Number of leases | lease 2    
Area of real estate property (in square feet) | ft² 1.1    
Number of buildings under lease agreement | building 2    
Optional term of lease agreement (in years) 10 years    
Fan Pier Leases | Buildings      
Property, Plant and Equipment [Line Items]      
Construction financing lease obligation, current and noncurrent   472,900 473,000
Fan Pier Leases | Construction in progress      
Property, Plant and Equipment [Line Items]      
Property and equipment, net   $ 499,000 $ 502,300
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.4.0.3
Long-term Obligations - San Diego Lease (Details) - San Diego Lease
ft² in Thousands, $ in Millions
Dec. 02, 2015
USD ($)
ft²
term_extension
Property, Plant and Equipment [Line Items]  
Area of real estate property (in square feet) | ft² 170
Length of lease 16 years
Average yearly aggregate rent | $ $ 10.2
Amount of optional renewal terms | term_extension 2
Optional renewal term length 5 years
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.4.0.3
Long-term Obligations - Term Loan (Details) - USD ($)
 1 Months Ended
Oct. 31, 2015
Jul. 31, 2014
Mar. 31, 2016
Dec. 31, 2015
Senior Secured Term Loan        
Debt Instrument [Line Items]        
Face amount of term loan   $ 300,000,000    
Interest rate, stated percentage   7.20%    
Contingent interest rate (percent)   6.20%    
Amount of principal repayment on quarterly installment payments from October 1, 2016 through maturity $ 75,000,000      
Debt instrument, repayment provision, period over which present value of interest payments is determined (in years) 2 years      
Unamortized discount on term loan   $ 5,300,000 $ 4,000,000 $ 4,600,000
Senior Secured Term Loan Facility        
Debt Instrument [Line Items]        
Maximum borrowing capacity   $ 200,000,000    
Minimum | Senior Secured Term Loan | LIBOR        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   5.00%    
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Stock-based compensation expense:    
Less stock-based compensation expense capitalized to inventories $ (845) $ (884)
Total stock-based compensation included in costs and expenses 55,472 57,384
Stock options    
Stock-based compensation expense:    
Stock-based compensation expense by type of award: 26,260 28,959
Type of award:    
Unrecognized Expense, Net of Estimated Forfeitures $ 206,783  
Weighted-average recognition period (in years) 2 years 9 months 29 days  
Restricted stock and restricted stock units    
Stock-based compensation expense:    
Stock-based compensation expense by type of award: $ 27,533 27,169
Type of award:    
Unrecognized Expense, Net of Estimated Forfeitures $ 223,184  
Weighted-average recognition period (in years) 2 years 9 months 11 days  
ESPP share issuances    
Stock-based compensation expense:    
Stock-based compensation expense by type of award: $ 2,524 2,140
Type of award:    
Unrecognized Expense, Net of Estimated Forfeitures $ 3,143  
Weighted-average recognition period (in years) 5 months 27 days  
Research and development expenses    
Stock-based compensation expense:    
Total stock-based compensation included in costs and expenses $ 34,448 38,217
Sales, general and administrative expenses    
Stock-based compensation expense:    
Total stock-based compensation included in costs and expenses $ 21,024 $ 19,167
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-based Compensation Expense (Details 2)
shares in Thousands
 3 Months Ended
Mar. 31, 2016
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price range, options outstanding (in shares) | shares 12,619
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 4 months 10 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 78.61
Exercise price range, options exercisable (in shares) | shares 6,057
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 59.71
$18.93–$20.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 18.93
Exercise price, high end of range (usd per share) $ 20.00
Exercise price range, options outstanding (in shares) | shares 138
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 1 year 10 months 6 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 18.93
Exercise price range, options exercisable (in shares) | shares 138
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 18.93
$20.01–$40.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 20.01
Exercise price, high end of range (usd per share) $ 40
Exercise price range, options outstanding (in shares) | shares 2,124
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 3 years 6 months 22 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 34.30
Exercise price range, options exercisable (in shares) | shares 2,119
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 34.29
$40.01–$60.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 40.01
Exercise price, high end of range (usd per share) $ 60
Exercise price range, options outstanding (in shares) | shares 2,210
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 6 years 3 months 29 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 48.09
Exercise price range, options exercisable (in shares) | shares 1,590
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 48.77
$60.01–$80.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 60.01
Exercise price, high end of range (usd per share) $ 80
Exercise price range, options outstanding (in shares) | shares 1,396
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 9 months 29 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 75.92
Exercise price range, options exercisable (in shares) | shares 654
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 75.31
$80.01–$100.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 80.01
Exercise price, high end of range (usd per share) $ 100
Exercise price range, options outstanding (in shares) | shares 3,550
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 9 months 22 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 90.65
Exercise price range, options exercisable (in shares) | shares 815
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 88.04
$100.01–$120.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 100.01
Exercise price, high end of range (usd per share) $ 120
Exercise price range, options outstanding (in shares) | shares 1,677
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 9 months 18 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 109.32
Exercise price range, options exercisable (in shares) | shares 402
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 109.26
$120.01–$134.69  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 120.01
Exercise price, high end of range (usd per share) $ 134.69
Exercise price range, options outstanding (in shares) | shares 1,524
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 9 years 3 months 11 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 130.63
Exercise price range, options exercisable (in shares) | shares 339
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 129.57
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.4.0.3
Other Arrangements (Details) - USD ($)
 12 Months Ended
Dec. 31, 2008
Mar. 31, 2016
Sale of HIV Protease Inhibitor Royalty Stream    
Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline $ 160,000,000.0  
Deferred revenue royalty purchase agreement   $ 23,200,000
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.4.0.3
Income Taxes (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 04, 2015
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Schedule of Collaborative Arrangement Agreements [Line Items]        
Provision for income taxes   $ 5,485,000 $ 299,000  
Unrecognized tax benefits   400,000   $ 400,000
Income taxes, interest and penalties accrued   0    
Income taxes, material interest or penalties related to uncertain tax positions   0   $ 0
Estimated reduction in unrecognized tax benefits in next fiscal year   400,000    
Parion Sciences, Inc        
Schedule of Collaborative Arrangement Agreements [Line Items]        
Provision for income taxes   $ 3,100,000    
Up-front payment $ 80,000,000      
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.4.0.3
Restructuring Liabilities (Details)
ft² in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2015
ft²
lease
Sep. 30, 2014
facility
Dec. 31, 2003
Kendall Restructuring      
Restructuring Cost and Reserve [Line Items]      
Lease term (in years)     15 years
Restructuring and related activities, leased office space, maximum percentage used - not more than     50.00%
Fan Pier Move Restructuring      
Restructuring Cost and Reserve [Line Items]      
Number of facilities decommissioned | facility   3  
Number of leases terminated | lease 2    
Area of real estate property (in square feet) | ft² 120    
Discount rate related to leases (percent) 9.00%    
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.4.0.3
Restructuring Liabilities (Details 2) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Restructuring activities    
Restructuring expense (income) $ 687 $ (3,272)
Kendall Restructuring    
Restructuring activities    
Liability, beginning of the period 7,944 11,596
Cash payments (3,931) (3,985)
Cash received from subleases 3,008 2,476
Restructuring expense (income) 203 (581)
Liability, end of the period 7,224 9,506
Fan Pier Move Restructuring    
Restructuring activities    
Liability, beginning of the period 5,964 33,390
Cash payments (3,156) (19,256)
Cash received from subleases 2,408 0
Restructuring expense (income) 233 (2,997)
Liability, end of the period 5,449 11,137
Other Restructuring    
Restructuring activities    
Liability, beginning of the period 1,450 869
Cash payments (439) (330)
Restructuring expense (income) 251 306
Liability, end of the period $ 1,262 $ 845
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.4.0.3
Commitments and Contingencies (Details)
$ in Millions
Mar. 31, 2016
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Restricted cash and cash equivalents $ 21.9
EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

<(L".;5/VV1G[?8 MY2?T_'OZ^L+A.M+7L\/U]P+%A4 1!8HO1SS'%!=-V,F>*C!=O#J6U#AJES9O MJ2ZW\RZ/9_(!K\J!=_# 32>T)7MT_F3CH;:(#KR)[.J:DMZ_GR61T+H0_O"Q M25S)5B:.30L.3 M(794BIN_!Y X[6E.+X5GT?4N%%A5LIG7" 7:"M3$0+NG]_GNL Z("/@M8+*+ MF 3O1\27D/QL]C0+%D!"[8("]\L)'D#*(.0;OYXUWUL&XC*^J#_&:;W[([?P M@/*/:%SOS6:4--#R4;IGG'[ >81-$*Q1VO@E]6@=J@N%$L7?TBIT7*?T9U6< M:9\3BC.AF G?LF@\-8HVOW/'J]+@1.S P]GE.P\W0<0K$^_-QC1.GZJG:GM; MLE/0^0 Y)$@1(?F,8%[\TP[%QPZ'8D$OOJ:OK@RN(GV5NM]MOA987PFLH\#Z M?Q,N(?G=]JH'6^RH M/%BV-)C:-V:>OFZGPW[^,1LG=X50Z\@U_<=$);:8OHP)O(;C:4]/[US(F$UH7PUL&PO=V]R:W-H965TZAM0OOW]870)*JV M+WAF..?,&5^*$5=2VRWMG.LWC-FJ \7M%?:@_9\&C>+.IZ9EMC? MZTA2DN59=LT4%YJ61:P]F[+ P4FAX=D0.RC%S<<.)(Y;NJ#'PHMH.Q<*K"S8 MS*N% FT%:F*@V=+[Q6:W"H@(^"M@M"O=[;N$!Y3]1N\Z;S2BIH>&#="\X/L$TPCH( M5BAM_))JL [5D4*)XN]I%3JN8_JS7DZT[PGY1,AGPFT6C:=&T>8O[GA9&!R) M[7DXN\7&PTT0\[,QC=.GZJ%<_TY<7#I>1OIPR1>\+'K>PA]N6J$MV:/S)QL/M4%TX$UD5VM*.O]^YD1"XT)XXV.3 MKE1*'/;'!S*_TO(34$L#!!0 ( )"(HT@Q35+1G $ +$# 9 >&PO M=V]R:W-H965TV:-LZU*\9L MT8#B]@);T/Y/A49QYT-3,]L:X&4D*8>>DT/!LB.V4 MXN9K Q+[-9W1?>)%U(T+"99G;.*50H&V C4Q4*WIS6RU601$!+P*Z.W!G@3O M6\3W$#R6:YH$"R"A<$&!^V4'MR!E$/*%/T;-GY*!>+C?J]_';KW[+;=PB_)- ME*[Q9A-*2JAX)]T+]@\PMK ,@@5*&[^DZ*Q#M:=0HOCGL H=UW[XL[P<:><) MZ4A()\)U$HT/A:+-.^YXGAGLB6UYF-ULY>$FB'AEXKW9&,;NA^PN]_/*V"X( M'6$V R:-F-F$8%[];(GTN,0F/:"G?]/G)P[GD3X?'?ZC_N)$8!$%%K^V>(PY M=/5L:3 3KOA\*;L=#MOTCB3'WB>M;R&)VYJH2W9HO.3C4.M$!UX M$\G%DI+&OY\ID%"YL+WR>S-&ULA5/;;J,P M$/T5RQ]0$X=LJX@@-:U6NP\K57W8?79@ *NVA]HF=/^^MB$TB:KV!<\,YYPY MXTLQHGUQ'8 G;UH9MZ.=]_V6,5=UH(6[P1Y,^-.@U<*'U+;,]19$G4A:,9YE M/Y@6TM"R2+4G6Q8X>"4-/%GB!JV%_;\'A>..KNBI\"S;SL<"*PNV\&JIP3B) MAEAH=O1^M=WG$9$ ?R6,[BPFT?L!\24FO^L=S:(%4%#YJ"#"81,%*U0N?4DU M.(_Z1*%$B[=IE2:MX_3G-I]IGQ/X3. +X2Y+QJ=&R>:C\*(L+([$]2*>W6H; MX#:*!&42O+F4INFGZK'DV;I@QRAT@=E/&)XPJP7!@OJG+?AEBST_H_/OZ>LK MA^M$7\\.\^\%\BN!/ GD7XYXB=E<-6%G>ZK!MNGJ.%+A8/RT>4MUN9WW/)W) M![PL>M'"'V%;:1PYH \GFPZU0?003&0W&TJZ\'Z61$'C8W@;8CM=J2GQV)\> MR/)*RW=02P,$% @ D(BC2'(5;8R@ 0 L0, !D !X;"]W;W)K&ULA5/;3N,P$/T5RQ^ 4[=05*61* C! Q+B8??932:) MA>T)MM.P?[^VDX:V0O 2STS..7/&EWQ ^^Y: $\^M3)N2UOONPUCKFQ!"W>% M'9CPIT:KA0^I;9CK+(@JD;1B/,MNF!;2T")/M5=;Y-A[)0V\6N)ZK87]MP.% MPY8NZ+'P)IO6QP(KTR> MJRW-H@504/JH(,)R@'M0*@J%QA^3YE?+2#R-C^J/:=K@?B\^I.R=1WVD4*+%Y[A*D]9A_+-<3[3O"7PB\)EP MFR7C8Z-D\T%X4>06!^(Z$<]NL0EP&T6",@G>7$K3]&/U4/#L)F>'*'2&V8T8 MGC"+&<&"^K&ULA5/;3N,P$/T5 MRQ^ $Z>PNU4:B8(0/*R$>-A]=I-)8F%[@NTT[-^O[;2AK1"\Q#.3<\Z<\:6< MT+ZZ'L"3=ZV,V]#>^V'-F*M[T,)=X0 F_&G1:N%#:COF!@NB222M&,^R&Z:% M-+0J4^W95B6.7DD#SY:X46MA_VU!X;2A.3T67F37^UA@5M\AOL;DJ=G0+%H !;6/"B(L>[@#I:)0:/QVT/QH M&8FG\5'](4T;W.^$@SM4?V7C^V VHZ2!5HS*O^#T"(<1KJ-@C8LM/Z/Q[>G'AL$CT M8J;GV?<"JPN!51)8?3GB&2:_')*=[*D&VZ6KXTB-H_'SYBW5Y7;>\G0F'_"J M'$0'OX7MI'%DASZ<;#K4%M%#,)%=75/2A_>S) I:'\,?(;;SE9H3C\/Q@2RO MM/H/4$L#!!0 ( )"(HTA/ &_3H $ +$# 9 >&PO=V]R:W-H965T M^^'+6.N[D$+=X,# MF/"G1:N%#ZGMF!LLB":1M&(\R[XQ+:2A59EJS[8J\M(/(]/ZH]IVN#^(!P\H/HC&]\'LQDE M#;1B5/X%IR=81KB-@C4JE[ZD'IU'?:)0HL7;O$J3UFG^4]PMM(\)?"'PE7"7 M)>-SHV3SA_"B*BU.Q TBGEV^#7 ;18(R"=Y<2M/T<_58\9R7[!B%+C#[&<,3 M)E\1+*A_V()?MMCS,SK_FKZYNCB,UCL;/F[=6U]MYS].9O,.K&PO=V]R:W-H965T<.>-+,:)] MCG??]EC%7=:"%N\$>3/C3H-7"A]2VS/461)U(6C&>9;=,"VEH M6:3:DRT+'+R2!IXL<8/6PO[;@\)Q1W-Z*CS+MO.QP,J"+;Q::C!.HB$6FAU] MR+?[=40DP(N$T9W%)'H_(+[%Y'>]HUFT HJ'Q5$6([P"$I%H=#X[ZSYV3(2 MS^.3^L\T;7!_$ X>4;W*VG?!;$9)#8T8E'_&\1?,(VRB8(7*I2^I!N=1GRB4 M:/$^K=*D=9S^;/A,^YK 9P)?"/=9,CXU2C9_""_*PN)(7"_BV>7; +=1)"B3 MX,VE-$T_58\ESS<%.T:A"\Q^PO"$R1<$"^I?MN"7+?;\C,Z_IZ^N'*X2?34[ MO/U>8'TEL$X"Z_^.>(FYNVK"SO94@VW3U7&DPL'X:?.6ZG(['](ALD]X6?2B MA3_"MM(X&PO=V]R:W-H965TEJM7M8J>JA/3LP@%4;L[8) MW;>O;0@-""E[P9[A^YF!L;-!J@_= !CT*7BK#T%C3+?'6!<-"*KO9 >M?5-) M):BQH:JQ[A30TI,$QR0,4RPH:X,\\[D7E6>R-YRU\**0[H6@ZM\1N!P.011< M$J^L;HQ+X#S#,Z]D EK-9(L45(?@*=H?4X?P@#<&@[[:(U?[2 ;.G9 U_CMI?ELZXO7^HO[3=VNK/U$-SY*_L](TMM@P0"54 MM.?F50Z_8&IAYP0+R;5_HJ+71HH+)4""?HXK:_TZC&_29*)M$\A$(#/A(?2% MCT:^S!_4T#Q3WH\NM_'MP62E4#B!9*IQJFK4:G:2Q,^K'LY+2@"TBO+.M-O8FF ,.E7';>[M7X^$8 R.[ MRU&?[YO\"U!+ P04 " "0B*-(^[_9^:,! "Q P &0 'AL+W=OYI%"Z"@]%%!A.4$3Z!4% J-_TZ:7RTC\3(^J_],TP;W1^'@"=4?6?DV MF,THJ: 6O?+O.+S -,(Z"I:H7/J2LG<>]9E"B1:?XRI-6H?QSX9/M/L$/A'X M3/B1)>-CHV3S67A1Y!8'XCH1SVZQ"W ;18(R"=Y<2M/T8_54<+[.V2D*76$. M(X8GS&)&L*!^MP6_;G'@%W3^/7UYXW"9Z,NQ^W;SO<#J1F"5!%;3B)N[(UYC MMC=-V,6>:K!-NCJ.E-@;/V[>7)UOYV,Z1/8%+_).-/!+V$8:1X[HP\FF0ZT1 M/003V<.:DC:\GSE14/L8;D-LQRLU)AZ[\P.97VGQ'U!+ P04 " "0B*-( M3,"#KM&BVIBU3>C^_=J&T!@AT1?L&9_+ M##!.!RX^9 V@T">CK3QYM5+=$6.9U\"(?. =M/JDY((1I4-18=D)((4E,8I# MWS]@1IK6RU*;>Q-9RGM%FQ;>!)(]8T3\.P/EP\D+O%OBO:EJ91(X2_',*QH& MK6QXBP24)^\I.)X3@[" WPT,\FZ/3.T7SC],\+,X>;XI 2CDRB@0O5SA&2@U M0MKX[Z3Y96F(]_N;^HOM5E=_(1*>.?W3%*K6Q?H>*J D/57O?'B%J86]$3+$SPW7_.0%1VG"7*>=^J M\8>>L_.-\13:.?F"9VE'*OA%1-6T$EVXTM-F!ZWD7($NPG_0'ZW6=]H<4"B5 MV<9Z+\8Q'P/%N]NE-=^&ULC5/+;MLP$/P5@A\02K*2IH8L M($Y1I(<"00[IF996$A&2JY*4E?Y]^+ 5VS"07L3=U35WA MY*30\&R(G93BYM\6),X;FM-CX47T@PL%5E=LX;5"@;8"-3'0;>A#OMZ6 1$! MKP)F>Q*3X'V'^!:27^V&9L$"2&A<4.!^V<,C2!F$?.._!\W/EH%X&A_5?\9I MO?L=M_"(\H]HW>#-9I2TT/%)NA>8/[GA=&9R)'7DXNWSMX2:(>&7BO=F8QNE3 M=5\7J^\5VP>A,\PV88J(R1<$\^I76Q3G+;;%";WXFKZZ<+B*]%7J?O\? N6% M0!D%RM2_S*Z.>(ZY')*=[*D"T\>K8TF#DW9I\Y;JS)!(Z%\)O/C;I2J7$X7A\(,LKK3\ 4$L# M!!0 ( )"(HTBDR7&PO=V]R:W-H965T; _@R+N2VNZRWKEA2ZFM>U#EN/G8@\1IEZVR4^%9 M=+T+!5J5=.$U0H&V C4QT.ZRA]5V7P1$!+P(F.Q93(+W ^);2/XVNRP/%D!" M[8("]\L1'D'*(.0;_Y\UOUH&XGE\4O\=I_7N#]S"(\I7T;C>F\TSTD#+1^F> MG='9]_3UE<-UI*]3]_O-]P+%E4 1!8IYQ/7-$2\QQ543>K:G"DP7KXXE M-8[:I<.>-+,6KS93L A[ZE M4':'.^?Z+2&VZD R>Z=[4/Y/HXUDSJ>F);8WP.I(DH+0+%L3R;C"91%K;Z8L M]. $5_!FD!VD9.;?'H0>=WB!3X5WWG8N%$A9D)E7#UI_A>2EWN$L6 !E0L*S"]'> 0A@I!O_'?2_&D9B.?Q2?TI M3NO='YB%1RT^>>TZ;S;#J(:&#<*]Z_$9IA%60;#2PL8OJ@;KM#Q1,)+L.ZU< MQ75,?];91+M-H!.!SH1-))#4*-K\PQPK"Z-'9'L6SFZQ]7 31+PR\MYL3./T MJ7HL:;XJR#$(76#V"4,C9C$CB%>_V8)>MMC3,SK]G;Z\11()]&7-\<\1)S?]6$G.VI!-/&JV-1I0?ETN;-U?EV/M!X)C_PLNA9"Z_, MM%Q9=-#.GVP\U$9K!]Y$=K?"J//O9TX$-"Z$]SXVZ4JEQ.G^]$#F5UK^!U!+ M P04 " "0B*-((ZT-L*0! "Q P &0 'AL+W=O#HE.SAV1 [:BW,OR,HG YT0^?" MBVP[%PJL+-C"JZ6&WDKLB8'F0!\W^V,>$!'P6\)D5S$)WD^(KR'Y61]H%BR M@LH%!>&7,SR!4D'(-_Y[T7QO&8CK>%;_'J?U[D_"PA.J/[)VG3>;45)#(T;E M7G#Z 9<1=D&P0F7CEU2C=:AG"B5:O*55]G&=TI_=3+M-X!<"7PCW632>&D6; MWX0396%P(G80X>PV>P\W0<0K$^_-QC1.GZKGDN?W!3L'H0^88\+PB-DL".;5 M;[;@'UL<^8K./Z=OKQQN(WV;NC]DGPOD5P)Y%,B3 ./YPU82M]E2# M:>/5L:3"L7=I\Y;J3R3=WA9#**%7\*TLK?DA,Z?;#S4!M&!-Y'=[2CI M_/M9$@6-"^%7'YMTI5+B<)@?R/)*R_]02P,$% @ D(BC2#RI_:V] 0 M>P0 !D !X;"]W;W)K&ULC53+;J,P%/T5BP^H MP02F$Q&DIJ/1S*)2U45G[<#EH=J8L4UH_[Y^$!H04KK!OI?SNL(F&X5\4PV M1N^<=>H0-%KW>XQ5T0"GZD[TT)DWE9"<:E/*&JM> BT=B3-,PC#%G+9=D&>N M]RSS3 R:M1T\2Z0&SJG\. (3XR&(@DOCI:T;;1LXS_#,*UL.G6I%AR14A^ A MVA]3BW" UQ9&=;5'-OM)B#=;_"T/06@C (-"6P5JEC,\ F-6R!C_GS2_+"WQ M>G]1_^VF->E/5,&C8/_:4CR,7\137-,RE&I'IJOUVT-W!I18PR M,MF4*]WTOGO.21)F^&R%%IBCQQ"'B68$-NJ;%F1I<217='*;'J\2QHX>>_>? M\6V!W4I@YP1VTXC1YHA+S#=2)BN39"$0;YHL,;O;)NG*)%T())LF2TRZ,L%7 MIX.#K-TE4*@00Z?],9B[\SU[(.YT?<'SK*7PA1;]Y:K/_YO\$U!+ P04 " "0B*-(61@D M>Z0! "Q P &0 'AL+W=O*VQOL0?L_#1K%G4]-RVQO@->1I"3+L^P7 M4UQH6A:Q]FS* @?.Y X;NF"'@LOHNU<*+"R8#.O%@JT%:B) M@69+'Q:;W2H@(N!5P&A/8A*\[Q'?0_*WWM(L6 )E0L*W"\'> 0I@Y!O_'_2 M_&X9B*?Q4?UWG-:[WW,+CRC?1.TZ;S:CI(:&#]*]X/@'IA'60;!":>.75(-U MJ(X42A3_2*O0<1W3GV4^T:X3\HF0SX2[+!I/C:+-)^YX61@UY.+O%QL-- M$/'*Q'NS,8W3I^JAS->W!3L$H3/,+F'RB%G,".;5K[;(SUOL\A-Z_C-]>>%P M&>G+U/U^_;/ ZD)@%056TXAW5T<\Q]Q?-&$G>ZK M/'J6%+AH%W:O+DZW\Z' M>(CL&UX6/6_A'S>MT);LT?F3C8?:(#KP)K*;-26=?S]S(J%Q(;SUL4E7*B4. M^^,#F5]I^0502P,$% @ D(BC2+@^DI6\ 0 >P0 !D !X;"]W;W)K M&ULC53+;J,P%/T5BP^H@22TB@A2TZIJ%R-57SFO*VSR0:IWW0(8],F9T(>H-:;;8ZS+%CC1 M-[(#8=_44G%B;*D:K#L%I/(DSG :QQGFA(JHR'WO516Y[ VC EX5TCWG1/T_ M I/#(4JB2^.--JUQ#5SD>.)5E(/05 JDH#Y$]\G^F#F$!_RE,.BK/7+93U*^ MN^*E.D2QBP ,2N,4B%W.\ ",.2%K_#%J?ELZXO7^HO[DI[7I3T3#@V3_:&5: M&S:.4 4UZ9EYD\,SC"/LG& IF?9/5/;:2'ZA1(B3S[!2X=F.N&^7["U<.1&KC&PV[4L_?>B>BS2+(;.VIK_P13P: V;GMK]RI< MCE 8V5VN^O2_*;X 4$L#!!0 ( )"(HT@'51F6Y0$ ,8% 9 >&PO M=V]R:W-H965T00"*"U'15=1]6 MJOJP^^S <%%MS-HF=/]^;4,HN)%(7V*/.>?,&<(@BC^&M6[, MV@]?PGBDW28$(R&8"+%GC ^)C,T?6.(TX:Q'HL7ZS_,/"LZUB%)&RILPH:E^ M.+VDP2Y*W(L66F!. R8P&']"N$K]9HI@F>(4S.C!.GUC.=P8>C@ZC-<%0DL@ M- *;46"_+K"U!+9S!Y%W\XZ6F#MN:6E_4$L#!!0 ( )"(HTB3N\<&PO M=V]R:W-H965TZ:EE42$Y*HD9:5_7SYDQ0X,Y"+NKF9F9_DH)S1OM@=PY%U);0]9[]RP MI]36/2AN'W [?^T:!1W/C4=M8,!WD22DI3E^8XJ+G16E;'V8JH21R>%AA=# M[*@4-_^.('$Z9*OL4G@57>]"@58E77B-4*"M0$T,M(?L<;4_;@(B GX+F.Q5 M3(+W$^);2'XVARP/%D!"[8("]\L9GD#*(.0;_YTU/UH&XG5\4?\>I_7N3]S" M$\H_HG&]-YMGI(&6C]*]XO0#YA&V0;!&:>.7U*-UJ"Z4C"C^GE:AXSJE/]O= M3+M/8#.!+026C*=&T>8S=[PJ#4[$#CR&7BO=F8QNE3]5RQ8E?2 M*C!=O#J6U#AJES9OJ2ZW\Y'%,_F 5^7 ._C%32>T M)2=T_F3CH;:(#KR%_&&;D=Z_GR61T+H0%CXVZ4JEQ.%P>2#+*ZW^ U!+ P04 M " "0B*-(!W 2V3T# "?#P &0 'AL+W=OPL>\UDED9JN5KN'E:H>=L\T<1)4P%GL--U_O\8X MJ9E&RN02L/-FWAB_AYG94?9O:B>$#C[:IE/S<*?U_B&*U&HGVDK=R[WHS#\; MV;>5-L-^&ZE]+ZJU#6J;".(XB]JJ[L+%S,X]]XN9/.BF[L1S'ZA#VU;]OZ5H MY'$>LO T\5)O=WJ8B!:SZ!RWKEO1J5IV02\V\_"1/2QY-D LXG0L*@K3[&:]W9 MZW'\)^4N['( N X!\!8^$ADR_Q6Z6HQZ^4Q4/MJV#SV8.#]D,1D#DQMR@[M MZL?9]P7DY2QZ'Q)-,,L1 Q;#SHC(9+]( 5.*)7CA4,37$W!4([<)N$M J"!! M"1*;('$)8+K(;JQRQ.06DY109M=I4D233FCX19H1DXTT<9R4UVDR1)--:)*+ M-)E'Y-Q@AH=R.F$ M%P0>;&&6$.3H0(XGR4H*$W8Q2PF"9.EDCS*"(!GV,9L:F5(K]BC+;Y8DMA\K M*)+T#9@D64;1)'8@*RF:+#TFSAA%+("="C%!E YT>GDQRM,#;&A@!%F";^@[ M5C(.!"IL:0""+L&W=)HDE!<_8$_#U-.$O09L5TAN%29@'T)*$";X/F0 %+5@ M'T)&T"7X)VH)E,>*S0HY1963(S5/"3S8T5!0-%E,U$]Y@0$V-)041?J&-B8C M'#(<^YE/_%Q2/B&Q43F[59 <&Y #09#<-R#CC%+KE^]=3A D]\]43ONNQB[E M"4&1W#]4*2S8R#PEZ)'[1K[CM!W"3N8909 .E+L=BO'K+?(:J%;T6]LGJF E M#YT>.Z7S[+D7?03;@'W"%[-]M16_JGY;=RIXE=JT<;:#VTBIA2DCOC<+WIEN M^3QHQ$8/M[FY[\?^<1QHN3^UP^>>?/$?4$L#!!0 ( )"(HTCD@M*U;P( M (T( 9 >&PO=V]R:W-H965T<>VX2$O(+)I^T M1(@Y7TW=TIE;,M9-/8_N2M1 ^H([U/(G!TP:R/B0'#W:$03WDM347@! XC6P M:MTBE[$W4N3XQ.JJ16_$H:>F@>3O'-7X,G-]]QIXKXXE$P&OR+V>MZ\:U-(* MMPY!AYG[ZD\W/A 0B?A=H0L=]!UA?HOQIQC\W,]<(#R@&NV8D("\.:,%JFNA MQ#/_T:*WG((X[%_5U[)<;G\+*5K@^J/:LY*[!:ZS1P=XJMD[OOQ NH98".YP M3>6_LSM1AILKQ74:^*7:JI7M13V9 $VS$P)-"'I"G\=."#4A_"XATH3H1H@> M$F)-B+]+2#0AN1&2AX14$])1!D_-KER;)62PR F^.+2#8L?Z4PXG0H0K.WQ! MJ!S*)5?1=VFU&IA6YX$A$%EM M&!@;8CE$)%:G*T,DM!9C>HEMF(V)29X7'([6)I0"H19(GPM$(X%("D1*(#5- MMFK"%"25D#0" -A0JR%J$@5#V%TS\)!LER9ZO;C:HQKZR=L1=#SX8GQ_ M*".P)5EJD,KBAYDYJP/DVD!FX5W@YB%0V?<&)V&#R%'>FWR1=_"(?D%RK%KJ;#'CY[<\N@\8,\2=@Q?^ M(I3\VZ ?U.C 1#?E?:)N2S5@N+M>_OT72/$/4$L#!!0 ( )"(HT@UYKRP MY0$ *H% 9 >&PO=V]R:W-H965T5$)RJLU27K#J)-#2%7&&B>\G MF-.F]8K<[;W)(A=7S9H6WB125\ZI_'L$)OJ#%WCWC??F4FN[@8L<3W5EPZ%5 MC6B1A.K@?0GVQ\PJG.!7 [V:S9'-?A+BPRY^E ?/MQ& P5E;!VJ&&[P"8];( M@/^,GO^1MG ^O[M_<]V:]">JX%6PWTVI:Q/6]U )%;TR_2[Z[S"V$%O#LV#* M?:/S56G![R4>XO1S&)O6C?WP9.>/9=L%9"P@4P%)7? !Y&)^I9H6N10]4AVU M[R[8&[FT)L89F6S*+5WWP^ZM"/TPQS=KM- 6@29PF>8R(5HAH@4@V$8,F=9HT]MWG,2E>D>(% M*=TDQ;-F0O]94K(B)3,2R;)-4C(C/=]3NB*EBYYVFZ1T]NM%Y.FF=BO4;H'* M-O^Q"TWP!"1;0;*%0; )66K("H)GY["C%_A)Y:5I%3H);8ZT.\V5$!J,D_]B M7G=M+LYIP:#2=IJ:N1SNDF&A17>_&:?KN?@'4$L#!!0 ( )"(HT@19X^? M1@( 'P' 9 >&PO=V]R:W-H965T MY%)<-4Z>F;57GF?L(NNJ(:\#FF3OPCA4E MC:A8 S@Y;9UGN"F@@1C$KXIT8C0&VOR>L7<]^7'<.I[V0&IRD%H"J]>5%*2N MM9**_-&+WF-JXGA\4_]FTE7V]UB0@M6_JZ,LE5O/ 4=RPI=:OK'N.^ES"+7@ M@=7"/,'A(B2C-XH#*/ZT[ZHQ[\Y^2;R>MDQ /0$-A"'.,L'O"?Z=$)A,K3.3 MUPN6.,\XZX!HL3YMN%%PKD64,E#)"#,UVV57K[D/_@1_EH1O^+[EI_&Z0# 3"(Q T.]",#79V#0L)K:8 M,(V60,48%,4I6K<2SJR$$ROAHA6+B0PF7G1;C"%)\("/:.8C&OE R:*-:!3# M3Q,O\1:MC&'03T(O77<3S]S$DUV)U@62F4#ROUC-?UGO@2O2@VR@Y7.90*)'[@C\4CW@^BWI,?&_=F6"03":GX\[*FJ4 M\+,I]@(4:Z*,[6=[K1F&)YE\FS%I_)3\S/52/ GDE5Q=[;+Y62:0F4=4>*JWVT)[9Q$G0 DZ!;+;_ON8CJ3WK+ Z' M@,F;>6\,;XQG9UF_-@9!'4:E_=K(NLU8- MZWW0'&N1;?N@L@B D"@HL[SR%[/^WE.]F,E36^25>*J]YE266?UW*0IYGOO4 MO]QXSO>'MKL1+&;!-6Z;EZ)JA,K411=)L7\9TSZG[,+U*\OV;_UY2KY+UDC5K+X MG6_;@U)+?&\K=MFI:)_E^;L8:^@5;F31]+_>YM2TLKR$^%Z9O0_GO.K/Y^&? MA(QA]@ 8 ^ :0/FG 6P,8*X!? S@*" 82NDG8IVUV6)6R[/7'+/N]:"/"EYW M251F3U7?],-^?H>[;PM&XUGPUB4R,,L! R,FL6%6.@9LB+6.B.@5$BB15J6 ME$(?SP:&-)Y.P% "UB?@8QFIM50# V2:A",2;B2@5A(3 ],D(2()C03,2F)B M^#1)A$@B;;X9A-,)8I0@UA3$:":JX:T9(/'P3!/..%&'#;G^''E34X(T);HF ML&H:(%$/"0E+^"U)GP)O*DJ1HE13E%J)5JE6^Q=* <+TEB8$)9RE3JHHP7V! M&.]/Y)#B0VNA]SJ68L]3T%40NV=-$'6I%K<&:O8&NVU-$+C4@[L#-:UO;:5+ M!$H=>'"#H(;[&;'SF""'EDQQCZ!&DV .K8SB+D%CXQ%'MM=Z277[)V0X',BP M_6EBE,SL9+JQ:1RZ]AJ*K4U3@XW;V5*-#4)G-L".!7)OPP;L6*"3+7LY8N[7 M^V$]A\E>O!PQXZ,@/$K6(&;B^I)0 (JR\]-S9L>(@,-H<>"-CP$-^[+ "V,1@V)HF]9MW&/'5N M&H!M#*:-;[#I-F:1,QO#-F;&PLLY ML;)REQ38=(S?73-V$@M=:@[U#U%FKSG0]F#';"]^9O4^KQKO1;9J.]?OY'92 MMD(E) \JX4'MRZ^#0NS:[C)6U_6P4QT&K3Q>-M[7W?_B'U!+ P04 " "0 MB*-(C?EG7_H! #4!0 &0 'AL+W=OBT]9 2CTQ6@C]UZE5+O#6!85,")?> N-?G+F@A&EE^*"92N E);$ M* Y]?XL9J1LOS^S>N\@SWBE:-_ ND.P8(^+? 2CO]U[@W38^ZDNES ;.,SSR MRII!(VO>( 'GO?<6[(ZI05C [QIZ.9DCD_W$^:=9_"SWGF\B (5"&06BARL< M@5(CI(W_#IIW2T.R9:8EQWL-%P8$:V,=#'2+NUQN=UK'L5!AJ]&:(8Y.$QH,>%KN(8Y M3C%W%:P3K,8(YS$.X80>Q>L6 M0GL+[_ \:\D%?A%QJ1N)3ESINVRO\9ES!3J$_Z+?8:5;[+B@<%9FFNBY<%W' M+11O;SUT;.3Y?U!+ P04 " "0B*-('J$> M\$ "0&0 &0 'AL+W=O M=UZ:JF?NNWYJ:I_-;L\;X/?97%H M[F>[MCW>A6&SV>5EUGRMCOFA^^>IJLNL[2[KY[ YUGFV'8S*(H0HLF&9[0^S MQ7RX][U>S*N7MM@?\N]UT+R495;_M\R+ZG0_4[/SC1_[YUW;WP@7\_!BM]V7 M^:'95X>@SI_N9]_4W8..>\B ^&>?GQKG=]"3?ZRJ7_W%7]O[6=1SR(M\T_8N MLN[K-5_E1=%[ZD;^=W+Z-F9OZ/X^>_]CF&Y'_S%K\E55_-QOVUW'-IH%V_PI M>RG:']7ISWR:@^D=;JJB&3Z#S4O35N799!:4V>_Q>W\8OD_C/TDTF?$&,!G MQ> R#F^ DP&^&>B;!GHRT%(#,QD88A".N9K@<%F2\^[I G<[#U]Z1AUF.&!@PZH((.^_L$. /L03''+@!5AX" M."9MR^;"KL)PP MYXT3\>'Q4#95(& #E VX;-A,6TZ8B8T!8!=U[<-TJB5\J-0I] 2"39CE!)HV M1@R63[^UA\/()"#90%0\E:^>[-983J!Q**4 #!O+-<%%&@4BJJB**E]&>?%1 MKD)VYPZP>W]-8'$LT%)%Q519AU W*YZ0=>=N4J6NQ,C'H;6"PUU1>5:Q%R,K M<$%5526?/7@5%4.5>BQB/C"NT&D^VU<>2$4",D"E$"*/#'].0.2K[A7Q(;!( M1(AJ(;A:B"!8(Z "!O#9-0*J.>!K#G]D@:$GHK[>%B(26J$/#I>@MH1H.;T7QE\0!N,07&B&H&H(D/;CW%UPP/ MD'CYJ*U -X'* Z0?GRT/$VB<4U<>.IW(]1:"YC[ZN2\X=9!F*ZK/IAK2;$6W MW$#+;K@ENH5$@GSY[X$@B05DWK55DKQ'OX:P[&98>:@O5E 7(A4'E(@#>N*@ MD3\J/)22Y!I2!4%)HX:R3FV"Q>)6#:EXX*?% ZEXH*!=0UF_YL-D#1M2B4%! MRX:)M\<5BUI[*%0H"3#5(10T;2CLVF[AKC^QH'JE!6V;=FL0E6+*-R8W8-?Y M4/'3@K9-NPU9-V^>C0RL: TU1%M:>B]!'8 MF8W7L6FC^%Z$PHQ 2/6[AUV^D/(MI'8ETIJ4;R ]5"PJ^C154NTK*=\:::_& MNMX^$ES7/@JR75,YU=:CQ(NAMIZL\+GN@T3QH<*L76&^UCIJMZR[T3H2'-,Z MALYCZ#*OGX<7 $VPJ5X.[?B0]G+W\I+A&_2/L8=P>AK%X5=GFTO%T7^U/8_XSX\XPN#\:*MCN?W M'Y>7,(O_ 5!+ P04 " "0B*-(-$A8]/P! "#!0 &0 'AL+W=O0J._E%PPHG0HKEBV DAA28SBT/<3S$C=>%EJ@O#]X@7=/O-?72ID$SE(\\HJ:02-KWB !Y<%[#?;GQ" LX&<-O9SLD?%^ MX?S#!-^+@^<;"T A5T:!Z.4&)Z#4".G"OP?-1TE#G.[OZE]MM]K]A4@X*J D'57OO/\&0PM;(YAS*NTORCNI.+M3/,3(IUOKQJZ]^_+%'VCK MA' @A"-AK+-.B 9"]"#$_R3$ R%^$.Q98]>*/8@S421+!>^1;(FY'<%>PX41 MT;H,*'%!&N(\Q01OD0C!FL'JS;"N8UC.!58 M*W&:(:)5%U-(%/^'BVAQ&)$5B(8V=L\%XH5 ; 5BY\!/YBX;Y])A=@ZS?5YC MNZBQG=9(HK4:1X=Y<9C-=@USFF)VF^2YD61A))D9B5>OSARS[!9/[BH#<;6/ M7J*<=XUR?^28'>?*:VCN^B)_#/8G-QX>,EG:DBO\(.):-Q)=N-(OR3ZBDG,% MVIR_T4=0Z8DX!A1*9;8[O1=N2+A \?8^\L:YF_T%4$L#!!0 ( )"(HTA_ ME?]Q]@$ ),% 9 >&PO=V]R:W-H965TSVKBN*&B@63ZR#5KVI&*=8JB._N*+C@$M#HL0- M/"]V*6Y:)\],[)7G&>LE:5IXY4CTE&+^]PB$#0?'=VZ!M^922QUP\\R=>&5# MH14-:Q&'ZN \^_M3JA$&\+N!0*@RC^M&O3FG6P;U)OI&T3@I$03(0ISS8A' GAG1"92JTS4]=W M+'&><38@T6']L?V]@G,MHI21*D:8HVF7C5[S,(XS]ZJ%%IBCQ00&XT\(5ZEO MI@B6*8[!C!YL)3@M$.'C#.&JB-#PH[&(Y+% M!*(C$ X"J2/!78K@=W"P;=E ME:WM@\7$MHU![&^B3BM4&CPV$Z_,Q',SB?=8(%D))/_;CG0ED'ZA'>FLT' 7 M[S:[L0!%2;2RXLY^=@K\8H: 0 7K6VE_J"DZS9GG0%^65?RHYH\=%W>9/.OP M!7YA?FE:@NPLK" GCP !D !X;"]W;W)K&ULG9M-<]M&#(;_BL;W1(O]WHSMF/NX?Y_FG7+._.%VW67Y;Y]WUY?M\V&]VC:?=[/]\V:SW/VW:-;MR]4%7+S^X:_5P^/A](?Y]>7\ MQW5WJTVSW:_:[6S7W%]=_ *?;B"ZD\W9Y.]5\[(?_#X[>?^E;;^>/OQQ=W5A M3DXTZ^;V?SQK;EIUNO34,=;_]N/^O.FIPN'O[^._MMYOD?_ORSWS4V[ M_F=U=W@\NFLN9G?-_?)Y??BK??F]Z2<13@/>MNO]^=_9[?/^T&Y>+[F8;9;? MNY^K[?GG2_<_V?27C5]@^POLCPO OWF!ZR]PY()YY]EY7K\N#\OKRUW[,ML_ M+4_+#9^.YKO3(,>19\?)[,\?S^'J_OKMVB6XG'\[#81L%IV-/=O8,8N;H47\ M.V\,)T;T]<[,@MWOM[UL[#3 W@R@#\/X/L!')YDY^2B MLTE=&$K(QDS?)Y#[!'0?/SU ) -$--,P/4 B R3D01R=:6<3N^6TQ<4T9G:3 M!@&),;@L6+E,W,G:E2MD@(+F,^KHH@SF\\%[:T>G@ZR*$6SC\X9%-!GD318, MP8 $[0J#I4-8Y$49C4EOU$T7BHD&1J-"[$HP2> 2!132*%.N;=$NE*/ .IP\ MQTN3WJ@_&H*!/%JLW6"[9&.4E)7T '#X !! X.@!X/ !,%Z@N.$!8,8G-&Y2 M=X35R/A\B((A*-!.G8(=!=H)4O#"#5/P&[4)L9/5)HX>$ [G:LD0%&F7U(&A M#+HL2!2]D7P34$R=)/VZ,KT;QTWJSUL4=H^SLZ!2]A1.K\[.GL+IK2 ML!KQE#Z/Z1,4<)X]HZKI\Y0^+RF _9 J837B*51>4@![E$[KU0BR$U8CGC+J M4=HMDDU+&?7J^M=3 'T1G']^&L"*2;T100$,1K! P4PZ4C&I.T(Q#H#61?#8 M'2C&P6K7)5 ^ ^*S4GR$855L4X%!38MB@NR*3582&,I[P+P+]GQ@[2;,^WCQ M$8:\U]LCV$S4'PGT5 CH5"B2*5&,@SK5!HIQ$*3:11A/M2@BRFPCI33&"2!";KM%EGO&-,G<932%]7T14I?E!2Z48E6I&A%2:$;I_-LQ:3> M;J> )I1GB^"Q*U% D[K0392\)&D))T14M0F"S61-D$2Y2Y)N5<+=JFH3!-D) MFR")8IQ0MZH('@,3Q3BINU6),IIPMZKR?B9.[MN*2=T1]IX(DRY(U8F2GC#I MX]5'FLZS%9.Z(_0P2#C/"AXV,\4XJ_-LIAAG09Y=9)@,1\6D[@@]##(Z#(H@ M;6:*;W;J<%#>LA?D@=Y(/E>*9)9DUCR>69$CRN2;*=AY"+:7O#O.%,FL3KZ9 MO6[-DG H>-8;R[@:P"2/0^8+A2PB"').^2#=-*&+U8PC"U MA+&"T+Q:O;55:C9O.,-T$@93+'A< ,.4$D8OE3!,*V&"*"Q!LF6PF73/,%&% MP3E4(D0Q3 9AU%D4#!-"F"P*SG1M6[-YPQDFJ3"8;9'JB/$(ZH0+(]HED(0% MACD7]@@&F8P&+: MQ@4KKU:]QRE*SBHF=@*D=O(@Z&<#$RB!U:=(IBD"*TJ15IO^F/((B/1(LD9, M>P1(?%1=(Z<%B2F*P&&0)+%EFB)P>I"8'@B<""3W'I"8<@B<'B2F'0(G LF] M R0F"@*'09(4XDP6!'I=$#!A$#@12%II$#!M$#@]2$S7 UX$DM>"Q-0_X#%( MDH)27O BT#R"*081 YS$;R>(Z8" H\Y&A?= -(!?3B>.9)[,8X\ MYD@"(Y/N@-=SQ,0[X$4<>2U'3.(#7L\1D^= ,)(UTJIO@,EO .EOO$2I DR M WH%#C )#@011^$='#%M#>C%-<#4-1!$'(5W<,24,X"D,]Y*GDN8=@;TXAE@ MZAD((HZTXAA@ZA@(>HZ8/@:BB*/>*HF]92H:B)@CD;>,HVCU4V8<(4U+'/\R MXZM1-^,4#7LC-1]\D?1I^=#\N=P]K+;[V9?V<&@W5Z>OH]ZW[:$YCF8^'K?X M8[.\^_%AW=P?3K^>WHCONF_/=A\.[=-5_VW@'U])OOX?4$L#!!0 ( )"( MHTC O5-B_P0 ,? 9 >&PO=V]R:W-H965TTC.S)@9NQ:, \QZ\^_#A\>+VF)I MYC(VGJ?6D[K[P4.;2UE]K0]9UJR^%_FI?EP?FN;\$ 3U\R$KTOI3> MRJI(F_:R>@WJJWHDBK M_W997EX>UWK]_L.7X^NAZ7X(MIO@-FY_++)3?2Q/JRI[>5S_JA\2H@[2(_X^ M9I=Z]'W5D7\JRZ_=Q9_[Q[7J.&1Y]MQT(=+VXUN69'G>16IG_O<:],>D_I766E/D_QWUS:-FJ]6J?O:1O>?.EO/R17==@NX#/95[W?U?/ M;W53%N]#UJLB_3Y\'D_]YV7X#\%UF'^ N0XPMP$:?SH K@. #0@&9OVZ?DN; M=+NIRLNJ/J==MO5#"Z^Z(&WD5;N8NK_LMVOX]=L6#6R";UT@![,;,*;'&!\B M&2-(WR!!2\#+PC 6IA\/PPQ(\P& !8 ^ %Z7@2[)T[", 1/V&*V,-00^7.+B MVDT! 2%DA- A9+V$!@SU&+"QE\P8(]H9RXA8APAYB=C1)+]X-R]Q(-JH>2+$ MB)!#)/02H=$L78I(1UXV+JY-.)EY0B$C%#J$HOD $0L0+:W:F 6(!54;CY9* MW5*]M92,8:'&D 3KT8J+@1)4[14T3*6\9"8@TT3N5$D+JO8*^BD1/V2:"!P7-YLC!B9/$I4Z[6A<+0G!QTKBT M"%9EN$H9M;1Z#=<7H^>K-S%C\8AL'*-@IKLG&S-?E(DQRQ)MN"88F*^XY J2 MS\)EP^!\.24&/[!K7%V,HRX@>:+D:F!H<97P/C:AI$K&30H810)!-KQ1322I MDFAA_GCOF5A2)?&R68"W)RA!E8!:OFO NQB<+@:!' %O3UCN/.ZLA\A[C'M/ M@[43V^+ M 40$.)M"A+O 3A[^YF 3!/A70P2[P%VGH@?,DV$:P%(O >0+$7T M@11Q90%'640AN&3 8O"QDT6A/Y7' ZN319)[M+(E0\= MY0-)B+O7)(N="'*508D3P;&$ &@E*4XN(R@Q&+C0/2#7!I2X!PS]53<]#=O4!UO8@DTUPX[&(O8KDJ6($7V=FQ*FC4!OWR[^#B* I# M 2,N(%;@67;6$1#MOU4[(-GV<(VQ FNSLWYKXU!9Z'Z(*Q4)W,^.E)LG2\;+ MQL'%L3:"!T7BPD>N2Q*DFKA2T6*71%QB2.*2R+$_1AGE]Z@NKMT_+;BI$)<: MDO@D<@Y@_.U$"XT2<8DAB5&B>:-$[BF-DB3J[IA&=$XS@,);HHR_LUT<:E3< MYP>CX\IS^IK]E5:OQU.]>BJ;IBSZ0\^7LFRR-IKZU"[OD*7[VT6>O33=U[#] M7@UGM,-%4Y[?CYQOY][;_P%02P,$% @ D(BC2!->TI-O P 51 !D M !X;"]W;W)K&ULE5C!%4V]*GUNE-=%^V_-:W8>>DC_[+Q7.X/O-\(5HM@LMN6-6VZ MDC5>2W=+_Q$]Y)#U$(GX7=)SI[Q[/?D7QE[[Q<_MT@][#K2B&]Z[*,3CC>:T MJGI/(O+?T>E'S-Y0?;]X_RZ/*^B_%!W-6?6GW/*#8!OZWI;NBE/%G]GY!QW/ M$/<.-ZSJY%]O<^HXJR\FOE<7[\.S;.3S/'R2AJ.9W0!& Y@,ICAV SP:X ^# M2)YT8";/]:W@Q6K1LK/7'8O^VT8/ M[V3H1G3QRFDTN9KF'W;17A=!&\]8XT MS'K @,2@"1$([]80H(=8@V(.M@"YAL#S$;!Q""SM\7B(;-Y!9#B(I(-H$A7O,C!A2E3B-S<3J:\ M(!=]0:ITJ"JF)275MZU,4.+DR1 M@NC6#@)36,!%6$!5#$R(_1:EH2!$+O=?4U8@<6@A2 R=(W8^B<8G=- H,#4* MB$L7Z?>D:S<[ ^9TM0-3\2!UZ"9-RV) 5MJY!L.A2S^9B@>92_5DRDW_#D78 M/@]H,,"?)H) F=9JVN[E%-MY&W9J^# 13;O3I/P(_;1G[*_%!#W,NQ]N5HMC ML:>_BG9?-IWWPKB8)>48N6.,4T$OO!?5?1 S_K2HZ([WKT2\M\/4.RPX.UZ& M^.D_":O_4$L#!!0 ( )"(HT@!&84BVP, . 3 9 >&PO=V]R:W-H M965T/FQ5Q\NG6ZT3D@+:^F_MD MG\*PV1YUF3>?S5E7W3][4Y=YVUW6A[ YUSK?#4%E$4(4J;#,3]5BM1SN?:]7 M2W-IBU.EO]=!UOA*ME>(O;G4I=-2=3!;7> M/R^^B*>-E#UD0/Q]TM?&.@]Z\B_&_.PO_MP]+Z*>@R[TMNU3Y-WA56]T4?29 MNI'_G9*^C]D'VN=OV;\.Y7;T7_)&;TSQSVG7'CNVT2+8Z7U^*=H?YOI-3S7$ M?<*M*9KA-]A>FM:4;R&+H,Q_C<=3-1ROXS]I-(7Y V *@%O ;1Q_ $X!^!XP MM"X M(=;*&N)N/VP0KQ\)H9(X5(272F*-\NDN%P>518QYEA(NJ<,%O%S2A\_&1LA4 MQ8]Y9(1'9L_W&!\G$!&5?<28\1-HZIB4X*UXX\)8C14?;$@PIOT$^EUO[T#N M$P%*!!A3?P(]; S,;PRU-H&,^3^!'FC10?'84)\4DJ& "325':=WV,B93XH: MI7"<,I:,%-3FA'*$Q%"BH/8D7'_RUKH6MO6@LK@Z';%1L>"\" 5U*&%;5,HI MB'J+R.;V!*BY@&,N<>+M"3BN@8GE@W937%BB,@8?:BY@FTO"> :V%\0GY0?M7%1 M H%!ARH97"6GC!14?9 Z3>',52H_R&P6RO_^F4"3GT 4)W?$8^,@RH#C"$CE MC(Z<6=_G5($HYC8&J001&(U!^XT+(D:)WL8X.!$A*L:,P0_+#D?2K!14B"AG M-X8J$6-.8^P%0:(P\T\8%Y8F,<,LD>H:'5TKAKL@U2(FL]M"M8@IIRVIM5Z# M-$6_O;BP1"C&$A.ILM%5-N-[15(ERFAN6R15HG0^M.E+=UJQ$Q!C$D@J5^G* ME;,FI_*2.+O:#^MZR:G6!5'C#ZT-E5+7AV&CJ0FVYE*UX\[)[>YM,^L+#!LR M[_#5\IP?]%]Y?3A53?!BVM:4PX[.WIA6=RRBSYWTCCK?W2X*O6_[TZ0[K\<- MJ/&B->>W_;3;IM[J?U!+ P04 " "0B*-(PH#^V^T! !7!0 &0 'AL M+W=OQ/[,^<<_SY'=C%Q\2I;2E7PWK-!'L)6 MJ7$/@#RUM"?R@8]TT%\:+GJB="G.0(Z"DMJ:>@;B*,*@)]T0EH5=>Q9EP2^* M=0-]%H&\]#T1?Q\IX],AA.%MX:4[M\HL@+( BZ_N>CK(C@^!H,TA_ ;W%38* M*_C=T4EZ\\"P'SE_-<7/^A!&!H$R>E(F@>CA2BO*F G2&[_-F?^W-$9_?DM_ MLMUJ^B.1M.+L3U>K5L-&85#3AER8>N'3#SJWD)K $V?2_@:GBU2\OUG"H"?O M;NP&.T[N2X9FV[8AG@WQ8H#)AP8T&]#* !R9[>L[4:0L!)\".1+S9\.]E@L3 MHI,#W8RTI3TNMWHM$YP7X&J"[C2/3A-;3;REJ'P%AHL$:(!-BGA%$5L_LGZ8 MIY\'H%4 L@&):R.+[B$'UX;39%:3YPAOB2I?M,,Y_APE6:$D=RAP$\5IL-6@ M;)?GFRR^*HGP5\XE7<&D=S#Q)DSJ;0-3A---&%^5[> 7#@:O6+#' N%NDP5[ MQX^1?G$V67Q5FL51MH(!WAT8R9G^(N+<#3(X>*ZJSH03?6ZE=N M*1AME)EF>B[%XN/M&5O>TO(?4$L#!!0 ( )"(HT@''R!;X ( &\, M 9 >&PO=V]R:W-H965TT]>:PXVYJ@(O< H< K M6%:Z:6+V7JHT$2>59R5_J1QY*@I6_5WR7)P7+G8O&Z_9_J#J#2]-O"YNFQ6\ ME)DHG8KO%NXC?EB#7T,,XE?&S[)W[]3BWX1XKQ<_M@L7U1IXSC>JIF#Z\L&? M>)[73#KSGY;T*V<=V+^_L*]-N5K^&Y/\2>2_LZTZ:+7(=;9\QTZY>A7G[[RM MP2CTRS3ZA53+$TJ<7;DD=4/('[0\*HFTY'2D.2>!\UT0"S;#!@,!!#A_$T_V@2&"990H^ 4!A+\M3'C")6?42 MQR#/@T0X&L.LAV+(=#7$:ADQ!*1M&9TFH!8!-034$(16(673C082-MV(**%H M#+:Z ;NJQK?4^'TU,*JF@00&XB,2T5$QUU%7M026EJ"GA4 P31!:!.&]9Q-9 M!-'DV3Q'_:;[_JRFQU::>++ISW$O#48TB*:S8&2[&_4;ZL]H*/[O!8'O;2D& MFP+Z*J@_5NZZ!;5MC1&:T55L6Q.30;WQ# K;G)C>7:_M*.Q/&QSWW7+#X;=P MUQ79OL+!M,E;3/O Q20>%;ZZ ;NNQ[8I#GMZ:.C/H+"-BJ.[S\DV(8ZGG\LE MCN]_+L'V(:!!O3-\"+8/X6X?@NU#@(&*.N [4(@ XH9+@3;A7"W M"\%V(?ASJAV (OMLO=XP5?!J;^9>Z6S$J53-U-3M=K/U(YAA[ N>)D>VYS]9 MM<]*Z;P)I4&ULE5;;CILP$/T5Q <$V]Q7!&F3J&H?*JWVH7UV$B>@!4QM M)VS_OKX0%KQT0UZ";1X_%*3&?$5; MTL@[)\IJ+.26G3W>,H*/.JBN/ 1 Y-6X;-P\TVSMX+<^%4 =>GGE#W+&L2<-+VCB,G-;N,WS:P4A!-.)723H^6CO* M_)[2-[7Y<5R[0'D@%3D(18'EY4JVI*H4DU3^TY-^:*K \?K&_DVG*^WO,2=; M6OTNCZ*0;H'K',D)7RKQ2KOOI,\A5(0'6G']ZQPN7-#Z%N(Z-7XWU[+1U\[< M24 ?-A^ ^@ T!/A?!_A]@#\$(/AE0- '!%: 9U+1A=AA@?.,T<[A+5:/!WR2 M<*9()+,CL^=ZJ^MK3J]YD,#,NRJB"69C,$AC4.H/&$_RSXJ@J<@&C0B"!,V) M;,<8E( YS&[*L\"(;V7K:P*_)PCN$P060: ) DT06R8;DXB!Q!H2I2!$< ZV MF\+B&(;WW826FW#D)D@6$$060?1H/6*+()XXB.8RW1A,9/[9^Q*))9%,).)9 M"8.!YC&&*WA?);54THE*,JN2/I8(!':O@8E(.M]L8Y#O+T@%?NII.-9)P0(* M9%.@1Y\,:/<:]"3GQ;"IR$FH92S7S Q< MLQ&TO7T_#!\Q^3]02P,$% @ D(BC2$."GX/( 0 S 0 !D !X;"]W M;W)K&ULC93;CILP$(9?Q>(!8G,()!%!:K:JVHM* MJ[UHKYTP!+0VIK83MF]?'P@%A)2]P1[SS__-&..\%_)=U0 :?7#6JF-0:]T= M,%:7&CA5&]%!:]Y40G*J32BO6'42:.F2.,,1(2GFM&F#(G=KK[+(Q4VSIH57 MB=2-6FM."/E !Q^N''IG5C M[]_LR)"VGA -"=&8$.]X/=)PSBA4'L#)+!()M7V?HJ MO29UFC CSR') I),(?OMZE;,->ESR'8!VH6?5%Z;5J&ST.;0N_->":'!.)&- MV9/:7"UCP*#2=IJ9N?1_FP^TZ!YWQWB!%?\ 4$L#!!0 ( )"(HTC4+(R% M?P( $H) 9 >&PO=V]R:W-H965TQ]-W;*U7W)^604!.Y2DP>R)7D@KGIQHUV NAMTY8)>.X*,B-76 M $B"!E>MGV=J[J7+,WKE==62E\YCUZ;!W>^"U/2V]J%_GWBMSB67$T&>!0/O M6#6D915MO8ZTK?Y.#;<>T#&0.IR8%+"2PN M[V1#ZEHJ">=?O>C#4Q+']W?U+RI=$?X>,[*A]<_JR$L1+?"](SGA:\U?Z>TK MZ7.(I>"!UDS]>XM-/%J"GN0FH)Z"!,/BX"6%/"!^$ MZ+^$J"=$"=%!'*GB@74T/U0O3L M>QX#D 7O4LC %!J#% 8MT8 )A+[3!)DF!1H)Q "Z3#8F!KDPVS'&B=B-$0F< MCC2TRA$J?M1'$4X+1)9 I 3"7B":%H@M@=B((#:S;'6M-"95F!#TOVFKQ+)* M#*O$^5I,3#IMDEHFJ2&P<)J8F.6TR<(R68P%(' 5K5B,BI;&Q@9;LD,";OS8?SIG.V.AD:[PM39 M;19H8?D$HPVD(=U9;=W,.]!KR_6G=9@=C@?/2&Y UGP!5QN]R3]D\NR"S^0[ M[LY5R[P]Y6)[4SO;B5).1'3@2:16BH/-,*C)BT/$3_UM-JIH+:),(ZSJ*WJ+EPMU-ACOUJPLVCJCC[V 3^W M;=7_6=.&798AA&\#/^K#40P#T6H137&[NJ4=KUD7]'2_#!_@?H/E %&(GS6] M<*,=#,D_,?8\=+[MEF$\Y$ ;NA4#124?+W1#FV9@DC/_'DG?YQP"S?8;^Q=5 MKDS_J>)TPYI?]4X<9;9Q&.SHOCHWX@>[?*5C#>E N&4-5[_!]LP%:]]"PJ"M M7O6S[M3SHM]DQ1@V'X!C $X!F/XW@(P!9 J 1%6J,U-U?:Y$M5KT[!+P4S7L M-MQ+>#^02.9 %L-55RV7'GU9I5 NHI>!R,*L-085!B9$)-EGIT![BC4:X3@W MP<9"D.LS$*<(HN*)+@+CZP2)0Y H@F0D #O)3I>A,;G"?"J2= ZTL4%%C*EDTQI5>.QGA"[=HNM>F9%M!Y!6D489WGAX0GX MX&RPILKFK6V#/'88T)T'+8K"@\+U+]QL8' =#(F'4,"T)^8IF85M1M@HE1PR M#ZF ZV-(;Q:+ZS[(?,22F34A 1^?@^M3R'W$8H-\5L6U,UA^)CX[[9H0REO% M@JX+,?80"UHN-'?0U,J(&K4"B4\ZKE,1;I4*NB9$])#*"-(5$4@\OBKH6A6) MAU!L$/$Y,[A^1M//!#T87 -B>K-.7 .B;<#Y/V,T#4B2)"GFA9(90B$%@L>W M%EV;HNE XK-_K@&QN'E57 -BZ;,JI>D>B/]E'Q,&)7PX8T3&<;:E_4$=\WFP M9>=.Z"/C-#I=)1YP. X[XVMYQ= 7@G>:U>)4'>CWJC_4'0^>F)"';77.WC,F MJ,POOI,B.LI+T-1IZ%X,S5RV>WTMT!W!3F^WG.FJM?H+4$L#!!0 ( )"( MHTBN'S\VW@0 $ = 9 >&PO=V]R:W-H965T7!]\/K_MN>)!LULFUW.Y0%?_Q7GPMRG*(U#O_ZX-^> X%Y]>7 MZ+^/Z?;5?\[;XFM=_G/8=?N^MF(5[8J7_*WLOM?G/PJ? PT!MW79CO^C[5O; MU=6ER"JJ\I_3Y^$X?IZG;U+AB]TOH'P!=2V@QP+)9#16\[>\RS?KICY'[2D? M.D\^]/)F"-)'COJZM>/MF/WT]'U#6JV3]R%0H'F:-&K4R*LBZ:/?M5"AQ9.: M%2>M/P^@61WU&$#[ .;S (8%,&, XP-0F.1QJN6DL5.2RLKLM M)I$;14H -IQ+J0&NO,B#-1NPO_;A^$H#@!6*#-)#G%]) %M>E"[J( ZQM !> M7K2DY3C%T@& >=&RC#C),D29@!"<4IDM94QQ3)4 &/,BSY@2L4 F-8ZSD@!C M7C0Q9@#&%$=9*8 Q+YI&BI(*:3H.L]( 9*'(6,"'PZP, )D734-2FQ@8D8K3 MK A@S(LN+8?,^HK#K"P F;)A1@IQXCBK$&=@PE6<4Y4NAHQSJC($LFP.F<$@ MTYQG+0#(O,CY=0A@PUG6$H#,B_Q041(QXC1K!4 6B@SPNZ]O5LP:@,R+IB%I MTE@ 0U)SG+4!*-/!XIHRI.DXSIH RC2%*3D $Y%_&*,X4X,1Y-AJ@S,Q7VI:0]^2;%V4#0&9,F)$&QISA.)L 9T)"<$Z- M7;POP#DU#H#,BSQDZ0"9^/A#:L[9-BD G!=-P/6.@ \'VV0(<=ELV&B(!.)H MDP"("T4$<$"<;)( <5XTC<],Q):6=1=QSDD!]-%\#9Y*X 6(..6D ?IH/FNG M_:QM%F;'F:> >0*6VG2S\45+220.,UF 1"^Z[(X(;+XC3CTY #\O\O@A^R/$ M,:<4P,^+_(1GD14+<9'?3A!9K '2+2?=2H Y.U^2 M&X'X<+:M IBSBJ6D@&6)Y7C; &\"?B$L9]6:I:!9SJHE #0ONH &[I'8F[UJ M"X!FYV_&LG\UML"*VW*FK0-8L_,=:TG(/HGE4-L48"T4$3):.-,V0UC+@K;K MYSK@Y]MQK)T 6'/SA;G60!\YSK23 &MN/GM+E<4WYPK)[(2K*IK7\2"OC;;U MV[&;CK*N3Z^'A5_4>$+V(=^L3_EK\5?>O!Z.;?1<=UU=C4=L+W7=%7U%1-PS ML"_RW?6F+%ZZX=+UU\UTP#?==/7I 0 !D !X;"]W;W)K&ULA53;CILP M$/T5BP]8@PE)-R)(&ZI5^U!IM0_MLQ.&B];&K&W"]N_K"Q 2H88'[!G.909? MTD'(#U4#:/3%6:L.0:UUM\=8G6O@5#V)#EKSI1224VU"66'52:"%(W&&21AN M,:=-&V2IR[W)+!6]9DT+;Q*IGG,J_QZ!B>$01,&4>&^J6ML$SE(\\XJ&0ZL: MT2()Y2%XB?9Y8A$.\+N!02WFR-9^$N+#!C^+0Q#:$H#!65L%:H8+Y,"8%3+& MGZ/FU=(2E_-)_=5U:ZH_406Y8'^:0M>FV#! !92T9_I=##]@;,%5>!9,N36P1W_41.WH\6CP_%MC<"6R MI1VMX!>55=,J=!+:[#>WU4HA-)A*PB=32FVN@3E@4&H[-?L:27\R?*!%-YWS M^;+)_@%02P,$% @ D(BC2"*WPW&ULE57)CILP&'X5Q .,S69(1)":I6H/E49S:,].X@0T M@"EVPO3MZRVIH:9)+WCAVWYC['R@_3LK">'>1U.W;.67G'=+ -BA) UF+[0C MK7ASHGV#N1CV9\"ZGN"C(C4U""%$H,%5ZQ>YFGOMBYQ>>%VUY+7WV*5I>2RPE0Y.#..U8-:5E%6Z\GIY7_*5CN @51B.\5&9C5]V3X M/:7OX<(X;6X4WVOPAVZK5K6#?I-! M0W,30D,([X0@_BT\%C'9;[*5@* M>"]%A+(GEHNIH?H@>O9:)"C,P54*C3!KC0D5)@HR%V9C8YPJVQ$B\19 J$3M[5QX6)A MPV;CQ),XL14G0;$SC\8@$QG.Q-G%5IP);#9.,HF3C.(DSCB)%><)"S2Q0",+ MY+1 3@N[6&05^T2(=!(B'85(G2'2^66?]P.GO M#Q_O>(-)S?__9+'!7R=-8)<+G=]V;4#:*X/090:L$Z[#9_(-]^>J9=Z>&PO=V]R:W-H965T411TX95:6(OO"K919*FQ2\\$!=*$?^]P83UZQ"$U\!K_9^Q-;[X=UV&L<\ $ M'Z260.KQCK>8$*VDG'\-HI^>FNBNK^I?3+DJ_3T2>,O(S^8H:Y5M' 9'?$(7 M(E]9_Q4/-61:\,"(,+_!X2(DHU=*&%#T89]-:YZ]?;.(!]H\ 0X$.!(@_"2F-;84TX@=DJ@J.>L#T2']>8"5@G,MHI0#5;TP6]-?&WVO MLGQ11N]:R,-L+ 8:#)A#[%P$7"8C)E(9S*8!_30VT!'(\N6.2+FZX ,<%P/@!'SCU@5XU-P:"#YK^,9$S@BCF M9S/+17!@EU;:PSE&Q_OBV M&)-891<_J=-1JYMNW!!\DGI9J#6WL]]N).NN5]EXGU9_ %!+ P04 " "0 MB*-(E#5*YBP# "8#0 &0 'AL+W=O51&J\6NT>5JIZV#V["4FLVB9KDZ;[[Q=CX@*E"KW$ MAKR9>0PSS["\L/YE.%+*@[>VZ895>.3\=!]%P_9(VVJX8R?:B7_VK&\K+H;] M(1I./:UVTJAM(D HC=JJ[L+U4LX]]NLE._.F[NAC'PSGMJWZ?QO:L,LJQ.%U MXJD^'/DX$:V7T6RWJUO:#37K@I[N5^$#OB\A'B$2\;NFET%[#T;RSXR]C(.? MNU6(1@ZTH5L^NJC$XY66M&E&3R+R7^7T/>9HJ+]?O7^7RQ7TGZN!EJSY4^_X M4;!%8;"C^^K<\"=V^4'5&I+1X98U@_P-MN>!L_9J$@9M]38]ZTX^+],_*5%F M;@-0!C ;S''C$^$Y$(L9 MY%"F:YI]723D5D.,B,9Q)F,"9-*3%;$L3,;.@CCI$AO<\DM+KG!Q1EFDVMA%J0@V$G& M0N7);3*%1:8PR"1.,H46AB"4.[GH((@SC[Q@9/M$ N(O&0!4)\DD.V'1 ;R*?+L2VI. O:PJV107''HVD0--R M18M\DA0=10@ID ?;*G"J4='*="U6SYI M*0/EDQU;]7#FTU"ZI 'YI*%TT **(O.@8PL?SGTZ2A>U)(X+-Y_PI Z*9<&*H_M M#W>D'7A;VA_D16 (MNS<\>E0.<_.EXT'& _,UOQ&7$*F*\.[F_7R5!WHKZH_ MU-T0/#,NCN/R)+YGC%/!#MT))3R*:](\:.B>CZ^9>.^GB\,TX.QTO0?-E['U M?U!+ P04 " "0B*-(IZGTHH:ED7LO9FRP)V30L.;(7:G%#<_*Y#8+>F8'AOO M8MNXT&!EP09>)11H*U 3 _62WH\7JTE 1,"'@,Z>Y"1X7R-^A>*E6M(L6 ) M&Q<4N ][> I@Y ?_-UK_HT,Q-/\J/X4=^O=K[F%!Y2?HG*--YM14D'-=]*] M8_<,_1:F07"#TL8OV>RL0W6D4*+X(46A8^S2RO2FIUTGY#TA'PAY,IX&19N/ MW/&R,-@1V_)P=^.%AYL@XI6)]V9C&7>?NOMR.I\5;!^$SC"KA,DC)I]G X9Y M_:M#\HLA>128)('Q[?\"DPN!212XZ5W.SUWJY#)A[OHAH[N+*>SD7%J^A5=N MMD);LD;GCSB>;HWHP$MEHRDEC7_(0R&A=B&=^=RDNTV%P_;X4H??I?P%4$L# M!!0 ( )&(HTA-U4@3YFL '3! 0 4 >&PO>]TO M?ZCK;?1EO2KJ?WAVM]UNGG_[;;VXR]9IW2LW60&_W)35.MW"G]7MM_6FRM)E M?9=EV_7JVZ3?GWR[3O/B6;0K\G_=99?EKMC^P[/Q;/[LCW^H\S_^8?O'E^5B MM\Z*;906R^A5L,?OL5W^+UA]*XLMG7T;?1NXN6 M02]A156Z@I4LLR_1#]F#_]SEKJIPU:_S>@'/_4N65@B9Z&6Z;2SA_'R0G \' M+5.]SE=9%5W">[=EU9CG;5K=9M'%8I'!4_#,DI]OA>*/#YO&_(/^^3^UOO Q MJ_)RV;IV=;#_QW_[;YVG9\/A-7S9P!__29DW^.P_-6!U :\N^?55>NO_>I.N MZL;*U4F6ZS6@T=6V7/P:1U>$V]&'W;;> L+E16.LRQ*.O*@!T/"I+E?YDJ!^ MM85_< %U5-Y$'S9X&(">=72Z*]+=,H=GSN#N_'3U,CH].9,[%.5%].-=N:MA MJCJ.3IR_NZ[0V/_Q4_8Y*W99_=S_X6-5+G>+;53) W%49-O&V^5#N@)8J(>: M>UZMTNL2M_0Y:WWJQW(+Y]8^1@VPP4NAMOS6W+50,U@5$# MFBWN:+8E#+(J-X0;;2]"$'[9W0$%X M2=&IFBZ\.#/I LAY7NQP7V;^Z#H#TIOA$7W.:Z2_\*<:>IM^:>[BX\%/OL^V MT0JF][\_?P3AE5)0%KK0"%,6EY@*0ML$;[_^<5=OL M2]OC#1Q]D=;Y BYUO8P *'R/SQJT+%_MD"CL>4R(S0Z)"=Q\_6 $]&^Q6S'$ MVU8 +S 1:9^]_9&#B!A01I >[N YO &$&&%BUDVWW&'>"!;B<("!"&>8ZL?T M2XP_K79(G_RVB!8D M("P>\(O[M%K2?<,],(E&J, M\8=^[;^-@DW-J (TZY==O<7S:R$Y^X'1?7C[ MGU"$[ZON:G/2 V]M"UJ_2%=IL#?(A?(%[G71-EET^O.;5PU" M ((CJ@ U\-I%!H_"+$&V\*8 5KPMJP"V?ZRR39H;-D:S"WXY@&E!RLYG@'L M601>3XP2=D.,O&6)(+'=Y@BG\%C?E>7R/E^M@F+'NVQ[!^(F[I.O$*+#Y:1XF=UD,,O2$A?5^6R8)K>-6 4%H;VO7Z:;'+>\RM(ZB\KK57[+;&_OFU=9 MD>-UP(L"\P,E60.I2(N]+S+\+2CN?<-%5.O- \"7?5%,[2L!>?! '2 ]> R] M$6!!>L--'1<&I;62=)<70&1Q;'_B(^9M/U1AB=[[+.&#PHA8?\!!'[P0/O*. MHT:U,=^RK$3DEJ1ET" 6S8?17/.\WJ2+[!^> 6.KL^IS]NR/45 <1(DCJ^J_ M_N4_B-QM'P(:G3J"RT3M2G)2EAIX WI>MKP&4K?R/5>BVY8QY,;0@',_^ MN[' 0]<0XT799 O4SE8/OX^2T31.9I-XVA_3"\EH$@_[DW@VF&EE^ZLV[4[8 MN+U+$"@ CP!ID!F> _-8\#T,W//=&H7[;!F4PDAB/!-%J>OE97:3+_(648_E M(]ZYH-0W@E!-=G:04,;CUD$M[EVUS4)90CCN)OFVQ M3&JM!@G(:R93:& JZWR/!;%QU316[U/M&F\V$/W0-QAK#WVZ[#)$8H1];;KCD]GG".D[;Z-/X%^U7 !CD.P@ M,Q^%S%SN)S/,"#U%C11P4<>[7GX9)C,MX&P:*_C:GHHA JFMK4N-VE[8]QPL MO"(YXQ0>HT](,QEJWO&'Y8*F[MNE=[\!#*9UH0QBX6VT YRLHNNL #"!- &+ MK_5FOV:0)A&#!\^O4T1_7#JLFY5^D1 / 7RG!=D"_$'/M9UHU\ '/=>VXH9O MH67%C><.,W:ANOQZ5=X_TLB%K]_0Z[;%%L4+E!A:M#5MKZG1I@$J.%RJ'/37 M0ADKT68"GTF75V;"@X9^F0%R YO30G*Z1D'WWSIQ1DO]759:OCT@19[3J@!, MZ[!3P3:]F263:DLKZM)C.VP*8>785VRM%SJ$^$Z=:Z]R%[(9[SVI?8B3DP%B MS^E^W(&\FN(V 7,/,DF^2[?RR\&OO$(PP#78(2-$R],F:(MI)

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end XML 73 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 288 270 1 false 78 0 false 11 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.vrtx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (unaudited) Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (unaudited) Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (unaudited) Statements 4 false false R5.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterestUnaudited Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) Statements 6 false false R7.htm 1006000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 2101100 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies Basis of Presentation and Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - Product Revenues, Net Sheet http://www.vrtx.com/role/ProductRevenuesNet Product Revenues, Net Notes 9 false false R10.htm 2104100 - Disclosure - Collaborative Arrangements Sheet http://www.vrtx.com/role/CollaborativeArrangements Collaborative Arrangements Notes 10 false false R11.htm 2105100 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 11 false false R12.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2107100 - Disclosure - Marketable Securities Sheet http://www.vrtx.com/role/MarketableSecurities Marketable Securities Notes 13 false false R14.htm 2108100 - Disclosure - Accumulated Other Comprehensive (Loss) Income Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncome Accumulated Other Comprehensive (Loss) Income Notes 14 false false R15.htm 2110100 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 15 false false R16.htm 2112100 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 16 false false R17.htm 2113100 - Disclosure - Intangible Assets and Goodwill Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 17 false false R18.htm 2115100 - Disclosure - Long-term Obligations Sheet http://www.vrtx.com/role/LongTermObligations Long-term Obligations Notes 18 false false R19.htm 2116100 - Disclosure - Stock-based Compensation Expense Sheet http://www.vrtx.com/role/StockBasedCompensationExpense Stock-based Compensation Expense Notes 19 false false R20.htm 2118100 - Disclosure - Other Arrangements Sheet http://www.vrtx.com/role/OtherArrangements Other Arrangements Notes 20 false false R21.htm 2119100 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 2120100 - Disclosure - Restructuring Liabilities Sheet http://www.vrtx.com/role/RestructuringLiabilities Restructuring Liabilities Notes 22 false false R23.htm 2122100 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 23 false false R24.htm 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies 24 false false R25.htm 2302301 - Disclosure - Product Revenues, Net (Tables) Sheet http://www.vrtx.com/role/ProductRevenuesNetTables Product Revenues, Net (Tables) Tables http://www.vrtx.com/role/ProductRevenuesNet 25 false false R26.htm 2304301 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.vrtx.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.vrtx.com/role/CollaborativeArrangements 26 false false R27.htm 2305301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 27 false false R28.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 28 false false R29.htm 2307301 - Disclosure - Marketable Securities (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.vrtx.com/role/MarketableSecurities 29 false false R30.htm 2308301 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeTables Accumulated Other Comprehensive (Loss) Income (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncome 30 false false R31.htm 2310301 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 31 false false R32.htm 2312301 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 32 false false R33.htm 2316301 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseTables Stock-based Compensation Expense (Tables) Tables http://www.vrtx.com/role/StockBasedCompensationExpense 33 false false R34.htm 2320301 - Disclosure - Restructuring Liabilities (Tables) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesTables Restructuring Liabilities (Tables) Tables http://www.vrtx.com/role/RestructuringLiabilities 34 false false R35.htm 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies 35 false false R36.htm 2402402 - Disclosure - Product Revenues, Net (Details) Sheet http://www.vrtx.com/role/ProductRevenuesNetDetails Product Revenues, Net (Details) Details http://www.vrtx.com/role/ProductRevenuesNetTables 36 false false R37.htm 2404402 - Disclosure - Collaborative Arrangement - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementCysticFibrosisFoundationTherapeuticsIncorporatedDetails Collaborative Arrangement - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) Details 37 false false R38.htm 2404403 - Disclosure - Collaborative Arrangements - CRISPR Therapeutics AG (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCrisprTherapeuticsAgDetails Collaborative Arrangements - CRISPR Therapeutics AG (Details) Details 38 false false R39.htm 2404404 - Disclosure - Collaborative Arrangements - Janssen Pharmaceutica NV (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsJanssenPharmaceuticaNvDetails Collaborative Arrangements - Janssen Pharmaceutica NV (Details) Details 39 false false R40.htm 2404405 - Disclosure - Collaborative Arrangements - Parion Sciences, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsParionSciencesIncDetails Collaborative Arrangements - Parion Sciences, Inc. (Details) Details 40 false false R41.htm 2404406 - Disclosure - Collaborative Arrangements Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCollaborativeArrangementsBioaxoneBiosciencesIncDetails Collaborative Arrangements Collaborative Arrangements - BioAxone Biosciences, Inc. (Details) Details 41 false false R42.htm 2404407 - Disclosure - Collaborative Arrangements - Aggregate VIE Financial Information (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAggregateVieFinancialInformationDetails Collaborative Arrangements - Aggregate VIE Financial Information (Details) Details 42 false false R43.htm 2404408 - Disclosure - Collaborative Arrangements Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsCollaborativeArrangementsJanssenPharmaceuticalsIncDetails Collaborative Arrangements Collaborative Arrangements - Janssen Pharmaceuticals, Inc. (Details) Details 43 false false R44.htm 2405402 - Disclosure - Earnings Per Share (Details) Sheet http://www.vrtx.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.vrtx.com/role/EarningsPerShareTables 44 false false R45.htm 2406402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.vrtx.com/role/FairValueMeasurementsTables 45 false false R46.htm 2407402 - Disclosure - Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesDetails Marketable Securities (Details) Details http://www.vrtx.com/role/MarketableSecuritiesTables 46 false false R47.htm 2408402 - Disclosure - Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeAccumulatedOtherComprehensiveLossIncomeDetails Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeTables 47 false false R48.htm 2410402 - Disclosure - Hedging (Details) Sheet http://www.vrtx.com/role/HedgingDetails Hedging (Details) Details http://www.vrtx.com/role/HedgingTables 48 false false R49.htm 2412402 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 49 false false R50.htm 2413401 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) Details http://www.vrtx.com/role/IntangibleAssetsAndGoodwill 50 false false R51.htm 2415401 - Disclosure - Long-term Obligations - Fan Pier Leases (Details) Sheet http://www.vrtx.com/role/LongTermObligationsFanPierLeasesDetails Long-term Obligations - Fan Pier Leases (Details) Details 51 false false R52.htm 2415402 - Disclosure - Long-term Obligations - San Diego Lease (Details) Sheet http://www.vrtx.com/role/LongTermObligationsSanDiegoLeaseDetails Long-term Obligations - San Diego Lease (Details) Details 52 false false R53.htm 2415403 - Disclosure - Long-term Obligations - Term Loan (Details) Sheet http://www.vrtx.com/role/LongTermObligationsTermLoanDetails Long-term Obligations - Term Loan (Details) Details 53 false false R54.htm 2416402 - Disclosure - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseDetails Stock-based Compensation Expense (Details) Details http://www.vrtx.com/role/StockBasedCompensationExpenseTables 54 false false R55.htm 2416403 - Disclosure - Stock-based Compensation Expense (Details 2) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseDetails2 Stock-based Compensation Expense (Details 2) Details http://www.vrtx.com/role/StockBasedCompensationExpenseTables 55 false false R56.htm 2418401 - Disclosure - Other Arrangements (Details) Sheet http://www.vrtx.com/role/OtherArrangementsDetails Other Arrangements (Details) Details http://www.vrtx.com/role/OtherArrangements 56 false false R57.htm 2419401 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxes 57 false false R58.htm 2420402 - Disclosure - Restructuring Liabilities (Details) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesDetails Restructuring Liabilities (Details) Details http://www.vrtx.com/role/RestructuringLiabilitiesTables 58 false false R59.htm 2420403 - Disclosure - Restructuring Liabilities (Details 2) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesDetails2 Restructuring Liabilities (Details 2) Details http://www.vrtx.com/role/RestructuringLiabilitiesTables 59 false false R60.htm 2422401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsAndContingencies 60 false false All Reports Book All Reports vrtx-20160331.xml vrtx-20160331.xsd vrtx-20160331_cal.xml vrtx-20160331_def.xml vrtx-20160331_lab.xml vrtx-20160331_pre.xml true true ZIP 78 0000875320-16-000078-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-16-000078-xbrl.zip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

B?&Y-.>[GC+/?CRWVNY_J1U]3G&9*3!O)CKZ7D>?ZK*?-?[7#861=: MZL3YW,$96;3/)=HC'+S'LF@;(%IVG/-$MT+0N8)R?NXX"[9USGAK1)UE^S+P M].;,.6M"Z_+F[2!7%FQ+ ==6@LTER^9&X1WL,XNQV=:X9?S,8FQ4M+P9]J%<55TQC=E\>,=M=7U^_?<7WM\F \;^"5^<+/HN.99=@U_ M[OS2CS=]TG <=#Y_.K.2;TK/LVMEWP]C36=[N1"86N0U\@PX[A3R'CDE X,1W#_TKO7 M/W[J#)+-UUY^_T5W4Y;II_ZXVQG\H^B489I$;O-QA)U!$5DI,&=!&(X#11PB MC] (*_SZQXO[^+KN2_>4^%'WYNKAAK>5QX[PVW@+4B0$.\XI]XA*3KBQU! K MM/.27<$J^Y=M@S;C$6G%'@1WIJ M&1D/7UDD8DK?]B)!1D7O5!0V!$X#L91K%!@C1A(&?'D]%RY7?FF1C+3'9HNO M"Y"\C$0AKN'K6%B.HN581,N8P1*T$:.+W^:_FUY]_[E017T'OY:=P>6P5WS[ MS^)V&\9+'C1RA&$6N0U*4R9Y^BXGVF#'YR'1RB\MD#&ZNAH-J\U#T\X&;VXF M"5?4Y1X9;K=8I ":=%[57UCEKRYC\[3\Z[X7*U9'DY^ M[5QMHT[!."6554:BR ,7.B 6I4*(@38K@5[_^/?P[D/X[U=O_VK>_6)<^/W# MI3,_OW]U^:M[]?VK7\PL8?-?3Y3UAU\!R?[@0?&_5@NI?QVEA=>=@;D:W0PG M\P0NIME39]:='E[:O?O'/\WOCT74Q_=>5J=])F5_UQ__,3>W%4=ET?\\#-^Z M7ZIV+:,R;6F;8N2U;QK_U.D/?QZ-Q_;VKT7O,PC_73&H%HZ/O_2OYT]O[8R_ MQ,'HS[O[%EY^]ZLOQD!'?7_&_>]%SXSO;GTDXBYOF='Y"SJK4#@$ D[0(^PY M!D\4;636@P$8:WQ0,RI?168BL9!@J'_Y?H-HCB2]\/N[++T'Z7GA X1/*S5 M"VHD1)0@+29B!' &84=QKZ77 M,2)!B%\4GX3P*$XBO2P;)(+%C D>% 0VHPRES =+L-4 6ABM.4:DB>)'$\YL MP2K'M6T\H\*:!&6C9#P@9R0F'GZD 'B5Y;$F/J7H\>+:9NGEN#8K/6$0TEP& M@-V$.XTU!#5,HUEA3AE]1O'EN#8K/LQ\1,B8B)SB!L3'A/8L>NXB MA#;J:G%-4'T:UYEE8SGU04O,E2>< W;T/@8CG0HX4NG#HFQ2T49N+9R'KA_= M;OII_+9SV_DX*.[*2DLQQTI*@2:L -YJ&AP7F!L!% N$+5'68E-+3233;(IM MUU.Q)YT/W/][I^RGFR_A'LCM)U7NVB] Z&[0&8_[G_K3W<%O/DVSVCG1+7WX M]FT)#"AO;3$LX.D^_+E!B@8C(Q@BT4G/K<<&,G"L- -&":-Y#3D**8[$&;"N ME50R( T\MA*62AY=-!!\(:>D7@2#M*NE)Y(3@H]'9Z,D2*.5PD4D#3'<@;,D M2CK*D(N!1(MK(0YSH?=DS;NB6X#%PDV_%I.]3!$ 5" LB*B%XC0(PP)C2C%. M*\)KZH9E-!>R4#PEAZB['!,)H:T>!N4N5J M/Z++FZ+W,RA&FD@ 5=J+S2:ZX$G$-'!(XCD'0W;@HTF@1"%C6#DE^Y/;*+-Q$+"4,LZ$")Q1X.QHY,AH%D$-P7B"'8A[M#C>NRT?=_>)/SK9CJ)<3T: M)E0[)_>93\)K[P%OU#P$ M9("SAH8HJ. !NYK+AA'4\$)K>?G[L"R :_\N>I<5T$Z/W_-W$YA@43BJ&"6& M"O-^X(!"'B,@]N*3T#Z0P M]@"*7*S/C9-:B:R=;-O'%4FE70"D+9B 2,<@!W-8(<(C849#5EIS102I6E[] M;.Q:EX,;ZYT3'LE /;=::4VM\4P)B9G4P=9&QN"6)HVL2;Y($JPAJW*TDVW[.",*#HAZC(,.CDMEE/;>0HHFH@S"NUII_((NJ8+NS:Y>KS^= MU7K;Z8.@7>>Z/^D,9I9T[E@Z9Q"_8S0.<<&E%VF.QC.,"0=@'%C-LT)R44VW MS0UG(TU/'<$Z#ZJ-YR 2S9%5'"-E J$<>V:-X9RR&DP51! MV)-&<*\IXP^C M%8]6"VL_+IYO]JX O1SW)\7[HOS:[Q;3%=/OBN[H\[!ZR]\[@YLEZUKYW;K6 M54A=44ZL,M9"> 0@JS!CX/DT#I(;3FJ%7*Z(6 !A1QY2$]BWJY=83MD&YT \ MH<9C;;0('($Z,B(HCH").=%*U4J$611;B.+7T3"]J!Q53:SO2_J;RFA:48^$ MB:",/'BV'<2-Y[0G#60 MF#GM.,924RFDC!K8K05EM4R"BUJ!-8OB,&Z<$L8P@;@:M"*:Z: \N'$OE!1( MN7I.MS@9DN6PER\GV$A$"/).(2[!EP>,D:78$V:MBK4%YL]L 8-!.O2BZ"T_ M5_CN?(N=@;5@WO*4+%BI.&* X) V3%D;O'9.U8IT7%*UD%EL1=CAAG+PDW-6 M9\%6.ZE"Y,)SZX*EG&'AJ3"@!S+45D9 $KRH'TUDS>YGQ*RLJ; H-'?.2R# M&?!7J(H@+)C(E:Z!(:SOMZZ=GD$;@ F5+NV!5A91P3D(/@@&T$0K+8@36-;, M@#-)GG4H)S,#!?A6"*JL8X9'(HW@V!(4F,(6(U&OG#'&5/-9]L+I>FR 8+4ZV[ MT4O%YO2"F\G]\K%..81QCN_[B2Q;J;_L8,RG?<7>+G_!EL=OKW0[R%=KKA6+ ME"NF%=?:(:\4=^" YO9IT06#@7=A%X% (C(M-4,7&2Z(].&VZW#RP MSA(YAGDXCP%A8V^<"UQC2#( 5C,O,/?-IW=%9Q#& M*3B^+4?713FYK4]+X+EN>_?WIT#Y.,'CB^L2!E]]W1?C;MF_GA)R_]I:.[>? M4XNM93-V?':J4U-G/;,<_ O +6J=PTXX24,JO"$TR[FJ^1:NK31?,",1*#."03YIZT/<'&2[5#CNYM"\\&10TK[?6?H M^\7G427N34&=&DM9#-1K';@'K*D\3Q$%@?,*%Q,QKM-'YJJ M0NF!C-2#ABC-N9 A*DU%C%=*[*3!$C40II3?7<;2M9- PJAO>;!"4,D]\@H M)9A&F*196AMQ+1\E3$F-Q%:4[+5;1GMBTIXHIR GL(&F=0A"$V2CTRS$^J8D MAB1>7&\X^_D=Z%K'J!@#MHPX@C0 $,CCG$7*X$@0!XLCM05;0!=1E.]"5^ST MRZI$X_OC[F"4FI6M7T3T\("]??CSK^ G4E9V^W/*R>9WP-[?U1G7OG+M%]:U2NK+/YU\[ _NG;OS)UI4Q6,[[%Q\4HY6P#:CFJCM14F[:31 MDD3-.&,(#+2^8S7MHEDFYB5<:P9KR7.Q-@4R9 351-*8RF^.V8JUTF A#*K9 M--RX& 6:S5KZ7*RU!FO!B7 LE:0X"2[@BK5&Q1!D+2T_/4N/.WY%+"9.^6 B M5B0HQ)"KQH^-YHK75$L(3M5QK79V(5.;'2)EH$526THBQ'J *@+PO99(!6H) MJG?'@-B"V\7:YW.(B C/08MA>P5, X**AHEL:8V*ER;#"-2X\4)B6:S]MD< M(J1-CGJ(.-803JTVWEO% L48\E"-:GL"3L_2XX[?>8BO:49'!,&=IY!^\;04 M&4OL)"2/]65TFB[.5VS%AZ^=_B#MS(VC\GUG,).R[X6RJQUD/LC408*':@6% MXJECJ[=82ER;9:%$"KU@$9LH>B+Y:Q*Z'YT8RK;:2 MO]T,"S;-7]UH )\=3><"3%FF7C25QME;\[DLJK\?L]VWG1)>_[[;!ZTMQI?# M[B9S)()8(KQ+:2Y!U#)JK?5ILH4)4U_52=):SWGHM\M8-_-H B8$(YI[P^RH M7=6,YW(XK2>]^;3BD?N-X+=X8S6["?O?I61$8N09!9<0P4>:%*H%Q'80!78U M,6#"MY#!P7G9)/'M81RV/S+?1L,"_CM>:R&S%4!!*;@(;UA$G'M*TX0"I8X2 MKKE#MCZ_C+8QC_,4C6B>95D7'61@VHF8FF^PM*Q,1 R)F*>$BEK90%<-Y%ZV M_$YE6L!K&JR&0.L$QUQ8'*AP)'@+X C;>E3.IG4D2# K%0O!AP7LI7&0H"N* M'>28C#"#I*+.UI(?C=HDEH?GEQ=(3J7Z2$L)\-D%Z7'J=F,)U%8[MJ9& 10Y:1&OYQ2!05"8@D9BG,*96NQBPLGZ"3Q^-6RC=/ MI5_&4^NQ]B'PP%4P.J3& C8BRB#U7-(Z5>WO7!O'L9T]G@\Q:0SW$I+:5)F, M!A)S$KWVRYH\8W4":YQI967*/ES^/)UCOWMI-_U>N+$IDYGDD+"':0C<8F-;I-([L&$#6Q]O/'R[J2U!#*G M)173_==-']+4GT:CWI_]05J*-TO >'QS5>T ?DX^.ZJ"=YC1F)9 ,FL<)I": M8,LCL;&>L&/!%A>,'XDKLXR_6W9>S;F_^3CH?YZVO]VK]&0-CJD3"@KP'RZ% M?#,UC6+H'2Z+)8>E..T'VFE.7!$432(B 2) 1, 1#N196(^>)J@D:Y@22U@:>^G#@U#N7*^4]-1Q25U1OAT@XX7IA"%M0 M=8!AK&M$QBEBT51[ZH \IC0E.EIK$09P(E0MK@I1+19YGF&L:6,D'8L61"*M M2S5O*[EQQ@3#91I-S9!32Y&%_9:G&L8ZLX"$0P3(M0-A *.)T4Q3C2R,PT?C M=6T8 J7MI<<8QCFN6YE9[G_?%"2=ES;?[7UT=564W7[:G'5=E)MJPAJ"A-). M42L\T0Q;G*;.J3/$I,Z.:V;*MF9[EM5J6977"<,5OO@X>9SKV=2EBT=*"99! M&P@X:5>;J&3FK3:1TUJU,YN$14P""D1)I*CC MB.C41QN$95P,3O%:E,5:NPE,XFT7WK$%/Z'00M!32:R6\"A@Y6GE(9#@UH9:396$U-MA%8GC4 M448CM C.RH!L)!<9J]JJ(!.E1A8Q '-'A^HS8\Y?96K;I[XB@ENC(L8(,,6 N@S%4T70DLS%, M,E5?IY-E]HQ^C@/\H& N&4,IX.BO8$&40 M=QKA2 DW@8;:JMGS$583DLC][(Q9&[01+!IE>+3!AH (H> B U>LOL$GR^P9 M#4Q2#M9DM7.(<8.4UJG#"$0SIU,3GUI :YZP&FX-:>\4M0S"#C;<>6TXU\11 MK25DGUS6%@TU-NHT5H-).E25I"T# C@'WB>"T_&(*RHAQZSMCCHN))MV[+X< M=LNT5-47T__NW'_;4S!,B:T'B^3*$B4$LI$!@I$ .7EM4I!JL=#_9Q?R#C>L M#?V4#>,8&VG27GZ>&HJS&(ES6#**K*D?R7V!,>*UA?1OW?QCV!__Q>E+>%*]? M?;\W&=7JT1A+*S)G1^&UA#VJ'&!1\-]="HJE=9W:O#;0F!^[&%4U\;F9O)E5-:V M$&V6 B@G#4X(0VQJW,12I^EH+*B)KAH6+FDL.CW5;-[&5M.S-]EKN1XB0\*" M5[:25?T=53IL0&"O(Z>.B^.2?3D>W^S,:0:I2&"0DF"7>G V&5664UUP"X2 MLJR%*V&"(J&P6D/RE):]R%VOUQ 5,=.!$P1A44?C@_20^%I*1#"6+2570N"1 MB#^-W#< CR>=80_\W(XL!JSDTKRN,X%S9#EX$6D0Y/',"8+QLI;>V[!XAJ#] M"5_+;)F:'( #M-C3M($8%,,+K0C1CEJ'R)[,WDQXY6%VVTS!(Q'.268ALG$. MH)_B%.L09->6*E[O4\^(7&5UU>=W(VWMABWAD!-8&*?M;D%7(M!2F^D]@YS'F1(G4^#PH#6K,>6+SDQ7"M)R2*M MJ^C9F^P-<$P)R-"==(*!CV7>&T5Y6HZ&(XXLZ!K*O$BS#.S 5)O)I.Q_O)FD M_8T?1LN/2MI9(-((8XT46@<"@"E8'[T+D-0&B(ZH0]\@ M5.P"4ER@","4$ZZ,HS%M)W(@4>WK4T&_/' M[T>#WLYZ2HSR8(W18P5>2W%M-$8&0U[D*(B]YK\UD%VC<(: G6C;H(K: #W, M$6D UZ8^[]8PB#?2.)*V.]?8Q[1<7*^TGKA4$[D[UVB\>]$,LER/";9 )8^> M:I1V!Q.KDVPCJ6\SQX@MKH)8H&$W^C9Q+R04 CY(<+!AQ(TF&C-.(33K9?M' M&28,+P:CU?2ELO3E,)U D732=L;]\7OPS9W>F^%]Z[9WG4E1;V_)?J-_NQG< M/A1@?QX-/X,[ODHOK%5GWQ?#_JC\>=09CA=*NN]27XWY2FY_V+^ZN5JX;Y:8 MN=OAN[W1L H%'SO#/]Y\^@0QH9=N^_G2OGE7KP,OU!!D2)4;H25/7?NMCM6J M&,Z%306H630[O*E>E8HV,_G6M@Q/3*9X3S:O'C<"@$>\C03\ M&9>0='@DK 6,0X(CQM4Y MY9#\<$>8!BB,;#JV,D!>ZO%RUHB]6+,XR-6LFM;I^]VWG=OJGV5_V.U?=P9+ M>NZR-]T)OCB"TD#P"A[#)P1$,:2]9A:E>K4TR%G!:F4%R=?;RZHQK>;"[\/. M50+%_RYZ:7*I?HC5X@+%_8<^W[>-&,X@';24,"6"^))A/'',LW./!QJS"U@QIW1(95H#H5<*Q1C7#C'XT]766+/UPC[HF _M M'.<&#E@Q&(RQ="FM@^R7<.4!IAEG33HPI)8WT*<-?-I1^EWQM1C>%'LUE@J( M19X.1I,>D@:GM2-*,2N5PE%S4E]%#,FK6"!Y&17[T+DNBV#IT Q.!'*&2O4J@IY,? UZ/V?_ M9V45H^F,@DAM.E_=1&%U.D5-I'W0]?W.%B'^E P[ M<:-(RBQ3FFF1CNX AP: 7 >+%))I9E[5&Y]CM+#T93=.S![(>#THJA+LL&>F M0;SZ?><*"R8L+<<)6"O+3:0J8$XL\A!6!+:T5HK$8">+0]A,UM.'L:$0P[$ M)TTC5P*P/00<+HC25GDFF0VB[H($PXOQ>]=AE/VO4[5*+3Q_'4W>?/H$?[P= M#?K=VS HNM,W]6ZZ]1%M"D%""\AF),-:"@ZCL0#NK.22&N5]1+5557IA^=N. MQ!UT7.NG?P$X.0IZ1@)7$EL2,04T@ D'*Q(U.$ 5742#AQK8CE5P1!T@;1>5 M8PH,QBK!6/2 #1$*S-6;"W IUE(^WHVT=4P%?.4!5TDO6%J=+;2V8 :&"0\^ M> #)85V:7&" :J)5U02F\JG-?RZAI.K M27KZ$-9Q',S01<>U,A@!X &_*0BQ3"B7#L3D]9.:5G/\<$.X;^J?S,%\[O0A MS:NB'P3[A6+,1A%%&9TP04LJ':B2-E53RZ10TF G:R)B2BPZTR?2>^3!KS6G M2&5@J:[&0)3,0D(8$KJU:04;9NM.3SOEL-#"#V'4@_.U9"@E*U$*I$+2U9I MK#;"&1+VH'$=WY$!QAOJA-"4.P;!&O(#A2'P<2JLK\U!K3&O78A<5V5\R&0? MGWPL9K[KC_^8W[PR*HO^YV'XUJU.O8%__MDI>ZOWN4JCYU[S9O*E*.^H MFJ%S]7N:NG=ZS5)'CSP@"*TZBE6K?9^H6+^LAVF'()CP2DCH9%$H-EJ2$O9%B"&N)K=9"#VN&V4PLG ME\\C8><9:!FVVC"NG+%:!A)\\)4U:A,86.BZOC ;!)EEWMB(RZ5+._=8L"!R MBX-4),GT/@._N:"PD<"#CV_]<6,"$\L0"U%Q#CDJ2$I0S; R#B&WR[S1 M$P?XH2BOI@?GED#8QN.Y#V=BR]XT_JG3'_X\&H_M[5^+WF?0^7?%8'J.VI?^ M]7RKD\[X2QR,_KR[;_-"[\ZWQX7>LTO0(I4B8(4==@*I:+S :>KC-3UQT4FO4\VP MMH=7DP5CW$32$^G?L%; "JJ0QX@$S'FD2(&S<%X$>!19Y&OUKJJ@O"_YH5,. MX:;Q?8^(M >ANPW+R6R%+E(,RN"LTHI+RFP43#*MG8"'U6*WDL<.%A?H.T4? M"5]*RQ[$UOD[2RPD.: )Z0@\1SD)R$0G)*!@X01!M6.WYXC%\@G$^O[@9K+8 M1&$S;R4*CC(#^;@@7$H-RJ CM]8J:["Q*YN<;.#M'35[$;R>OU$'XXBU$O * M=\@HC3@FD@B,JY.G]^3O,H(_?4J*_NG>=:8] 6^&R[OU[.Q%K$!".YS.0/5< M2V\M<9(8"W$>-)K42E,7A"^L#-Z%O,,-:X-S8: V@5"&0?&Y,1P<"IBH9='& M&$W]!$BRV.5I[U%=70]&MT7QOBB_]KO%O![Q M=+=#M1'M[E36].N274_;R%5%!EDN38VN/%> %$ ]@T00&W1J1%$K:0P*03C$_-K"';5P5&A36/7KJ-HW"\\G M9#7^,(+7S5Y/GP&T_8]BLN(<]=HZU^I%M8T2#\2D+<]OKM.K-^1XB"9$)26A M2G#! CA+#>%QWX6O;#CJ;.,V\ MH5(3'"VA/"!A'*!P%D-,>Z1M_0Q4BMDY:?74>T$F=_=3NF]E%X;]G+=)=@?=H;IN*R9:9&G'-_3NFE^CQSPF7D9TH;7:"D2Z>2>M%>,\2C7 M-6#?DG=-9/>SS;!;1",ESA.3H!A -*)-Q6[-(<7CM;FAQ;FO%O/\V2:W">,J M=9.NN4,]Q8HTAU^F*,3E#$UIYYT6)V/YO+55&B&+#$45MN=#!< M:,6Y"H)JH^K+#6I[ UK,]&?SN8:Q(*7SD@.O T!P"I'/(44$YQC;=:L'&\#N M(\&;J^[[%0F_U8_!I9G_QX\._KMB5_WQK/Y>66-J,.0FD^9R#=\41 M@DT47(MJ-7^JJ1!G:WUPME2#5>+,ZM!L3.RI-589D]J;@![ WY 7)W50PCIG M:NJP2^#-.M%.R*XC-M[&$%QTA$E)=)SJ!/P8D3^P=198($2K/!&.>613QQ@#27I2%L*TMFI];I[U MY.1Z\FP@01+('(@-VH*SD#X5T:9Z8H-U6M6[B.V2=F9M.3?X0)2A%AF.K,32 M>AFG\(%2;24Q:V=9LI[LK2='GAZ*2BLF@[<*,D5FA9SB"AR#PLK6^QDUTP7, MUEX:APQ;AQ^DU2$HXE-_3PX80B/(&$4,)/*8VNLVWM+/4AV>KY9@@]0NIA:\ MD5MATW'%,CJ<5MUI$6L+J7-XUQ08WCP!/[#$(IRR8D"V9Y?5 <^$SV#=)!;CVB: MMDV'^0BID+*""BF;#_3/7C6>#0H0'IVWX#^B)5S#_VD7**7<8D,P#;5TX8)* MT<1"Y-EKR+,!@]2(P=NH?20B'2AJ/7-8((*8%-KC# Q:TA,0T #GSAIMN.34 M$>T1<2$B:J21R-?V]&5+?X$M!"6-E%JJC9.< V10R&HM($64@BE7WS*>M>,9 MM./YP(**1!D#*:*)'+F@(L8,>VJ\3(2@@(QU /LL,S3*^OQ0 M-O<&S"8^WQH%R5#4@!$ 8*:C.)6C!D<%N:7#6-0/G)(J3ESZ105JTDTC#C"*$<;3U/9=93/SJ$UZ'=UJRJ>SOY&VI'@N(S4 M@(-@@HB0S@ -J'Z^,MU^[NOX3-ICP]7.:L1%VD#K(.PZS8/SFG,M(C."84TM MJN\JVJ7NUT@6[:-'R*;FYJD+D4SG3$?+O!?""*PY#:*^16V77&<3DWX:C7I_ M]@<['MPG@$C"$)61,\Z$-(8@BA!DWLYPK^LKO1!=Z(9W_]VM:7E@2 M8"65"=(*3GC:E>\-MSHB2C6*]0;[FFK\A/&O:R#/G%(D$JN0D)P2JKRFE 5& MHB>.'5X633NTG6BM/0O!0USBX&J49F!-VF($$9W7IQ&?((L3G\$.;A.$:--Q MWY0#:M&2*PX2-:D[LM*U?1H8,:$VC@R^.[HJ4O/W6(ZN4E_U_O &@--=U^_1 M<&PFD[+_\6:2A/-AE#Q::KX.0X6[ID):U3JW48H!\"Y:I AU'ADCP"ZTIDA8 M$A&! %UKY7!!U+Q?/02GCL]YT3S.*Z2)MQ'IX A/CE):;5U,JAL0L_5BO:+Z MF3EOBT\01:?W?>A\@YC='XY*>,T]*R"+F7]+:E8] 4Y,OHS@2NKZ5UG^[EVE M/2%!!44Q^*^HH@:4*%/#)V&8=TN8A5.O.KXCOPXVOL:P=4,':HRIX]%QY'D MT"D-\3)B[3V!7$;6#WF] -> =[7_(W(57G>70$_M;O=VY3)0[)%T@-(0MUY9 MR%((Y&F:0\ T]=.^(9 N&7Z-CB>0VB@GA;VUZ6 /Z;2D+@".)2*%!XJG2Y'J M4PSL:.S9H,O!.A*=(>G -1Z\!?*PLD8",D ^U \4X$PM\P^'I+51HJ0R':/- M'>-4<1V$]DAXGSJV61&#J/$'Q$R.S9\CX4,^6\L2:73">L=@Y)9H3+E+IR\* M:RV1-1='$^S==]C%^&VGO]41)//135/F*;(1,\^-)$I)YU-'K;32P^):C42L MH'#Z^9THVV!4!FN$B36I7,.#4B8=BN((XTXPI;FJ&97".Y!6%IUQX8OI?R^' MIELU%(4[;Y.^[\Q&II"C"I).IE$ZI%R#H%DD7D&ZS0.KK82[()#[B$5ZUQ/U MQ!%L8#?BAD@F-0Q"I 4<&L: A7-&DRAQJ"T4OZ +?=T/1/^[HEOTO^XE!&) M<9F1%FO"4_F8"RPDY6F/6SI0O*XQ8MLA/%+U]%%L.B.*6"%3)TLM(BB/4PX; M;XQ"$C$?ZKLM ,'7G.731U'>%+V9"MG]','#T5,SUW:6DR 8<6P ["C+$06[ M849[!4 [0-"LC_""0+Y2,^XGT7S<\6_R; P27Z4X1L%S+&'\"HM(4[L.AP.O MU1-3"85L(>.#C=\7GXJR+'KOBJ_%<+'PNH6 P0-*;9GP &@Y!>%RB2CC$C. ML*K>$P\>H)LL<8&F)PY@@X2$)#SZ5$/U%KP@L0#L-$=!,:<-4K7#6RY @C5$ M]Y0!I-1C.(%490_S8L$;Q[#R 9"R94;I*"S0KF4D%"13/P>*;J)]AIPGT+V! MZ=0 +E:8^&065C-CH_(6(T*]TWKQ.+37/S(I-SF%K>FN#.5>0@\U^9U9KU$4 MP:9.D)#+4>VT\I$*4M4YC:GOL%Y+_'*:#C..#:+@/)WHPI5RPD-$K3 [:(\! M=*BQ134P0% =%QY@-'<3U?=/W:'@>[\VG:C>/>T6U!E*/"22$?3>*1HDA%A. M ;$A8>H-!SG9Z)RV(?080]TD1B>CIQ1TT%*>NA-C8BR"[,H(@'>^IHZ2DDV> MX.DC?3QY)4V$[7X$**?>0+YBN5<<7(5)$Y5(44_J17I:_]RZ*.:4,]F(ZSDA,) MHR$1 J04#T' M@M!9*TGN/;1IB66:MM[956W9T#8Q*&#(YQ.H9FD_IP?LXAW%3C.;3FRMYQ/^R/OQ2]-%,Y!I:FDQS'1?EU$=]M M6I& "61P+!J%'8B622NU9]BI* PC)-:B+NC$8GED(T5/'L"Z:7P(,=ZDD^!! M]) )2)5ZI" &GL):'6F],08D08O!=+\1K.IOM#H!D$@$@**IR0\'HI6D+BK! M@K9IMKI>!Y&DY@ >O[T]3>O8)[$)$#$B9%:"J\ -91AXR" U"<36^Q>+:BW6 M3C2]Z_SY2P?4N0]??X*F:L&8HZFK+N+P/P7^R!@#<8!JFDX=J9_1K5=HZDJ" MGDK^.D8'P:P%HT+"0=!*)TIC"6@)E-5C)T0-8&A-#T+^?XW*/Q(\''6+\9,< M!;(J!3 CB ='D9PL1\$ M#:D94EX0R L]J]>"J52UF;V=1K"R%K6)UXXH'J-WR &O+>%*QW1N%!<4+-+5 MH0)FB$&,GJ-U15%I+4WKN%<=,9&J%<)K<%[> ,02T0AP'9")VAKW,)58(K4C M38##JC,(OXP&O:(<3V=]=V->8![R8;!]PC7'@%:2=DK OIAH#'&M%GP9C&QA M!AX@@B#U*C.#U!^)0U!_MTIU-VXK MR-@I42H=1)+J$BHUO04M94%%&DT-FG.4:O^KR+TC85<"UP8X0@(7FNB$72/@ M,&>]AFS;*1,)I_7^FAS0 ]Z)P&'QYI.#I+L_@2]6Y9-?.M_Z5S=7=E26HS_[ MP\^NELZ<_C6?E M[*^7.D1B3 T!CB"&&YD0(PC2)<3$*\O[^!JD37KASC+C5\ZY1]%M=JJDM[J M8-"F#84/-S_FS+5#E-WHZJHHT_DY;SO71;GIQ#YP(P1R3#!0)\%[&*ZJOJ:( MQH#@IS55BV4IR4417(8CV/?U&%6!94V'6#+L.:$289]U8P40Y U#JO//5(A/,' 4IU8H96F-"LT!.[L*B M=9$&SYT(EMJ(F($D/+DP);DQ;EW#D48*Z-A;K0_ONZ04(D">I@F+E- :5MU M(FV:H%!2K3N=(DO@H#Z+>2J41LY)'$U:?27!6&4EC9@)#TU!-(Y;E'E69# SHOZ M?,R)45'#W0&),NVM(!@ 1<1#UA'>. MI]V@R801()%0;W!VK)2I96>K']XY, )9$O#?1/"PE2<8R-)];P",( *,@I)D@;#V"G M/GE,,6+-ET832@N[A1!'J8M-6T@#16](4,S Q4E-\_"+T"C$TU,$C*GF42E,5#+AU;A'\Q9@QFJ4S MV9/0KZE5/1<+6G0>F)$WTY7&M-J7@,! M#C/&-4?&@?UR9#VC#MGZ42RGKN@TVO\98T7:G>F9C2H*F?H6)>0LB"B CFM:L24AZ+ D M<&;U,LTAV;(NC7AD(%IB810E"2Y@4DZL$HA M 'IB9NM], #O8*P/2URSI.41M9:30(WE3@&D4#C-# 04C"=RB?KNQ)!?BTG: M9/NV''WM]XJ>O?U]7/0NA[$_[ R[X#I,=]+_NE_/&B^%\"@MGX $3D1A#=7I M9&QP#1$95M,SCM)\\RSAVQ-WJ"%MZO@4*+<4S 84E$LNC+:,@Y<+J>T3K?>0 M9Q*1XXUHZL>?)B3ME8!109CC+I5NM:=!$1IB9)!"N%H204!$"_MTMZ?N4&/: MU XJIA& OZ#@V")!5C.AD=(A, &NI2:E"XS(XGZH@P[JH9W0$P1%(61Q0XQ) M*R>I#XK!>#0S 4O+E*LW""+POX5]BMN3=ZA!;=K('JEV ;E(7%H$:B$)(%8[ M(;B/!+O:BO8+P+P+[0/V'M-C$].=96$!_Z4]/& XA*O41,-YQJT%9\ %R&-9 M?UN!:K)XI& 'TC9PE#%-HS41D*SFBCAE-0'G1+S'*BI1[Q#-L*!X#\K6=2M> M'EVW8"Q6. :I4E_ P)E@RJ?F&-9X0:VV]0:&%[IFM;M1>)3A-0H_4$.LBM1I M[B*OU%"QJBH>_IK%T@[ZK$"P&M)CV#G,DI1+"0E@VFEBIA:XMEN!\ M(1MNQOB:I3+28.^U-RI!-TR4\1ZE=N=,1B[J3?H/S-/1I-H<6^WD>VR_".]\ M/(ADMPPP[22'< E %'(=8R*A*G7H!,>MO(:<9UD#H?E=A=O0]/0QK-U\S-+2 M.">(AA3;:^*YLM48 !>DILEKJHP[$W^3M./-IX<0^K[XO'5SH/F]KI(2$YP' M\_2!AX"UM5(2^,U*;@2;!2WCZ4<@@9FA?!4EL^0^7'Q*0&>*IH;BP$W&Y?0P M+>1,VKN?\JE:JG*!)83T^1X*2^C8F&XE2>;S>MD0O-&-=2L-^ M1#;*K0J0FO9,*,#P !:#EEI;S RB-,T@U* 9@,FC\&6=F_%.Q: =2=OF.//" MIGD_HP7"+O5=K6494BQXR@,2V2CA@;>5VD4+4".D%7_*\P@(BCE-663U](M1 MM@=?W.CJNBR^%,-Q=:KAO85.SV0 USTWW&EWDP^=;[MW$_:XZG:C2,001X)6 M2@;B$4W-U M,X!;>_#FGSK]X?VI%KX8]S\/TX4WY6\WG4'_TVW556'F(+*-BWJHH%K8X W7 MJ4&,Q9Q)8@@)"$*AKZV^ AXO49KS8_/OP[( AOZ[F&GL=\_Z34L,G<+6<1*( M27!? 8 S %;!,U$4G:FWNI'B[#GZH01<-ZB^8GK_Z5Q6FX#/T*^&.N3(A=BH3[61$9N:I:,M:312YO6"2/C=!".4[#&0"BGM@[R M.*5M&723W)X#0!H8,0H#4C60; F)L-=5HU K:+U7/55$O@0^/\'O&<"'3.(@ MO(F<,F'AGXR1Z!BW =?WA"S.^9\C1_?Q>^F\A A.#Q XX8I&); 7FC$34UA1 M]0(CEFP)P#TN)Q<./ZW&"<2G<0Z7CWI_)&@1%XQBEP[_((1J'IFV7 +NCQJ@ MX9/BP/[C> Y.;9JJT!X2N'2XM@P\0IZ$T@$V41GX$_!Q??YE)\TY/JOV5A%( M0J.V1B.M8SJB1P4FTOR\X)&DQOWU@9/M,=>A1]&D.)AZ RK[_]E[T^:VCB1= M^*\P=.^=MSO"4M>6M=AW.J+6'O78EEJR>\*?)B#R4,(,"' 4#;OKW\S#[@ M.""Q$ !ZO1BDR!P4)F5RY-969G4X= R2#9ZRT2 G).UF:5F:VS)CI1O3_!K MV:F &#VHC-&G4A)_X1R$T\EX&D'^%#Q_.#QZZ%N7W3-T#B$4F;6O.\, MES.@>(Q:I+4AAXSB4=#.* R!C174H6_1R?FSR,82IYHL@*1IXS3HN\XT)DA" M V4^@H.8!=6&<XRP84 MBP'C2B\SYS(#JEESBL21*M\F_H79I%C*UJ4LP7D11):U(#$:N=ZLNEP/[3\S M;U9R,,I*2]/HDH (-%T,=#0B)$ MUC-=4:7[>WQ]<+9QK$/32@3:AD3C:]!?>FN,#$KPR$-&3+HI9-^.2LH1KNB3 A:*$2HN>1FV?:*@9BTKXE+"U*,KZKD JEAEP7$! MDB?T3*HYE&=%-[UU9KWMGU7G75Q+]2-^">*1<:?_N?NI5RV:-K>L4"*EH+0S MP=J"&-@+%QE:VIB\-$&SYE0]82>'RO.$+UG45H@XJ+/X["38*(0V5(\63.#% M.Z.D%C2MJS0[Z#\7XQZKM%!)FR21$'!H$U()GB'.$'1]-VL9&E?.GI.(@]I] M58JD82LY0P;-F2W1!^8LS61'=W00NS_1&O'W7W_6__EU./[C/^.@U^M\HNN> M^%D_1$3Z>7)'+US[S\.J_KEF5OUN!&C(Q(^GW:I_6HW0EBU3B&P"1LR%%>[ M9&XUCX5+SPIP*9M%WP*C[FVPY*D32IC6)KB4#%7?<7!!9H?.L;B$2J4%FUHY 8#5$13"!Z!\QARQ+@=;8M7",15XXB\OO6R&8?H3YW1EYG9 MF>L?O489A4?H@A*']MAX&MH5T)9 ] #-3NNO]2+4NV@I&ZYWZ0%HL;EH+9@K M=/3G018(*N><5('F40VU1=Q\O8/9.N5-F0PT;M)&0!\3 0,,*U LJ&E**$7+ MYMB!UR@Y"[(8#R[H*4M?QF^O0V*"9J(CJZ5 G(N845M?2I(J-LIH4,3YABM_ MW[FNP4@9#.O!>=59G::^P01/OV1*E2M!2IO!HI\OTCHZWHO.\EP*7Y U,'/3 M_=99O MPFR75KW3?64F:L2!3)?(0*)7DVB/:*8G>&9*,PFCY(.6:5^TKJFGZ.7 UIV9! 4.,4CR99M6D MU&ZU#* MF86KG5_)9JM=EOH7F<[GD^0^02K&YE2LL44BWN:R.8Y:S<_J7&>UOPS\Z?]< M=8>5_]KI]NIACH/AQ\[#S9-6P8)21ZK^C!$X>BJ-.H$1E<\*<35"\68,C_X* M%ENV%9:W-:J6P40-"6/8@J 6@WV,=51P,DA;3'8\JV8##Z&T4#NA"O$+0DT, MW5"-Q[Y_1H>0EQ>-X'&5V$@GKB6- M7-RV2%IV=U,$'Q@=J@JTQ]3K-R3J98$ 7P61F@="W)DEV[0:2W"WE?#CU\ZBT:_SB689N_U1N4DZDT0"'&!&1>\0L$SWH:2 MM)B?@GW[):_^RMZPJ>N]JRUM&\3,Y59FB;%1!IVU,U9(B#%ZW):(%CD'#4R' M/1%3_WGDK\9?!D,ZL5IS1XSS(2HZ6D3?+I+P&(!H&GR8 3\9IE/ H_J;2&GF M^NQJ-QIW_6@(++30PU.+"VU&?"FJ/)U 4#+6VYE3RD15*Q9,53:WG2 MLA]E-% K($M(C2/XM,I;<"X+'VQ4HI@-&+W2LFLCL]XI04#PB6+*?18%()I@ M>VF/IKN-*XX7B9Y?4)\(!&K4:$T"6K07#!NB@A M6^>IBMDEFMH42RD--(?P5.OGH."@MCV4+",GZ"@!//,AA(116!&.)Q'G82,= MW?,G;OM]0I7\%0:=U;OSB5G]M7]&"=93_ @=R??/ZI=#9U2=4241/K]F!V%K M.H'O79$!KHW*N\OZ5M_ZS^^]3K?NYL)C[.:Z?0,:+[L*#!>0Q2O&'*.S!,SB#\20 I,=9\ MD U+5K,B^ M?G>^Q6Q3$5%+@4&"1,3-C$%+1VDSH:3P9D%MBS1HP65')*;IV-#5.2:,# M!G@:@E#-ECC4TM/,M6NY__KU%K5F^?[B%GK+;L)DM)=&8;2J92RY!(Q(ZH&V M7!FM7?,(ULU[WKW0MM+5A$1X2Q3&,T3T!P81=2D";/34'F_15>QF^]4]T?.A M&G>Z_>HL=X9]W*REDR654PH%#@U[\0Z!4?3J9I=<1G79#67+FEZCGV41O0ZG MP5C2!&F3CK&XJ$-DS3'HKZ7F2:@0G=3&"NN@:T!H)<0:R82%KEDUI"E"S_>^>R%E3,[SQ M1M<#.;0'F3B=W:B^F2X7C"AIC\Y D4,];:/G_R,ZC2:&R;R MH>KT\HBV')\V=>LN59=#Y%,-P%(U.AUV+R?AY>T*&F?9-6I;) (NIJ%24?/Y&79#2W M),DAZ S<9YM+!C"HXP[]3/.HC,NYBLACYLHAF5QI1/+.(^1'SHM27,K6.VD] M-Q$-<"-6:S=B"R;72JTMQO_>FP*(I[V11B7$U<51#Z;'#HJ_379OU- *A'$L M%!.LK]N*)RF52T5&GFWBC>O >V%R]^+3U7!4T_ZA^EKUY\_QI_S3!K=<_XY< M&E7]V0_=OFT)V+>LI&0"U\(+C+6#1_9).DV60*T[&NF 1I_Z1<2M3[Q^%N)Y M5,EE';(Q%EQ.7E(/2NF"$4!S%AI'"[ V\9=WM;K;/L9266DJZ=""9H D[55@ MUBCI!8;$"\:*.SZW])67MC6*EHV;RQR)B*(8)B%:$0JC^Y?2&>NS:C8QXTQN MAZ111=.U,4Y--#Y[4$>JFUZ4*PKW (QD!JB.Q5@E;:1I;-)RH4.#",$!YBYI M/;J@)ZQ\67HZ8LAOJ8>Y*)"A.%:BD;P(F@LU6SYX>_F]/A?=<.7C8?<4K2K! M%GP[_8O6J:M1?%!I0[@K"HAHZ4J)H;&\9*QCJ]'RMSR MMDW90=7)I%ATX+;D$!P4KIR5$(0+@2MFBVN @Z2)4AFRTI1O9Q6)\%YQQS<9S5'J]'E&+;_8_A9['1)Y%*F$V M)4>',:NR-AF:&AH4=7(0BR[H,#N?)]R8GMO[:_%+9_CY@2J6K=\,]@ E2IX5 M5?8@Y<$KK:E/J5 *I&L.@!!N[F+;HK5O1-NCEXQ,SH@<:!2()9=+_Z1Q MTUN?4K@$S"J?BP&AM0<=HF3.ZI(U"F&SR8.=#RJV0>,2G!J=YU$P\%)R, :5 MW'E=I 99C$;F]3J\0=IUP&>C=[1S@L*CY@ 6N< G[9&R#=1((QC#_= ./1-PT$YS M57=!!1D,RFES7-D32*20:_AU <924UA\ZW?]@PPJ,.ZH#W02%N/#@I"",94B M-XU")JL; 6Z#@%T0N*9H:B1)(V#2)B40T7@J6@3<&RXQC(S-QD>R[F'P7(1M M()DN2,2"4FGTT) S>"13(R3TD>95J@5W9\$]XL4VIA"F\/^693-&%SB")C3Z M&6+B7GB%>TD$9JN:/=NLFC_8V ^!:\HF=TE:%W1&VTEM4[Q&B%4\.K^@$Z1F ML0*G.]'/1M@&LFD3U7;1)!SK(4@>2% ]35>7&)>91C+6P6, ZPD$[LQL>DN- MR1 =QXR[%S%P=]$$2,ZSG%@S&\%KT7P&"M>536V+2<$P'A V)AY4$?A_9KU, MVC2KLM"FJ.>C:Q.''FD$'P>?4>VR0R^._^>:I<)]-J:!.(U3NR!0[\YJ@J$! MV$(D=.I%<)9-S*(D136"GK/FM0.A'XG@=DCANFA3Z8A0$_<(X],8D@]9FARB M*<;';!LN'93:!519D:Y-K*9"0E#-*"*%R)3-S"&,-NCJC%HP?]0(\731W.B" MKXK "D\V468-C'1H) #C&T1162?7 (W&NN4K77!7<:T%/Y9ORB@)T62$@SR M(C.=94PI.F0Q]0UM+-BL@ 977/"F.3^9T$H)81UP#-X5"]G*2#TY7%*@9#/A MK58PQ2NDQ598]F.LEBX6[:UDCDFZ!&[I;H#@0!WA7-8-WZ_Y"JAM]65/CN[? M]D^'=$R8JLF_U\Z#!8Q]7$GHU3%N\"4&C/:4SAS_*U!+FW<&A))Z.4A;O+IM MT;0DV6(07>(>L"B1L*RLY8(9GE7):%:#;.S,:]R9Y19T%9)F;S7,E#U34G]= MQ8!LT;LI@1 3K8YVLM!1LP#T HK!HC%/FJ,5G2-EV:*>2L)C2H+HPYH"&2/M M!!P=E?4,HQO4;XQX5+-#PFL,7:7B\XJR'@EU2ZAP- QE1;EC M8++D3#WYU8)KC!;8O-Q,OGN=]>RC@&3VEE!.1DL:8,H%VEP1,I.,[CT:#$Y4 M(T$O>$/?UR%RV5SN(%CBN.G"&8CHL$R,R46:Y! 1U34;"SM;#_-[XGKVS70/ M)CMJ>4 #R, ZD40@IB,R#U!<(Q0V\X= "T@<7'=ZX^LEM5D/(P7I3+8AH>EG MP*BY3I%.,RV4=U$T+_9IX^;0\\SWK[^R?6\!XQB\)H$[@6Z;JRSI_BC3TDL! M*L?&00''C=H2P4OO6(+(='E/)402$;Q*7@BLP1 M^-L $A%U=HXN\SG:"K1,/'"QH,1A17+I=OCHYO6_#09GH\;%IQ4T0S!%4WHS M0F,/*!@^@D,<'1QGU"^RF?*0S)I945FTCO77N:ST3+B$4:$2 &LQS4Z(*U. M)3EF=+,K,4;XYSBZZ_2Z"HWJ_-^Y^+QQJ'$_4 ML!(D9P[#W)(A2?2X431'/ME&T=9J"]L&*4LV 6TZ3S0=7&"PGJ!X%70*K,C@ MD99F!I#3Y3[U9%KZW<'PMESPY\%XWM$M0Y9.4"&.+M9* \9CJ,7HR$Y&&QVJ MX(*R!&FUG%MU8PUK+_'1$4GHYF.4"<6D@+54Y!2]<18"3<-H#JCDRE$SJ;67 M6+^\47) HE'@/HADZC)[2/HPTBHR4$]?R2[9($+F^6L/RT/HQR/UA55!R%@00E4 M='\=_^= IM*P8V#D7(RS>"&;+'69M@N5DPXHAXD! K@ 6H+W(M+\);6H78": MJQK9=*GS72WKSD53G8CJ%D7YCVIXVAU5[X?=T^H#^>\?![]7P\E/W8OYX&W1 M=8?-OSQ<-[_^'BXT_U;?"B+T,!RA.+YA?#RX_56J-]HU,<1LLT6,O*1'D,2" M30C5(DT\T@JX+MQ1T^^'.K=.OFS9CFR'W]_ZOMHW3MYM*_&=+=M5U"9-C51% MP;T-5M$-KY(TFB\NO9\_;YK:5?JJ=E-WM:GG4YO*9I5UI6W%:,O'@(:2SN^U M+)X[B?]E-'++2O7PMK)66?>TK[,V6*VRJSIAB$KI>^,MAM7L]] M?G!76PN\KTU5,YNJ5]E4'^HPG!E#$XQSL<'C[GJ9',:;?KY0ZGY35;NI>]I4 M/;.I=I5-C5JZ0'VYBO$0'(2LE>+9296L\;P\M*FZW=0];:J=]:ILE5WE 9(& M'Z!0IW_/+4-MQ7U%,PQT+?:A7;4O8%=_OB+>O#N_^0M=J%G88G9IGD%Q-&JA M2!%$G0<'*:WA,AAA@BR+6LUK#/%7".JV3MBA\/*YHXK5HL6Y0KT0&%,N%Y8@ M:F9%<5ZS0K.W(Y_I@'F[RW)NV%>[R0<7.L[>=;'"1V&M\@PCR C.8W 1.2^@ M,Y29LJF[22)SC>7;+3[ 0+(Q2,G9[+.BX81*4C*8)EXE9FTT>='<%<56R<"U MF_R,4>7<=(58I)7<)*[!&6LA9L]77W-'INTLE MTM0G:M.H; "TW8(G9?(B6PUSE8KM'A]9EMYL%'M]#SB3V8Q7:7MQ:)!NV+3M%R8:]1*+M%F\S$HTT?XEI8='O!8"@@><0="XQ&SU33GJWR=KL(6_8 M[O+60M&N)K X MX4T(&<$2F,AHK$+4I6CTI@[F;^%-UP2V.WHH8<[">,PFHG" 2(F'IW7T28&Z9&+$\^TIY_F MOV?J*GFXOG_+^\G<"_][9SCS]C@8C?G2)L+UQQJC*?/%96]P75535"Q+\1'T M3"8K7A+84()65/[IC)2)#&+C)JQUL.#,;2M$'P0K)V)\P\BI((H% M#U+%P%32WC*?2Y#1-WJE32Z7'S4S]6XTW6EJ111ER%" A>B9R,(+#B45)7A3 MT[68;SKPLECY9$V/ 4,"(W2RT8'4TCD/$$0,&/EEMF!8@X&YQM@OF:/K:CID M]-G(3ZH# [*@4?+R SC)D:U8"#0PK* /3%S0^S0K,OYCZK[^0M*G?]:#3MW M;YA\A"^MH!'3]6:I@ K%.)\P/(7L53:F\.)-M(7Q!Q.$X-Z8^8"K3PEHB8DPF9U[?7 M@8:6Z&*$8PY%PQ+ ?CB\=F^$;D7BT$5BI43WM$ $[J4MQ4RC3(. M7AY62]%/"X1)&+*+I)3*CJ8G8\#!2V!.&Q00'A\^<[%OF'KA M&L?'IL':'Z MW.U3@^_0P<>M&_[GB$&^2#PYX4%CF <1T3YDQ4)$'7VPPXFQ;_2N%/.)]!_5 MOCQW++A^>H NGWKO +BD[MS48A04#;2>[X ]75'&WNA=A8.MR!QN^L & M*R03Q3&:6*)=*(I9")Q;Q6EVQG.D#UIY.>3T0J .W2$+[5!0A(C6BA2+X4*" M9'F^E?AL>D&*5F2.76363C\XYQ(-((%D BC-,>R,Q#EU>UDY/.#0J@7MA!4(8!#2.BB]XP-]%L#(^F-%6&'WL*EW5RLOAIB]$ M]J 8:&^S BUD\%$6[06Z*!N2>Q#"&'CC6G]T]/*R?GK#>2DB2*E%LJ"C""([ M#).8+L5E+^5# N,P1H)68&;7]:&ZZ'1I*1%%8XCLO>KT:#2%>'@0P?VT"24C M]R4QRP(P$8+A+!='_2H5_D>_^NM[\YOZB;/T7%Q_D+HC8OASAZ2/93'N4XZ@ M%-.21QK]4UAT211\C3FN"#L:% 7WF_R)\U84CE@4'LY.W-]S*A13DC@PGCEF/?<.KHP&"1;U#%*(>L7W-:8 M)F)-"F$ZF;1E"A/&$,I8P:16D+,(DH;&F%0TF@LW,ZWZGD()=L%UJ2=1N+L] M##8E$ G7*QDZ1VI<"\%FNE+GDN&+&E +I25;T+_O"13J'>ZA#0Z$0SM]>@0M6O MSKMC,@A+[TUNFP<%[9M$["LQ[ %&!_8A981"%J/D7,RB5O+<\KF^7VL2N5T& MS?N6+3/(*,[ *E-?/>,I>.%=C(01%C6Q=/-:OGW^_+/3NZK6D)^'KWS: MI&4PWC ;@6=C2W!%H@L4@?,@&U>1%7>K[?Y#*]P!<6ONO3\[ZY)C[?3>=[IG M;_NQ<]D==WK+7%I 9*B+-M(5R,XY)E4)EFI;"^>L,?*<^A:+XV;4ZDH218E9 M1,D1+$-B/FB3BS6<:\?1PJAYYLR/]SXVSOP\Z-.#AH-Z+/E;?"1J\G@9DQ)3 MV4>OBG4('9@O'/EFHN&*.N4VAF$?,X/>=V@2]C*&:"&+ES':2*4_Q7.?DO*! M)UND-(V+^X=E>Y;,P4X%%4$1WM49C$"W057PTJ>$?#+'S:?5S2I3-OC,HHA1@X 44(Y Y>B, MT$7PAL\Y''^S$6-6,AK,ZJQ,"DX !S*GQ1<:U*F@R&)RW+E>?1GT,) ?32A9 M&)(]#+:45)I'FE41T"8P5ZAE"9<%E$@J-?;32>?T FF?6<*Z"WQTPH8I+"9C M$G,(=CGAW*Q"4CJ5@-& :RP0##,+V+O& M_V3WM7%#:]'PS)>OCQ>-C]=#6F MFQF_#!8[VH7)C$^) M$^O:[=/3JXNK'K[U[-WX2S6DMPVK+U5_U/U:X:(&%]52&^Z<8"4'D &20?MD M.6B4;,.REK(IUWR94+\@[F[D%;TSQD)@)B!Z@&R#C#9;%8MF&C1K=.(!8PR? M'PWU@KFZN@]U.D&)3@+!B:*]D\IB&)^<1)#!BV_X4&GAFV'C1G$,R!BR5+(X M0#02K!-&6U1_ES0-_&AVX>%\?JC'"V;I2B!&>6^*83QB6 #(G^!M*0)HW!$D M7Q:X)(-"N2#V>:%,_%"-.]U^=98[0SKI&"U+8J+#UBX*R!A(1L>M"29$CW)' M,:5M!)*O,80 -=_8_FCX"8\@N,*#S*X8@T8/+($=5[+T B&0D]DT7;$S((]5 M.]<_X'DZUG&J,!0P6] C QUL)"!,PQS MP3/$C4)DI[73*+TI-3@*UA@YW]CM!7-U=:R#(1OWW#CJ((^Q<0X./8HPZ%D4 M+UR+)M9QRX*WE\/&C;".%2K%F+D4-H&(&D7/!N.+$R""UHUL@^#+X^&7P]+5 MLKPQ!1$4@ X)O''45BXG:1(#!U(U +@S6H']9GBX)M11BEGA/2L*$.Z(;+6, MR=(E:XF>OI@FU'&,;C,=+3\?SNM$S@HW@A<;-7B+<9L)V4/4HAAIFIZ8,XSY MQ/%*UO[S.BSHQ(3D.E'CEFB]H_1@$-('9:-I9"&X/6*WO)_$3N94-^!8BJ% MI"8:,N@H%5,T&QH:D9_FSM2!RC?"U=7!3JZG$CITT(*#=L*)G$!15_7,E4_- MULI*'&^?4OG3^JT?O.-;T_7@U)+!['@O_L#+OTYMN'Y?X8?4QUQF-NN?=T_J*U+OS^B_7,SQ;^.'K]T-DV/!Z4IAUVL4?EZ4=?10!09+T M5%RHK%*HV1@"1A,12<9&H"T4S-5/+"![;:Y,B\PA<,4!&CBK:;Y3C,8&)96J MN2)+L8HWTH?(%2[6X:< M#0@>).(PI\!SK:)1S5K[N03) XO8:)WSF'QZG9",1F"HDD0/8M#N,4V5B5:% MJ$&F1B7$]M8Y ;3XPOL*$1E)D>^?WWN: GHIE M4)-!DC0H8LV^9VIME[HS:!<7HT]1RRQ4+=*T-"I/9Q13S#;5H#J%1(+%] M:JF\=C)LJ]<;_$Y-IN@#'ZI1-?R*/Y[]U]5H3.YTM!)M,SD"AM;=U2/OJ8#< M>L1Q#(47@V,K66Z$&*\%C5F<5L.5U[95@J9,^V-/:HSUNWM7&0P_=GK5"$'& MU;"_#%MDX3452X,2&:*TJ-&&0_',*.-X:IQDOC;P0ICTR[!S5GVH3JON5W): MRQCE3,IT99E;G\$&A+39)%R1?R&BTSW[40W?3V6^^,E:< M7@8T%YG@EZ5]-\6%[)3,Z$H:",<)I]>@Y&91VZ%BSQ;5(G(.KLX/)K"@'<)4 M;0POS+$830-+*D(WV$I$R>E\?FA=U!+/N M6-BSN?7TX$&PC'I$);W"6P-.T)%%-D$C(&T(C>3LJ+CR),.)\H)PSFD=$9'+ M:+SUI2A9."(\;^<'E**Y45H_C] \=E3C4V+1 /?!)Q#@K"Z(O;4M=')CFE<. MP&G[/)L\FY[8A]%TZ#N22X%+QB!)9R%JQF-!4%XC$R64F#)U.O8V&\Z=-38E$UAIWA53:JT > %[YEI2 M_7Q%"WQWGKJ]*QJ/_GA;GQ6ZDA1%!]T:]QY50*7)"TP#L>0H/C($0_D(IT/'+01+#K.D.3%[:.LY#LFL/&9T!EU M3]?>/R^3%<8AUN,&@% R&BJ@,R'\J!(+.RNMO'^+U[A%XI9U=G#DU$.T"-S( M>P6,[3@"NH0_BA#YD_;N8>+(4'SO+\@B#,XGK>$ZO0]5O_I]TO]M-OZ]28&F M',5K,74>U>GE$1U=H7Y/54RDZG*(Q-8V(%6CTV'W M"C8&?639__W+4HKOV3)AXF]59]B[]I\_#RMT+^AV^^/\QVGOBDI Z GXIC&R M]"8].A4;AZF\;C!$0O4$ M)MSQ,. [^M5HY$__YZH[JFL](O('WXI/P)]&W;/ZH_3RQ06U+>ST?NHBI!D/ M^A-_,;B>9()O'=<'_/H%/!9___5G/G==='U=A MTZQJR6R8X8:#+93!E]9):6RP =E7O(?%C *W-J/6I&07O/IQ\/M36!5]472I M+'(N(5*77UF*\(F:#ZDPT^-NBE6*;Y]5,X3<<2IV1E_H_W1:_Q5#*:HB0'OS MM=/M4ETAW6[DO5R>0&=<$@V,XD^60I$B'1EPF;+,A>% M-XHI.5,"PX][ [/Q.G=$Z8V%/?U2G5WUJG?GZSZ=,/CHW7GI]A'?HB%XVQ^- MAU<7S=*WVR><#X:CF2EF^,/#'O,%PH#%C.@0=C,(!VCB69FP5RABNC;

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